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Abstract 
Grainyhead-like-2 inhibits the co-activator p300, suppressing tubulogenesis and the 
epithelial-mesenchymal transition 
 
Phillip M. Pifer 
 
Tumor progression and developmental morphogenesis require transient or stable 
Epithelial-Mesenchymal transitions (EMT) to modulate epithelial junctional complexes allowing 
programmed migration, invasion, and anoikis resistance of cells.  Grainyhead-like-2 (GRHL2), an 
epithelial master-regulatory transcription factor, suppresses EMT and causes a mesenchymal-
epithelial transition to the default epithelial phenotype.  This body of work investigates the role of 
GRHL2 in kidney cancer, in kidney development using a kidney specific GRHL2 knockout mouse 
model, and in tubulogenesis using Madin-Darby Canine Kidney (MDCK) cells.  In kidney cancer, 
GRHL2 was not expressed in the normal kidney proximal tubule epithelial cells which are thought 
to be the progenitors of clear cell renal cell carcinomas.  However, GRHL2 could function as 
biomarker to differentiate renal cell carcinoma subtypes.  In kidney development, a large amount 
of evidence suggests Grhl2 is a critical regulator of this process.  However, kidney specific Grhl2 
knockout mice did not elucidate the role of Grhl2 in the developing kidney for technical reasons, 
and this area needs to be further investigated.  In the MDCK model, GRHL2 was required for 
cystogenesis, but it suppressed Hepatocyte Growth Factor-induced tubulogenesis, a process 
requiring transient, partial EMT.  Subsequent results demonstrated that GRHL2 suppressed 
tubulogenesis by inhibiting the histone acetyltransferase co-activator, p300, thereby preventing the 
induction of matrix metalloproteases and other p300-dependent genes required for tubulogenesis.  
A thirteen amino acid region (425-437aa) of GRHL2 was required and sufficient for the inhibition 
of p300 histone acetyltransferase activity, the suppression of tubulogenesis and the interference 
with EMT.  These results demonstrate that p300 is required for EMT plasticity occurring in 
tubulogenesis or tumor progression, and that GRHL2 suppresses EMT in both contexts, through 
inhibition of p300. 
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Introduction to the Epithelial-Mesenchymal Transition  
Epithelial Cells 
 Epithelial cells enclose organs and glands forming a protective barrier by directly 
interacting with neighboring cells.  In two dimensional culture, epithelial cells form an intact 
cobblestone monolayer with high transepithelial electrical resistance.  In three dimensional 
matrices such as collagen or matrigel, epithelial cells form spherical cysts that have a distinct cell 
polarity.  The basal side of the epithelial cell attaches to the extracellular matrix through the 
basement membrane, and the apical side faces the lumen of the duct where it can secrete 
molecules into the lumen and control the uptake of molecules.  Polarity is essential for the 
survival of epithelial cells as detachment from the extracellular matrix leads to anoikis.  Anoikis 
is programmed cell death caused by detachment from an extracellular matrix (Frisch and Francis, 
1994).  Epithelial cells form barriers through the interaction of specific epithelial proteins such as 
epithelial-cadherin (E-cadherin), claudins, occludins, and desmogleins (Baum and Georgiou, 
2011; Turksen and Troy, 2011).  E-cadherin’s extracellular domain forms a homophilic 
interaction with other E-cadherin molecules of adjacent cells, forming adherens junctions.  The 
cytosolic domain of E-cadherin is important for cortical actin assembly and the sequestration of 
β-catenin (Qin et al., 2005; Tian et al., 2011).  Claudins and occludins contribute to cell polarity 
by forming tight junctions which restrict integral membrane protein movement to the apical and 
basolateral membranes (Yeaman et al., 1999).  In the cytosol, epithelial specific proteins, Rab25 
and Ankyrin G, help ensure that junctional proteins are localized properly (Kizhatil et al., 2007a; 
Kizhatil et al., 2007b).   Two major characteristics of epithelial cells are cell-cell adhesions and 
cell polarity.  
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Our laboratory has proposed that the epithelial cell is the default cell phenotype in both 
development and cancer. Under this hypothesis, the epithelial phenotype is adopted 
automatically by a cell in the absence of genomic/epigenetic alterations or inductive 
differentiation signaling (Frisch, 1997).  Developmentally, E-cadherin-expressing cells are the 
first to emerge, at the late Two-cell stage; these eventually give rise to all differentiated cell 
types of the adult organism (Hyafil et al., 1980; Vestweber and Kemler, 1985; Larue et al., 
1994).  This idea has been invoked in recent studies from other laboratories to explain, for 
example, the mesenchymal-epithelial transition (MET) occurring at metastatic sites (Thiery and 
Sleeman, 2006; Polyak and Weinberg, 2009; Tam and Weinberg, 2013).  The regulation of the 
epithelial phenotype is important for understanding all of these processes.   
Mesenchymal Cells  
 Mesenchymal cells lack many of the cell-cell adhesion molecules that epithelial cells 
express, and therefore lack significant cell-cell adhesion and polarity (Taube et al., 2010).  
However, mesenchymal cells express their own unique markers such as N-cadherin, fibronectin, 
and vimentin which are not present or have low expression in epithelial cells.  Mesenchymal 
cells are able to migrate and invade as individual cells and can survive independent of an 
extracellular matrix interaction.  This property makes mesenchymal cells resistant to anoikis 
(Frisch and Francis, 1994; Scheel et al., 2011; Frisch et al., 2013).  Mesenchymal cells are 
essential for the formation of the extracellular matrix and may function as mesenchymal stem 
cells in some populations such as chondrocytes, osteoblasts, and adipocytes (Dominici et al., 
2006). 
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Physiological Epithelial-Mesenchymal Transition 
 Epithelial cells can transform into mesenchymal cells by a process referred to as the 
epithelial-mesenchymal transition (EMT).  EMT is associated with loss of cell-cell adhesion 
molecules and cell polarity and gain of motility, anoikis resistance, and chemotherapeutic 
resistance.  EMT is classified into three different types: Type 1- Developmental EMT, Type 2- 
Fibrosis and tissue regeneration, and Type 3- Cancer progression and metastasis (Kalluri and 
Weinberg, 2009).    During development, cells demonstrate significant plasticity by undergoing 
EMT and the opposite process, mesenchymal-epithelial transitions (MET).   In mice, the 
depletion of Snail1 and Snail2, critical EMT driving transcription factors, leads to failed 
gastrulation because the epithelial cells are unable to EMT thereby preventing the formation of 
the primitive streak (Hudson et al., 2009).  The reverse process, MET, is essential for neural tube 
formation where epithelial cells are required for neural tube closure.  Depletion of Grainyhead-
like-2, an epithelial regulating transcription factor, prevents neural tube closure in mice (Rifat et 
al.; Werth et al., 2010; Pyrgaki et al., 2011).   After neural tube closure, another sequence of 
EMT and MET is responsible for the neural crest delamination and the formation of notochord 
and somites (Thiery et al., 2009).     
Type 2 EMT occurs in organ fibrosis, wound healing, and tissue regeneration.  Wound 
healing requires myofibroblasts for restructuring of the extracellular matrix and wound 
contractility, and keratinocytes undergo a partial EMT to form an attached epithelial sheet over a 
wound (Savagner et al., 2005; Thiery et al., 2009).  Also, kidney epithelial cells may undergo an 
EMT during kidney fibrosis (Liu, 2010).     
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EMT in Cancer  
 Type 3 EMT occurs in metastasis and cancer progression.  EMT is a physiological 
process that is hijacked by cancer to increase survival and invasion.  Type 3 EMT gives a 
survival advantage to cancer cells by increasing motility, invasiveness, anoikis resistance, and 
chemotherapeutic resistance (Kalluri and Weinberg, 2009).  EMT can contribute to a 
chemotherapeutic resistant cancer sub-population leading to tumors that are refractory to 
treatment (Woodward et al., 2007; Barr et al., 2008; Li et al., 2008).   These characteristics allow 
cancer cells to metastasize from the primary tumor site and form colonies in other parts of the 
body (Kalluri and Weinberg, 2009).  Metastasis is responsible for the majority of cancer related 
deaths.  Carcinomas, cancers of the epithelium, undergo multiple genetic hits leading to 
uncontrolled proliferation during the progression from normal epithelium to an invasive 
carcinoma.   However, metastatic dissemination does not occur until invasive properties of the 
cell have been increased which are usually conferred by type 3 EMT.   Cells that have undergone 
an EMT are known to upregulate matrix metalloproteases (MMP) which are responsible for the 
degradation of the extracellular matrix allowing cancer cells to invade through the basement 
membrane and disseminate (Ala-aho et al., 2002; Culhaci et al., 2004; Yuan et al., 2005; Park et 
al., 2008a; Mehner et al., 2014).  After the cancer cell invades through the basement membrane, 
the cell can intravasate, be transported via the circulatory system to a distant site, extravasate, 
and establish a distant metastasis (Kalluri and Weinberg, 2009).  It should be noted that for 
metastasis to occur, the cells must become anoikis resistance because this process requires 
detachment from the extracellular matrix, which under normal physiological conditions this 
would induce apoptosis in epithelial cells (Frisch et al., 2013).   
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 Mechanistically, one of the most studied phenomena of the EMT is loss of E-cadherin 
and its subsequent implications in cancer.   Constitutive E-cadherin expression in cancer cell 
lines can inhibit cancer’s invasive properties (Frixen et al., 1991), and E-cadherin expression has 
been shown to inversely predict cancer metastasis (Dorudi et al., 1993; Younis et al., 2007).  E-
cadherin could block the invasive traits by structurally interacting with other epithelial cells via 
its homophilic interaction keeping the cells in close contact and preventing invasion.  Also, E-
cadherin sequesters factors such as β-catenin (Wnt pathway), NRAGE (pro-apoptotic factor), 
SMAD3 (TGF-β pathway), and YAP/TAZ (Hippo Signaling) on the cellular membrane 
preventing pathway activation, and the loss of E-cadherin can cause the activation of these 
respective pathways thereby promoting an EMT.   
 Cancer stem cells (CSC), also known as tumor initiating cells (TIC), have been shown to 
recapitulate tumors in a variety of different cancers such as leukemia, lymphoma, breast, and 
brain cancer (Bergsagel, 1967; Terpstra et al., 1996; Bonnet and Dick, 1997; Al-Hajj et al., 
2003; Gupta et al., 2009b).   The epithelial-mesenchymal transition can cause cells to acquire 
CSC properties such as the ability to form mammospheres, differentiate into two separate cell 
populations, and generate tumors in animals that recapitulate the heterogeneity of tumor 
histology (Mani et al., 2008).  The clinical significance of CSC theory is that one cell can cause a 
tumor recurrence suggesting the eradication of all tumorigenic cells is necessary for the 
prevention of recurrence and metastasis.  The CSC theory is still debated, and the percentage of 
tumor that CSCs comprise is controversial (Gupta et al., 2009a).   In breast cancer research, one 
of the most commonly accepted CSC markers is the CD44High/CD24Low phenotype.  In human 
mammary luminal epithelial (HMLE) cells, normal epithelial cells (CD44low/CD24high) undergo 
an EMT causing the cells to exhibit the CD44High/CD24Low mesenchymal subpopulation 
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phenotype.  This conversion is associated with increased ability of the  CD44High/CD24Low cells 
to form tumors in mice (Mani et al., 2008), and this phenotype is supported by TFG-β and Wnt 
autocrine and paracrine signaling (Scheel et al., 2011).   
Regulation of EMT 
 Many EMT promoting factors have been discovered, but only a few EMT inhibitory 
factors have been found.  Growth factors derived from the mesenchymal stroma such as EGF, 
HGF, PDGF, and TGF-β can promote an EMT (Kalluri and Weinberg, 2009; Xu et al., 2009).   
The activation of multiple pathways such as RAS/MAPK/ERK, PI3K/AKT, β-catenin/LEF, and 
TGF-β/SMAD3 (usually activated by the growth factors just described) lead to the upregulation 
of EMT driving transcription factors (Kalluri and Weinberg, 2009; Sanchez-Tillo et al., 2012).   
Two of these transcription factors, ZEB1 and Snail, are E-box binding transcription factors and 
function by direct repression of the E-cadherin promoter (Cano et al., 2000; Grooteclaes et al., 
2003).  Other EMT promoting transcription factors such as Twist, Goosecoid, and FOXC2 
function more indirectly, usually upregulating ZEB1 or Snail (Thiery et al., 2009; Taube et al., 
2010).  These mechanisms emphasize the importance of E-cadherin downregulation for EMT to 
occur.    
 Inhibitors of EMT have remained fairly elusive.  Bone morphogenetic protein-7 (BMP7), 
a member of the TGF-β superfamily, can prevent EMT and cause MET by inhibiting TGF-β 
signaling (Zeisberg et al., 2003). Other BMP family members are able to inhibit TGF-β signaling 
and prevent EMT (Cieply et al., 2012).  The mir-200 microRNA family is downregulated in 
EMT and when constitutively expressed, the microRNA family can suppress EMT by repressing 
ZEB1/2.  Alternatively, ZEB1/2 are able to repress mir-200 microRNA expression thereby 
forming a negative feedback loop (Gregory et al., 2008; Wellner et al., 2009; Gregory et al., 
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2011).  The splicing regulatory proteins, epithelial splicing regulatory proteins 1 and 2 
(ESRP1/2), are responsible for epithelial specific alternative splicing events in the cell such as 
FGFR2-IIIb, an epithelial specific FGFR2 isoform.  ESRP1/2 shRNA depletion causes an EMT, 
and ESRP1 overexpression causes MDA-MB-231 cells to re-express epithelial alternative 
spliced isoforms (Warzecha et al., 2009; Warzecha et al., 2010).   The first EMT inhibiting 
transcription factor discovered was GRHL2 which will be discussed at length in subsequent 
sections (Cieply et al., 2012).  Another family of  EMT inhibiting transcription factors is the 
ovo-like transcription factor family, OVOL1 and OVOL2, which function by repressing the 
ZEB1 promoter and upregulating ESRP1/2 (Roca et al., 2013).  
 Also, our previous work reported that adenovirus E1A establishes an epithelial 
phenotype, suppresses EMT, enhances anoikis, suppresses MMP expression through AP-1 
signaling, and acts as tumor suppressor (Frisch, 1991, 1994, 1996; Somasundaram et al., 1996; 
Frisch, 2001; Frisch and Mymryk, 2002).  One of the major functions of E1A is its modulation of 
p300.  A deletion of E1A n-terminus amino acids 2-36 prevents interaction with p300 and is 
unable to transform cells (Stein et al., 1990).   Of utmost importance in this work, E1A 
demonstrates functional similarity with the GRHL2 which will be discussed subsequently.   
Epigenetics and Post-translational modifications of histones  
The blueprint of the human body is comprised of paired deoxyribonucleic acids, DNA, 
with a double helix structure discovered by Watson and Crick in 1953 (Watson, 1953).  The 
DNA comprising one human genome is approximately 2 meter in length, but it fits inside almost 
every cell in the human body (Dancy and Cole, 2015).   DNA is organized on nucleosomes, the 
fundamental subunit of chromatin, and is packaged into a cell’s nucleus being about 10 µm in 
diameter.  A nucleosome is comprised of 146 DNA base pairs bound to a histone octamer 
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containing duplicates of H2A, H2B, H3, and H4 (Dancy and Cole, 2015).   Although, DNA 
contains the genetic information for all genes, it is becoming readily apparent that epigenetic 
regulation is essential for proper gene expression (Kiefer, 2007). Chromatin structure 
conformation is regulated by histone modifications and DNA modification which are some of the 
important factors that determine the “On/Off” status of the DNA/Chromatin complex.  The “On” 
state chromatin conformation means the chromatin is open and permissive for gene expression 
machinery to bind and function.  The “Off” state chromatin conformation means the chromatin is 
closed and inaccessible to gene expression machinery (Dancy and Cole, 2015).  Histone 3 (H3) 
is highly regulated during this “On/Off” switch, and H3 is one of the proteins studied in the work 
presented subsequently.  Post-translational modifications of H3 occur on the n-terminus of the 
protein, most frequently on lysine (K) residues.  Two of the most important histone modification 
are methylation and acetylation, but others modifications occur such as phosphorylation, 
deimination, ADP ribosylation, ubiquitylation, and sumoylation (Bannister and Kouzarides, 
2011).  Methylation of H3K4 is a signature of transcriptional activation.  Monomethylation 
(me1) of H3K4 denotes enhancer activation and trimethylation (me3) of H3K4 denotes promoter 
activation (Calo and Wysocka, 2013).  H3K4 methylation is mediated by the SET1/MLL histone 
methylase family (Yokoyama et al., 2004; Dou et al., 2005; Cho et al., 2007b).  However, most 
other H3 methylation marks such as H3K27me3 and H3K9me3 are repressive gene signature 
marks (Kim and Kim, 2012).  Acetylation of the H3 tail is a signature of transcriptional 
activation, and frequently occurs on H3K27 and H3K9 (Creyghton et al., 2010; Karmodiya et 
al., 2012).  H3K27ac is mediated by the histone acetyltransferase, p300 (Kasper et al., 2010).  
H3K4 and H3K27 distinguish the enhancer activation state.  The H3K4me1 and H3K27me3 
histone mark is a signature of a poised but not active enhancer, and H3K4me1 and H3K27ac is a 
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signature of an active enhancer (Creyghton et al., 2010).   Histone modifications are highly 
regulated to allow epigenetic control of gene expression.  
Plasticity in EMT/MET  
Although EMT has been shown to increase metastasis, recent emerging studies suggest 
that EMT plasticity, the adaptability of a cell to change between an epithelial and a mesenchymal 
phenotype, is more important than the permanent conversion to mesenchymal cells for forming 
metastases.  For example, when Twist1, an EMT promoting transcription factor, is transiently 
expressed, it promotes metastasis.  However, constitutive Twist1 expression prevents metastasis 
formation (Schmidt et al., 2015).  Other studies have demonstrated that a MET may enhance 
metastatic colonization (Kalluri and Weinberg, 2009). Conceptually, tumor cells exist as 
epithelial cells in the primary tumor site, when the primary site undergoes stress (hypoxia, 
chemotherapy, or other selective pressures), the tumor cells undergo an EMT allowing for 
anoikis resistance and increased invasion.  The EMT tumor cells can then spread to a distant site 
where the tumor cell undergoes a MET and forms a distant metastasis with epithelial 
characteristics (Bissell et al., 2002; Jechlinger et al., 2002).  The EMT-MET process is supported 
by the fact that breast cancer metastases express E-cadherin and demonstrate other epithelial 
characteristic (Kowalski et al., 2003).  The EMT-MET process has two significant implications.  
First, the prevention of either the EMT or the MET could prevent metastasis.  Secondly, the 
EMT cancer cells are relatively resistant to chemotherapeutic treatment making them very hard 
to eradicate.  The two clinical solutions to this issue would be to lock the tumor cells in the 
epithelial state and eradicate using standard chemotherapeutic methods, or design cancer 
treatments that specifically kill the EMT/CSC phenotype.   
11 
 
 As more publications demonstrate the importance of both EMT and MET in the 
formation of metastases, it becomes clear that cell plasticity between the two states may be the 
most important factor contributing to metastatic disease.   Both metastatic sites and tumor 
recurrences are often resistant to first line chemotherapeutic treatment because of either 
upregulation of compensatory signaling pathways or de novo mutations in the targeted pathway.  
This process is associated with cell plasticity driven by epigenetic modification machinery.  Cells 
with this plasticity are able to survive stressors such as chemotherapy, oxidative stress, hypoxia, 
nutrient deficiency, and matrix detachment.    Drug-resistance, tumor recurrence, and disease 
progression have been clearly linked to EMT and CSC (Creighton et al., 2009; Oliveras-Ferraros 
et al., 2012; Mitra et al., 2015; Ye and Weinberg, 2015; Marcucci et al., 2016).   
Importantly, both phenotypic and epigenetic plasticity contribute to recurrence and drug 
resistance (Scheel and Weinberg, 2011; Singh et al., 2014; Ye and Weinberg, 2015; Doherty et 
al., 2016).    In breast cancer, increased levels of mesenchymal circulating tumor cells correlate 
with cancer progression, and chemotherapy increases the shift to the mesenchymal phenotype 
(Yu et al., 2013).  Emerging evidence suggests EMT is driven by epigenetic re-programming 
(Tam and Weinberg, 2013).  For example, E-cadherin is epigenetically silenced by histone-
modifying enzymes leading to varying degrees of repression depending on the level of plasticity 
needed.  The histone methyltransferase Polycomb repressive complexes promote EMT by 
catalyzing H3K27me3 of the E-cadherin promoter leading to transcriptional repression (Bracken 
et al., 2006; Cao et al., 2008; Herranz et al., 2008).   Histone acetylation is often is sign of 
transcriptional activation, and during metastasis, Snail recruits histone deacetylases, HDAC1 and 
HDAC2, to the E-cadherin promotor leading to silencing (Peinado et al., 2004; von Burstin et 
al., 2009).  Clinical trials using epigenetic therapies to target drug resistant solid tumors is 
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currently underway using de-acetylating and de-methylating agents (Brown et al., 2014).  The 
ZEB1 drug-resistant phenotype, an EMT-driven cancer cell subpopulation with increased 
invasiveness and chemoresistance, has been reversed by using the HDAC1 inhibitor, 
mocetinostat (Meidhof et al., 2015; Zhang et al., 2015).  Furthermore, EMT transcription factors, 
ZEB1 and Twist1, contribute to epigenetic modifications that occur in plasticity, the CSC 
phenotype, and the drug resistant phenotype (Brabletz and Brabletz, 2010; Malouf et al., 2013).  
Introduction to Grainyhead-like-2  
Discovery of GRHL2 
The grainyhead-like transcription factor family is named for grainyhead (Grh), the 
Drosophila homolog.  The Grh mutant causes defects in cuticle, trachea, and head formation 
resulting in embryonic lethality.  Abnormal head granular sclerites lead to a “grainyhead” 
phenotype which is the namesake of the family (Nüsslein-Volhard et al.).  Grh was discovered 
for its regulation of the Ultrabithorax and dopa decarboxylase promoters (Bray et al., 1989; 
Dynlacht et al., 1989).  Grh interacts with the RNA polymerase II preinitiation complex for its 
transcriptional activity (Dynlacht et al., 1991).  Grh regulates trachea elongation, post-embryonic 
neuroblasts, epidermal wound response, and the promoter of the Drosophila E-cadherin 
homolog, shotgun (Hemphälä et al., 2003; Almeida and Bray, 2005; Mace et al., 2005).  
Grhl1 and Grhl2 were discovered by using Grh protein sequence in a murine GenBank 
protein search query (Wilanowski et al., 2002), and Grhl3 was discovered by querying similar 
protein sequences to Grhl1 and Grhl2’s dimerization domain (Ting et al., 2003b). Human 
GRHL2 has 94% homology with murine Grhl2.  The grainyhead-like transcription factors are 
part of the LSF/GRH transcription factor family.  Phylogenetic analysis suggests two distinct 
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branches of this family, the GRH subfamily consists of GRHL1, GRHL2, and GRHL3, and the 
LSF/CP2 subfamily consists of TFCP2, LBP1a, and LBP-9 transcription factors (Wilanowski et 
al., 2002; Traylor-Knowles et al., 2010).  The structure of GRHL1, 2, and 3 contain an N-
terminal transcriptional activation domain, a central DNA binding immunoglobulin fold domain 
similar to p53, and a C-terminal dimerization domain which is predicted to have ubiquitin-like 
folds (Kokoszynska et al., 2008).  The GRHL proteins are able to homo- and hetero-dimerize 
with each other, but they are not able to dimerize with other LSF/GRH transcription factors 
(Wilanowski et al., 2002).  
In murine studies, Grhl2 is observed at high expression levels in the primitive surface 
ectoderm from E8.5 until E12.5 when the expression starts to decline until E15.5.  At this time, 
Grhl2 is only present in basal layer, stratum spinosum and stratum granulosum of the ectoderm.  
During murine development, Grhl2 is present in kidney, lungs, olfactory epithelium, esophagus, 
stomach, small and large intestine, urogenital tract, oral epithelium, and submandibular gland.  
Interestingly, Grhl2 expression is inversely expressed in a spatial and temporal manner 
compared to Grhl1 and Grhl3 in the developing lung and kidney (Auden et al., 2006). 
Function of GRHL2 in epidermis 
The role of GRHL2 has been intensively studied in the epidermis and associated skin 
disorders.  In keratinocytes, GRHL2 increases cell replicative life span by increasing telomerase 
activity via upregulation of the hTERT promoter.  GRHL2 knockdown decreases cell 
proliferation, reduces epithelial thickness in three dimensional culture, and causes 
hypermethylation of the hTERT promoter indicating that GRHL2 partially regulates hTERT 
through an epigenetic mechanism (Chen et al., 2010b).  Importantly, GRHL2 is required for the 
upregulation of E-cadherin, claudin 4, and claudin 3, epithelial apical junction complex proteins 
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(Werth et al., 2010; Senga et al., 2012).  Grhl2 binds the Cldn4 promoter and the second intronic 
region of E-cadherin increasing promoter activity in both cases (Werth et al., 2010).  Since 
GRHL2 appears to be the master regulator of the epithelial phenotype, it is not surprising that 
GRHL2 correlates with E-cadherin expression better than any other transcription factor (Werth et 
al., 2010; Kohn et al., 2014), and Grhl2-/-  mice show a reduction in E-cadherin and Cldn4 
expression (Werth et al., 2010).  GRHL2 also suppresses ZEB1 and upregulates mir-200c and 
ESRP1/2 (Cieply et al., 2012; Cieply et al., 2013).  Mir-200c is a microRNA associated with the 
establishment of the epithelial phenotype by suppressing ZEB1 expression (Park et al., 2008b).  
ESRP1 and ESRP2 are responsible for promoting epithelial specific RNA splicing of multiple 
transcripts (Warzecha et al., 2009).  In keratinocytes, GRHL2 and p63, a member of the p53 
family, form a positive feedback loop which is necessary for proper epidermal development, and 
the loss of p63 causes an EMT (Truong et al., 2006; Mehrazarin et al., 2015).    
Both Grhl1-/- and Grhl3-/- mice show epidermal defects (Boglev et al., 2011), however, 
embryonic lethality of Grhl2-/- mice at E11.5 precludes the examination of epidermal defects.  
Grhl2-/+/ Grhl3-/+ mice have defects in epithelial wound repair. Furthermore, GRHL2-/+/ GRHL3-
/- mice have failure of eyelid closure and are born with open eyes. This suggests a defect in 
epithelial cell migration in utero (Boglev et al., 2011).   
GRHL2 prevents keratinocyte terminal differentiation by repressing the epidermal 
differentiation complex (EDC).  GRHL2 blocks the recruitment of Jmjd3, a histone demethylase, 
to the EDC gene promoters (Chen et al., 2012).  GRHL2 is also overexpressed in 
hyperproliferative skin lesions seen in psoriatic tissue (Chen et al., 2012).  A GRHL2 mutation 
causes an autosomal-recessive ectodermal dysplasia syndrome in two consanguineous families 
presenting with hypodontia, enamel hypoplasia, oral hyperpigmentation, nail dystrophy, 
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marginal palmoplantar keratodema, and dysphagia. Also, a fraction of the patients present with 
sensorineural deafness. When the patient’s keratinocytes were cultured, the cells had decreased 
epithelial features including defective epithelial adhesion junction complexes, altered cell 
morphology, mis-localizition of GRHL2 in the cytoplasm, and decreased E-cadherin expression 
(Petrof et al., 2014).  
Function of GRHL2 in neural tube closure 
Both Grhl2 and Grhl3 are involved in the neural tube closure.  In the murine model, 
primary neurulation occurs at three separate closure sites; hindbrain/cervical (closure 1), 
forebrain/midbrain (closure 2), and rostral end of the brain (closure 3).  For neural closure to 
transpire, neural fold elevation must occur in conjunction with non-neural ectodermal-induced 
formation of paired dorso-lateral hinge points (Shum and Copp, 1996).  Grhl2-/- mice exhibit 
failure of the rostral end of the forebrain closure (closure 3) leading to exencephaly and a split-
face malformation.  Grhl2-/- mice fail to produce paired dorso-lateral hinges at which point 
primary neurulation ceases and defects are observed (Rifat et al.), and these results were 
confirmed in subsequent GRHL2 mouse models (Werth et al., 2010; Pyrgaki et al., 2011).  
Grhl3-/- mice produce thoraco-lumbo-sacral spina bifida, but only exhibit exencephaly in 3% of 
the mice (Ting et al., 2003a), and Grhl2 substitution into Grhl3 genome loci did not rescue the 
spina bifida phenotype suggesting non-redundant functions of Grhl2 and Grhl3.  Interestingly, 
Grhl2-/-/Grhl3+/- mice displayed failed forebrain/midbrain closure (closure 2) causing fully 
penetrant exencephaly, and there was no defect in hindbrain/cervical closure (closure 1). This 
data suggest that closure 3 is dependent on Grhl2, closure 2 is dependent on total Grhl2 and 
Grhl3 dose, and closure 1 is independent of Grhl genes (Rifat et al.).  Axial defect, Axd, mice 
present with spina bifida caused by the upregulation of GRHL2, and GRHL2 downregulation in 
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Axd mice prevented the spina bifida (Brouns et al., 2011).  Since both the upregulation and 
downregulation of GRHL2 causes neural tube defects, the expression levels of GRHL2 is critical 
for proper development.  An ENU-induced GRHL2 nonsense mutation results in the previous 
published GRHL2 neural tube defects and previously unobserved defects; 
thoracoabdominoschisis, failure of optic fissure closure, and heart and lung defects (Pyrgaki et 
al., 2011).   The GRHL2 nonsense mutation causes down-regulation of multiple epithelial genes 
including E-cadherin, desmoglein 2, Ep-CAM, ESRP1, and CLDN4 (Pyrgaki et al., 2011).  This 
GRHL2 nonsense mutation causes the non-neural ectoderm to exhibit a mesenchymal phenotype 
leading to the failure of cranial neural fold elevation ultimately causing the GRHL2-associated 
neural tube defects.  The Centers for Disease Control recommends all women with the possibility 
of pregnancy to take folic acid to prevent spina bifida (CDC 1992).  Interestingly, folic acid 
supplementation increases spina bifida in Grhl2+/- mice (Marean et al., 2011). However, GRHL2 
has never been implicated in folic acid metabolism.  Since folic acid has been demonstrated to 
cause epigenetic changes (Li et al., 2011a), it could be downregulating GRHL2 leading to the 
increase in spina bifida incidence.  
Function of GRHL2 in liver 
GRHL2 promotes liver cholangiocytes, but not hepatocytes.  Mature cholangiocyte cells 
form larger cysts in three dimensional culture than liver progenitor cells.  By comparing 
transcription factors differentially regulated between hepatoblasts and cholangiocytes, GRHL2 is 
upregulated in the mature cholangiocytes, and subsequently when expressed in liver progenitor 
cells causes the formation of larger cysts by increasing luminal space.  In two dimensional 
culture, GRHL2 increases transepithelial electric resistance when expressed in the liver 
progenitor cells (Senga et al., 2012).   GRHL2 upregulates CLDN3 and CLDN4 which are 
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important for establishing epithelial cell barrier function.  Expression of CLDN3, but not 
CLDN4, is able to increase cyst lumen size in the liver progenitor cells (Senga et al., 2012).  
Rab25, a vesicle transport protein, increases cyst size and regulates CLDN4 expression and 
localization at cell-cell contacts and tight junctions.  These results were the first to demonstrate 
the role of GRHL2 on tight junctions and regulation of cell polarity, and its importance in 
cholangiocytes (Tanimizu et al., 2013).  During development, neonatal cholangiocytes are able 
to differentiate into hepatocytes and express low levels of GRHL2.  However, adult 
cholangiocytes express high levels of GRHL2 and cannot differentiate into hepatocytes 
(Tanimizu et al., 2013).   The overexpression of GRHL2 in neonatal cholangiocytes prevents 
hepatocyte differentiation, and reciprocally, the knockdown of GRHL2 in adult cholangiocytes 
allows these cells to differentiate into hepatocytes (Tanimizu et al., 2013).  Mir-122 correlates 
with hepatocyte differentiation (Laudadio et al.), and GRHL2 binds and represses the Mir-122 
promoter (Tanimizu et al., 2014).  GRHL2 is responsible for maintaining the cholangiocyte 
phenotype and preventing hepatocyte differentiation.  
Function of GRHL2 in lung  
Drosophila Grh expression finely regulates tracheal elongation and apical membrane 
growth.  Grh depletion results in increased apical membrane growth and longer trachea whereas 
Grh overexpression results in decreased apical membrane growth and shorter trachea.  FGF 
signaling inhibits GRH during apical expansion and elongation (Hemphälä et al., 2003).  In the 
murine model, Grhl2 is expressed in luminal and basal p63+/ Krt5+ epithelial cells of the distal 
lung epithelium.  However, Grhl1 and Grhl3 are expressed in the proximal lung epithelium with 
Grhl1 being expressed in MUC5AC+ goblet cells and Grhl3 being expressed in acetylated 
tubulin ciliated cells (Varma et al., 2012; Gao et al., 2013).  Grhl2 expression co-localizes with 
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Nkx2-1 in alveolar epithelial type II cells.  Nkx2-1 is a homeodomain-containing transcription 
factor essential for lung differentiation that regulates the E-cadherin promoter (Saito et al., 2009; 
Das et al., 2011).  Grhl2 depletion decreases Nkx2-1 expression, and Nkx2-1 knockdown 
decreases Grhl2 expression.  Conversely, Grhl2 binds the Nkx2-1 promoter, and Nkx2-1 binds 
the Grhl2 intronic region forming a positive feedback loop (Varma et al., 2012).  GRHL2 
establishes cuboidal morphology of alveolar type II epithelial cells, and its depletion causes the 
flattening of the cells which resemble alveolar type 1 epithelial cells (Varma et al., 2012).  
Human bronchial epithelial (HBE) cells which express p63+/ Krt5+ basal lung cell markers 
differentiate into mucociliary epithelium without losing GRHL2 expression when cultured on an 
air-liquid interface.  In HBE cells, a GRHL2 dominant negative protein lacking the 
transactivation domain downregulates E-cadherin, TJP1, and CLDN4 and causes the loss of 
transepithelial resistance (Gao et al., 2013).  Mucociliary cells are comprised of Foxj1+ 
multiciliated cells, Scgb1a1+ secretory cells, and p63+/ Krt5+ basal cells, and Grhl2 is expressed 
in all three subtypes.  When Grhl2 is depleted in the progenitor Krt5+/p63+ basal cells, there is a 
decrease in Foxj1+ multiciliated cells suggesting Grhl2 regulates the differentiation of 
multiciliated cells via a Notch3-dependent pathway (Gao et al., 2015).  Grhl2 may play a role in 
idiopathic pulmonary fibrosis where it is downregulated, and lung epithelial cells may undergo 
cell flattening contributing to lung fibrosis (Varma et al., 2014).  
Function of GRHL2 in kidney and placental tubulogenesis  
Grhl2 is present in developing kidney ureteric buds and collecting duct epithelia (Werth 
et al., 2010; Aue et al., 2015).  Grhl2-/- mice demonstrate decreased collecting duct luminal 
expansion, and Grhl2 depletion in mouse inner medullary collecting duct (miMCD) cells 
decreases luminal expansion in three dimensional culture and affects epithelial barrier formation 
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(Aue et al., 2015).  Interestingly, Grhl2 binds and upregulates OVOL2, an epithelial transcription 
factor (Roca et al., 2013), which is able to rescue the epithelial barrier and luminal expansion 
defects in miMCD cells (Aue et al., 2015).   
OVOL2 controls mammary tubulogenesis by regulating the epithelial-mesenchymal 
transition in mammary terminal end buds (Watanabe et al., 2014), presumably downstream of 
GRHL2 regulation.  The depletion of OVOL2 in mammary epithelial cells causes an EMT, 
depletes stem cells reserves, and reduces alveologenesis and milk production (Watanabe et al., 
2014).  Similar to GRHL2, OVOL2 reverts MDA-MB-231 cells back to an epithelial phenotype 
(Cieply et al., 2012; Watanabe et al., 2014).  
GRHL2 also regulates placental branching morphogenesis where it is expressed in the 
basal chorionic trophoblast cells (Walentin et al., 2015).  GRHL2 knockdown leads to the loss of 
basal chorionic trophoblast cell polarity and defects in labyrinth branching morphogenesis.  
GRHL2 upregulates Spint1, serine peptidase inhibitor Kunitz type 1, which regulates placental 
development (Szabo et al., 2006).  
Function of GRHL2 in cancer  
 Our laboratory was the first to demonstrate that GRHL2 is a tumor suppressor in the 
claudin–low breast cancer subtype (Cieply et al., 2012; Cieply et al., 2013).  Multiple other 
publications suggest GRHL2 can act as either a tumor suppressor or an oncogene.  The 
mechanism of GRHL2 on cancer will be presented here to clarify its effects.     
 GRHL2 expression is lost in claudin-low and basal B subtypes of breast cancer which 
exhibit an aggressive EMT phenotype (Cieply et al., 2012).  Constitutive GRHL2 expression 
causes a MET in the MDA-MB-231 breast cancer cell line and the HMLE mesenchymal 
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subpopulation (MSP) cell line.   In breast, ovarian, and colorectal cancers, GRHL2 and ZEB1 
have been shown to form a negative feedback loop where GRHL2 either directly or indirectly 
represses the ZEB1 promoter, and ZEB1 directly represses the GRHL2 promoter (Cieply et al., 
2013; Werner et al., 2013; Quan et al., 2014; Chung et al., 2016).   Furthermore, GRHL2 
prevents Six1, a developmental EMT homeoprotein transcription factor, from transactivating the 
ZEB1 promoter (Cieply et al., 2013).  GRHL2 inhibits TGF-β signaling by inhibiting SMAD 
transcription (Cieply et al., 2012).  GRHL2 also upregulates mir-200a, mir-200b, OVOL1/2 and 
ESRP1/2 (see EMT for discussion) (Cieply et al., 2012; Chen et al., 2016).  In anoikis resistant 
MDA-MB-231 cells and HMLE MSP lines, GRHL2 restores anoikis sensitivity (Cieply et al., 
2012; Farris et al., 2016).   The anoikis sensitizing effect of GRHL2 is partially regulated 
through its downregulation of glutamate dehydrogenase 1 (GLUD1), a mitochondrial enzyme 
that produces α-ketoglutarate.   GLUD1 promotes tumorigenicity in an orthotopic cancer model 
and correlates with advanced stages of breast and lung cancers (Jin et al., 2015).   GRHL2 
represses the GLUD1 promoter through a p300-dependent mechanism (Pifer et al., 2016).   
Upon paclitaxol treatment, GRHL2 suppresses the emergence of the CSC population in 
HMLE and MDA-MB-231 cell lines (Cieply et al., 2013).  This suggests that GRHL2 locks cells 
into an epithelial state preventing the emergence of CSCs thereby inhibiting cancer recurrence.  
In a murine model of drug resistant recurrent tumors, GRHL2 is downregulated in recurrent 
tumors compared to primary tumors (Cieply et al., 2012).  In another study, epithelial SUM149 
breast cancer cells were deprived of glutamine until a metabolically adaptable cell population 
emerged that is resistant to multiple chemotherapeutics and downregulates GRHL2 (Singh et al., 
2014).  The metabolically adaptable cell population exhibits reduction in histone activation 
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marks, H3K4 trimethylation and H3K14 acetylation, which have been previously published to 
correlate with a drug resistant state (Sharma et al., 2010).    
 Werner et al. demonstrate a loss of GRHL2 at the invasive front of breast cancer tumor 
samples, and GRHL2 inversely correlates with lymph node metastasis and higher tumor staging 
(Werner et al., 2013).  The study also anecdotally notes that basal cell carcinoma and non-
invasive bladder cancer have high GRHL2 expression and very rarely metastasize (Werner et al., 
2013).  In ovarian cancer cells, GRHL2 depletion enhances invasion (Chung et al., 2016).  This 
information suggests how the loss of GRHL2 can lead to an EMT and increase in metastasis.    
 However, GRHL2 has also been reported to be associated with poor relapse-free survival 
and metastasis in human breast cancer (Xiang et al., 2012; Yang et al., 2013b).   In Xiang et al, 
GRHL2 knockdown was confirmed to produce an EMT in human mammary epithelial cells.  
However, GRHL2 overexpression in 4T1 murine mammary carcinoma cells causes an increase 
in lung metastasis.  One explanation for this observation is 4T1 cells with GRHL2 form larger 
primary tumors thereby increasing tumor shedding.  Interestingly, GRHL2 is downregulated in 
the metastasis of the parental 4T1 cells arguing against GRHL2’s metastasis enhancing 
properties (Xiang et al., 2012).  In oral squamous cell carcinoma, GRHL2 binds and upregulated 
the hTERT promoter increasing proliferation and promoting tumorigenicity (Kang et al., 2008; 
Chen et al., 2010b).   GRHL2 is amplified in hepatocellular carcinoma and predicts early 
recurrence (Tanaka et al., 2008).  In colorectal carcinomas, GRHL2 expression enhances 
proliferation and correlates with larger tumor size and advanced staging (Quan et al., 2014; Quan 
et al., 2015).  In gastric cancer, an increase in GRHL2 copy number has been demonstrated 
(Cheng et al., 2012).  However, a subsequent study shows GRHL2 is downregulated in gastric 
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cancer and constitutive GRHL2 expression decreases proliferation and enhances apoptosis 
(Xiang et al., 2013). 
 The role of GRHL2 appears to be dependent upon cancer type.  However, it is very clear 
that GRHL2 maintains or establishes the epithelial phenotype in these cancers.   This is usually 
associated with chemotherapeutic susceptibility (See EMT section), and therefore the GRHL2-
expressing cells should be more responsive to classical chemotherapeutic treatment.  
p300 
Discovery of p300/CBP 
p300 and Creb binding protein (CBP) are highly homologous transcriptional co-activators 
that interact with DNA-binding transcription factors on an extraordinary amount of promoters.  
p300 (Ep300,KAT3B) and CBP (Crebbp, KAT3A) form the KAT3 histone acetyltransferase 
family sharing five similar protein interaction domains discussed subsequently (Arany et al., 
1995; Lundblad et al., 1995).   p300 was discovered from its interaction with E1a which 
modulates P300 HAT activity and function (noted previously) (Eckner et al., 1994; Bannister et 
al., 1995; Goodman and Smolik, 2000; Santer et al., 2011).  p300-/- mice die at E9.5-11.5 from 
defects in neurulation and heart development and decreased proliferation of mesenchymal cells, 
erythroid cells, and colony forming cells (Yao et al.; Oike et al., 1999).  CBP was discovered 
from its association with CREB transcription factor (Chrivia et al., 1993).  Because p300/CBP 
are highly redundant, p300/CBP will be referred to as p300 unless specific situations are being 
discussed where the proteins display different functions (Kalkhoven, 2004).   
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Structure of p300 
p300 is a 300kDa protein with 2014 amino acids, and its various domains interact with 
over 400 proteins (Bedford et al., 2010). The domains and structure of p300 are shown in figure 
1.  The nuclear receptor interaction domain (RID) is important for binding of nuclear hormone 
receptors.  p300 has three cysteine/histidine regions, CH1(TAZ1), CH2 (RING and PHD), and 
CH3(ZZ and TAZ2) which each contain two zinc binding motifs with four alpha helices (De 
Guzman et al., 2005a).  CH1(TAZ1) and (CH3)TAZ2 regions are responsible for interaction 
with multiple transcription factors such as HIF1, p73, twist, c-fos, and ets-1 (Frisch and 
Mymryk, 2002; De Guzman et al., 2005b).  The CH2 domain contains two functional domains, 
PHD and RING. The plant homeodomain (PHD) domain is a cysteine-histidine-cysteine motif 
found in many acetyltransferases (Bordoli et al., 2001).  RING (Really Interesting New Gene) 
domains are normally present in ubiquitin E3 ligases.  However in p300, the RING domain 
inhibits the active site of the p300’s histone acetyltransferase domain (HAT) forming an auto-
inhibitory loop (Delvecchio et al., 2013; Ringel and Wolberger, 2013).  Interestingly, p300 
mutations that cause cancer occur in this RING region (Delvecchio et al., 2013).  The kinase 
inducible domain (KIX) is a three helix bundle that interacts with CREB and other transcription 
factors (Chrivia et al., 1993; Thakur et al., 2013).  The bromodomain (Bd) is responsible for 
binding acetyl-lysine residues on histones and transcription factors (Chen et al., 2010a). This 
domain is responsible for forming a stable interaction with chromatin allowing transcriptional 
activation to occur (Manning et al., 2001). The histone acetyltransferase region (HAT) is the 
catalytic region for acetylation, and it will be discussed in greater detail in the p300 function 
section.  p300 C-terminal domain (1665aa-2414aa) can cause transcriptional transactivation, and 
its effects are potentiated by the p300 HAT (Stiehl et al., 2007).  The minimal domain for p300 
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C-terminal transactivation is 2000-2180 aa which includes the IRF-3 binding domain (IBID) also 
known as the SRC1 interaction domain (SID) (2050-2096aa) (Lin et al., 2001; Matsuda et al., 
2004).   The p300 IBID domain cooperates with SRC1, a p160/steroid receptor coactivator 
family member, to activate transcription (Sheppard et al., 2001).  
Functions of p300 
p300 facilitates transcriptional activation by the acetylation of histone tails and/or 
transcription factors via its intrinsic histone/lysine acetyltransferase activity 
(HAT/KAT)(Ogryzko et al., 1996).  Histone acetylation causes relaxation of chromatin structure 
allowing increase accessibility for transcriptional machinery.  In vitro, p300 is able to acetylate 
all four core histones (Ogryzko et al., 1996).  In p300-/- mice, histone 3 lysine 18 and 27 
acetylation is lost demonstrating p300’s specificity for these substrates (Kasper et al., 2010; Jin 
et al., 2011).  p300 also acetylates transcription factors leading to regulation of their function.  
p300 acetylates p53 in response to many stressors causing an increase in p53 DNA binding and 
protein stability (Gu and Roeder, 1997; Knights et al., 2006).  p300 acetylates β-catenin causing 
nuclear localization and increases affinity for TCF4 (Lévy et al., 2004; Chocarro-Calvo et al., 
2013). 
p300 may function as a signal integrator because of the dose limiting amount of p300 in 
the cell, and the multitude of signaling pathways and cellular processes that require p300 for 
transcriptional activation (Yao et al.,1998; Kamei et al., 1996; Vo and Goodman, 2001; Bedford 
et al., 2010).  This is further supported by the fact that a single mutation in CBP allele leads to 
Rubinstein-Taybi syndrome (discussed later) suggesting the protein level of p300 is very 
important (Petrif et al., 1995).  Also, enhanceosomes, a group of proteins that bind and recruit 
co-activators and basal transcription factors to promoters, in some instances contain multiple 
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transcription factors that bind p300 such as the IFN-β enhanceosomes (Merika et al., 1998; Yie 
et al., 1999)  
p300 has been demonstrated to be essential for the differentiation of muscle, erythroid 
lineages, osteoblast, oligodendrocytes, and stem cells (Puri et al., 1997; Oike et al., 1999; Blobel, 
2000; Polesskaya et al., 2001; Narayanan et al., 2004; Teo and Kahn, 2010; Zhang et al., 2016). 
In a similar process to cell differentiation, activator proteins that utilize p300 and additional 
coactivators that interact with p300 have been implicated in the EMT phenotype and tumor 
progression (Matthews et al., 2007; Qin et al., 2009; Santer et al., 2011; Zhou et al., 2012; 
Delvecchio et al., 2013; Ringel and Wolberger, 2013; Yang et al., 2013a; Xu et al., 2014; Cho et 
al., 2015).  The upregulation of matrix metalloproteases (MMPs) is associated with the EMT 
phenotype and contributes to tumor invasion (Radisky and Radisky, 2010).  Many MMPS are 
regulated through p300 and the AP-1 transcription factor axis (Westermarck and Kahari, 1999; 
Sun et al., 2004; Chou et al., 2006; Clark et al., 2008; Lee and Partridge, 2010; Santer et al., 
2011). 
Although the role of p300 in the acetylation of histone has been well researched, the 
effect of p300 on other histone modifications is emerging. Recent results demonstrate p300 
interacts with the SET1 complex through a p53 mediated event to regulate H3K4 trimethylation 
(Tang et al., 2013).  The SET1/MLL family (SET1A, SET1B, SET1C, MLL1, MLL2, MLL3 
and MLL4) is a group of histone methyltransferases responsible for H3K4 monomethylation and 
trimethylation (Yokoyama et al., 2004; Dou et al., 2005; Cho et al., 2007a; Wu et al., 2008).  
The SET1/MLL members are part of the Set1/MLL/COMPASS-like complex which include 
Wdr5, Ash2, RbBp5, and other proteins depending upon which Set1/MLL family member is 
present in the complex (Shilatifard, 2012). H3K4 trimethylation is a necessary, specific marker 
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for active gene transcription on eukaryotic promoters (Santos-Rosa et al., 2002; Ng et al., 2003). 
In the p53/p300/SET1C interaction, p53 recruits p300 to chromatin, and then p300 acetylates H3 
and binds the acetyl-lysine residues via p300’s bromodomain stabilizing the interaction.  Both 
p53 and p300 directly interact with SET1C and enhance the H3K4 trimethylation of the 
promoter. The p53/p300/SET1C complex promotes H3 acetylation and methylation thereby 
increasing transcription (Tang et al., 2013).  Interestingly, a recent study has demonstrated p300 
is a marker for super-enhancers that place it as a position to control cell state transitions (Witte et 
al., 2015). 
p300/CBP in disease and cancer  
 The loss of one allele of CBP and less frequently, p300, leads to Rubinstein-Taybi 
syndrome (RTS) (Petrif et al., 1995).   RTS occurs in about one in 100,000 live births from 
mostly spontaneous mutations (Roelfsema et al., 2005).   The causative mutation of RTS can be 
located in multiple exons and consist of deletions, insertions, or point mutations in CBP/p300 
(Roelfsema et al., 2005; Roelfsema and Peters, 2007; Viosca et al., 2010).   RTS is characterized 
by dysmorhphic facial features (low hairline, low set ears, arched eyebrows, slanted palpebral 
fissures, arched palate, mild micrognathia. and dental anomalies), enlarged first finger, cervical 
vertebral abnormalities, and RTS patients are at higher risk for sensorineural deafness, optic 
nerve coloboma, enamel hypoplasia, and congenital heart and renal defects (Petrif et al., 1995).   
Specifically relating to cancer, RTS patients are at increased risk of neuroblastoma, 
medulloblastoma, leukemia and lymphoma (Siraganian et al., 1989; Skousen et al., 1996; de 
Kort et al., 2014).  More generally, p300 has been implicated and discussed as a therapeutic 
target for HIV retroviral infections, platelet cell production, heart disease, and diabetes 
(Gusterson et al., 2003; Zhou et al., 2004; Kauppi et al., 2008; Mujtaba and Zhou, 2011).  In 
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these processes, p300 is vital for transcriptional regulation, and inhibition could have therapeutic 
advantages.   
 p300 exhibits both tumor suppressor and oncogenic functions depending on the context it 
is examined (Goodman and Smolik, 2000; Wang et al., 2013; Dancy and Cole, 2015).  As 
discussed previously, RTS patients have increased risk of malignancies during their life. Multiple 
studies have shown the loss of heterozygosity of p300 and/or CBP in cancer cell lines and 
ovarian, colon, and breast cancer samples (Muraoka et al., 1996; Bryan et al., 2002; Tillinghast 
et al., 2003).  p300 mutations have been demonstrated in ovarian, pancreatic, cervical, colorectal, 
and oral squamous tumors or tumor cell lines (Iyer et al., 2001).  Also, CBP loss of 
heterozygosity has been shown to correlate with therapy resistance in acute lymphoblastic 
leukemia (ALL) (Mullighan et al., 2011).  On a molecular level, p300 interacts with and 
promotes the function of known tumor suppressors, p53 and retinoblastoma protein (Gu and 
Roeder, 1997; Grossman, 2001; Iyer et al., 2007).   
 On the other hand, p300 overexpression has also been correlated with cancer progression.   
In nasopharyngeal carcinoma, hepatocellular carcinomas, and prostate cancer, increased p300 
levels lead to poor prognosis and increased aggressiveness of the cancer (Debes et al., 2003; Li 
et al., 2011b; Santer et al., 2011; Liao et al., 2012).   In breast cancer, p300 is overexpressed in 
invasive ductal carcinomas (Hudelist et al., 2003; Vleugel et al., 2006).  In melanoma, 
cytoplasmic localization instead of nuclear localization of p300 is associated with aggressiveness 
and poor prognosis (Rotte et al., 2013).  p300/CBP can also fuse with the mixed lineage 
leukemia (MLL) and monocytic leukemia zinc finger (MOZ) genes to form an oncogenic fusion 
protein and target p300 acetyltransferase activity to oncogenic genes in ALL (Borrow et al., 
1996; Ida et al., 1997; Taki et al., 1997).  On a molecular level, p300 is involved in the 
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transcriptional machinery of multiple oncogenic proteins including AP-1 complex (c-jun and c-
fos), c-myb, and human T-cell leukemia virus (Arias et al., 1994; Bannister et al., 1995; Dai et 
al., 1996; Zhao et al., 2011). As discussed previously, p300 is very context dependent in its role 
in cancer.  Because p300/CBP is a global transcriptional activator that can interact with both 
oncogenic and tumor suppressors, these effects should not come as a surprise.  
Inhibitors of p300 HAT Function 
 The HAT domain of p300 is responsible for the acetylation of proteins. The p300 
acetyltransferase domain uses acetyl-CoA and a lysine containing protein (usually histones) to 
form an acetyl-lysine-containing protein and coenzyme A with a sulfhydryl functional group 
(Dancy and Cole, 2015).   The acetylation step occurs in the HAT active site containing six 
acidic residues, and the lysine residue of the protein to be acetylated is usually surrounded by 
basic amino acids (Liu et al., 2008).  The acetyltransferase reaction is predicted to occur through 
a Theorell-Chance, hit-and-run catalytic, mechanism which involves no stable ternary complex 
and transient peptide substrate association (Cleland, 1963; Liu et al., 2008). 
 Lys-CoA, a bisubstrate of acetyl-lysine and coenzyme A, was the first potent 
acetyltransferase inhibitor identified and works by interacting with both individual substrate sites 
of p300, simultaneously (Lau et al., 2000).  Lys-CoA is highly specific for p300/CBP, but Lys-
CoA and its derivatives are not cell permeable making it ill-suited for therapeutics (Dancy and 
Cole, 2015).  Many natural chemicals have been suggested as acetyltransferase inhibitors.  
Anacardic acid, a salicylic acid with an alkyl chain, is derived from geraniums, cashew shells, 
and mango and has broad effects on all KAT families (Balasubramanyam et al., 2003; Ghizzoni 
et al., 2012).  Curcumin, two phenols connected by two carbonyls, is derived from turmeric and 
has acetyltransferase inhibitor affects in the p300/CBP and MYST HAT families 
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(Balasubramanyam et al., 2004b).  Garcinol, a polyisoprenylated benzophenone, is derived for 
Garcinia indica and is a potent inhibitor of p300 and PCAF. However, Garcinol is cytotoxic, but 
some of its derivatives show promise (Balasubramanyam et al., 2004a).  Other natural HAT 
inhibitor have been discovered, but they have broad specificity and only modest potency to all 
the HAT families which chemical modifications have not improved (Varier et al., 2004; Choi et 
al., 2009). 
 Since 2005, synthetic inhibitors for p300 HAT activity have been emerging.  
Isothazolone analogs were demonstrated to inhibit acetyltransferases, but these chemicals 
inhibited PCAF more potently than p300 (Stimson et al., 2005; Dekker et al., 2009).  Quinolone 
compounds also inhibit acetyltransferases and some of these analogs have modest potency for 
CBP and p300 (Mai et al., 2006; Mai et al., 2009).  The most promising compound, C646, has 
three aromatic rings and a benzoic acid and is a potent inhibitor of p300/CBP with great 
specificity over other HAT families (Bowers et al., 2010).  C646 appears to compete for the 
acetyl-CoA binding site and not the peptide substrate, and C646 has inhibitory effects on 
acetylation in cells (Santer et al., 2011).   
Although more than four hundred proteins interact with p300 and utilize it as a co-activator, 
the inhibitory effect of GRHL2 on p300 is nearly unique, shared by only one other family of 
proteins called the E1a-like inhibitor of differentiation (EID) proteins.  EID1 inhibits p300 HAT 
activity (MacLellan et al., 2000) and EID3 blocks the SRC-1/CBP interaction, while the 
mechanism of EID2 is controversial (Ji et al., 2003; Miyake et al., 2003; Båvner et al., 2005).  The 
effects of EID proteins upon EMT or tubulogenesis have not yet been investigated to our 
knowledge. 
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MDCK tubulogenesis 
The opposing roles of GRHL2 in establishing the epithelial state vs. p300 in differentiation -- 
including EMT -- motivated us to investigate a potential role for GRHL2 in inhibiting p300 
function.  Kidney tubulogenesis is contingent upon temporal and spatial regulation of epithelial 
cells in which GRHL2 plays a critical organizing role.  Furthermore, GRHL2 is expressed in the 
ureteric buds of the developing kidney (Schmidt-Ott et al., 2005; Aue et al., 2015; Walentin et 
al., 2015).  Madin-Darby Canine Kidney (MDCK) tubulogenesis in response to HGF models 
some aspects of kidney collecting duct tubulogenesis in vivo and requires a transient, partial 
EMT (pEMT) (Pollack et al., 1998; O'Brien et al., 2002; Pollack et al., 2004; Leroy and Mostov, 
2007; Hellman et al., 2008; Jung et al., 2012; Zhang et al., 2014). Kidney development involves 
multiple signaling pathways  (GDNF, FGFs, BMP4, HGF, and Gremlin) with glial cell line-
derived neurotrophic factor (GDNF) and its receptor, RET, being the most important (Costantini 
and Kopan, 2010). However, RET receptor is not expressed in MDCK cells.  HGF causes 
MDCK cells to undergo cell scattering in two-dimensional culture, and induces tubulogenesis of 
MDCK cysts that form in a three-dimensional collagen gel (Wang et al., 1990, Pollack et al., 
2004). Induction of MMP1 and MMP13 by HGF through AP1/p300 complexes is required for 
tubulogenesis in the MDCK model (Benbow and Brinckerhoff, 1997; Clark et al., 2008; Hellman 
et al., 2008; Chacon-Heszele et al., 2014).  Targeted knockout studies indicate a role for 
HGF/Met signaling in kidney development, and  HGF/Met signaling is a potent stimulator of 
Wnt signaling,  a crucial signaling pathway in kidney development, validating the in vivo 
relevance of this approach (Monga et al., 2002; Bridgewater et al., 2008; Ishibe et al., 2009).     
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Figure 1. p300 protein. A. Domains of p300 B. Ribbon and surface representations of p300 core structures. 
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Reprinted by permission from Macmillan Publishers Ltd: [Nature Structural and Molecular 
Biology], Structure of the p300 catalytic core and implications for chromatin targeting and HAT 
regulation, 3856130394085, 2013  
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Abstract 
 Developmental morphogenesis and tumor progression require a transient or stable 
breakdown of epithelial junctional complexes to permit programmed migration, invasion and 
anoikis-resistance, characteristics endowed by the Epithelial-Mesenchymal Transition.  The 
epithelial master-regulatory transcription factor Grainyhead-like 2 (GRHL2) suppresses and 
reverses EMT, causing a mesenchymal-epithelial transition to the default epithelial phenotype.  
Here, we investigated the role of GRHL2 in tubulogenesis of Madin-Darby Canine Kidney 
(MDCK) cells, a process requiring transient, partial EMT.  GRHL2 was required for 
cystogenesis, but it suppressed tubulogenesis in response to Hepatocyte Growth Factor (HGF).  
Surprisingly, GRHL2 suppressed this process by inhibiting the histone acetyltransferase co-
activator, p300, preventing the induction of matrix metalloproteases and other p300-dependent 
genes required for tubulogenesis.  A thirteen amino acid region of GRHL2 was necessary and 
sufficient for the inhibition of p300, the suppression of tubulogenesis and the interference with 
EMT.  The results demonstrate that p300 is required for the partial or complete EMT occurring 
in tubulogenesis or tumor progression, and that GRHL2 suppresses EMT in both contexts, 
through inhibition of p300. 
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INTRODUCTION 
p300 is a co-activator of transcription that interacts with at least four hundred DNA-
factors to activate transcription from thousands of enhancers/promoters, mostly contingent upon 
its intrinsic histone acetyltransferase (HAT) activity.  In this context, it is viewed as an 
“integrator” factor that serves as a nexus among multiple signaling pathways and programs of 
gene expression (Yao et al.; Kamei et al., 1996; Vo and Goodman, 2001; Bedford et al., 2010).  
Accordingly, p300/CBP null mice die at E9.5-11.5 with massive deficits of mesenchymal cells 
and erythroid cells, as well as defects in neurulation and heart development (Yao et al.; Oike et 
al., 1999).  p300 is essential for the differentiation of muscle, erythroid lineages, osteoblast, 
oligodendrocytes, and stem cells (Puri et al., 1997; Oike et al., 1999; Blobel, 2000; Polesskaya et 
al., 2001; Narayanan et al., 2004; Teo and Kahn, 2010; Zhang et al., 2016).  A recent study has 
demonstrated p300 is a marker for super-enhancers, positioning it to control cell state transitions 
(Witte et al., 2015).  
Grainyhead-like 2 (GRHL2) is one of the three genes comprising a family of mammalian 
transcription factors related to Drosophila Grainyhead, the first zygotically encoded transcription 
factor expressed during the maternal to zygotic transition (the MZT) (Harrison et al.). GRHL2 is 
important for epithelial barrier assembly in, for example, the morphogenesis of kidney collecting 
ducts, placenta, lung alveoli and the mammary gland ductal system (through OVOL2, a GRHL2 
target gene) (Gao et al., 2013; Watanabe et al., 2014; Aue et al., 2015; Walentin et al., 2015). 
Grainyhead factors are also critical for diverse developmental events that involve the formation 
of epithelial barriers, including epidermal assembly, neural crest formation, and, in the adult, 
wound-healing (Wilanowski et al., 2002; Gustavsson et al., 2008; Wang and Samakovlis, 2012; 
Mlacki et al., 2015). GRHL2 activates the expression of multiple genes encoding epithelial cell 
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adhesion molecules (e.g., E-cadherin, desmosomal proteins, tight junction proteins), and due to 
its widespread expression, may be generally important for enforcing an epithelial phenotype 
(Rifat et al.; Senga et al.; Wilanowski et al., 2002; Ting et al., 2003; Ting et al., 2005; Auden et 
al., 2006; Werth et al., 2010; Boglev et al., 2011; Cieply et al., 2012; Tanimizu and Mitaka, 
2013; Aue et al., 2015).  Correspondingly, GRHL2 expression plays an important role in 
suppressing the oncogenic EMT, thereby functioning as a tumor suppressor that enhances 
anoikis-sensitivity (Cieply et al., 2012; Cieply et al., 2013; Mlacki et al., 2015); in fact, the gene 
most tightly correlated with E-cadherin expression in human tumors was GRHL2 (Kohn et al., 
2014).   
 The opposing roles of GRHL2 in establishing the epithelial state vs. p300 in differentiation -
- including EMT -- motivated us to investigate a potential role for GRHL2 in inhibiting p300 
function. Kidney tubulogenesis is contingent upon temporal and spatial regulation of epithelial 
cells, in which GRHL2, which is expressed in the ureteric buds of the developing kidney plays a 
critical organizing role (Schmidt-Ott et al., 2005; Aue et al., 2015; Walentin et al., 2015). 
Madin-Darby Canine Kidney (MDCK) tubulogenesis in response to hepatocyte growth factor 
(HGF) models some aspects of kidney collecting duct tubulogenesis in vivo and requires a 
transient, partial EMT (pEMT) (Pollack et al., 1998; O'Brien et al., 2002; Pollack et al., 2004; 
Leroy and Mostov, 2007; Hellman et al., 2008; Jung et al., 2012; Zhang et al., 2014). HGF 
causes MDCK cells to undergo cell scattering in two-dimensional culture, and induces 
tubulogenesis of MDCK cysts that form in a three-dimensional collagen gel (Wang et al., 
1990,1991 #4686; Pollack et al., 2004). Induction of MMP1 and MMP13 by HGF through 
AP1/p300 complexes is required for tubulogenesis in the MDCK model (Benbow and 
Brinckerhoff, 1997; Clark et al., 2008; Hellman et al., 2008; Chacon-Heszele et al., 2014).  
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Targeted knockout studies indicate a role for HGF/Met in kidney development, and, relatedly, 
HGF/Met signaling is a potent stimulator of Wnt signaling,  a crucial signaling pathway in this 
process, validating the in vivo relevance of this approach (Monga et al., 2002; Bridgewater et al., 
2008; Ishibe et al., 2009).  
Herein, we report that GRHL2 promoted cystogenesis but suppressed tubulogenesis. GRHL2 
protein interacted functionally with p300, inhibiting its HAT activity and transcriptional 
activation of target genes, including matrix metalloproteases.  A small (thirteen amino acid) 
sequence of GRHL2 was important for inhibition of p300, suppression of tubulogenesis and the 
reversal of EMT.  These results mechanistically position GRHL2, an enforcer of the epithelial 
default phenotype, as an antagonist of p300, a co-activator of differentiation-specific genes, with 
important ramifications for developmental and tumor biology. 
 
RESULTS 
GRHL2 suppresses cell scattering and tubulogenesis 
 In light of the epithelial programming role of GRHL2, we tested the effect of HGF on 
GRHL2 levels in MDCK cells.  Interestingly, we found that HGF down-regulated the expression 
of endogenous GRHL2 protein levels at early time points (figure 1A).  When constitutively 
expressed in MDCK cells, GRHL2 significantly inhibited HGF-induced cell scattering compared 
to vector control cells (figure 1B).  Conversely, MDCK cells with GRHL2 shRNA knockdown 
demonstrated enhanced HGF-induced cell scattering; retention of E-cadherin expression showed  
that EMT did not occur in response to the knockdown of GRHL2 alone (figure 1C and see video 
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in supplemental figure S1).  GRHL2 had only modest effects on the phosphorylation status of 
two established HGF/Met signaling mediators, Erk and Akt (figure S2).   
We then examined the effects of GRHL2 on HGF-induced tubulogenesis in the three-
dimensional collagen model.  GRHL2 expression caused the formation of larger cysts compared 
to vector control cells, consistent with previous reports in hepatic bile duct cells (figure 1D) 
(Tanimizu and Mitaka, 2013).  GRHL2 significantly suppressed tubulogenesis/branching 
morphogenesis following HGF treatment (figure 1D); a similar effect of murine Grhl2 was 
observed in mouse inner medullary collecting duct cell line (figure S3A), indicating the 
important role of GRHL2 down-regulation in tubulogenesis.  Conversely, the stable knockdown 
of GRHL2 prevented cystogenesis (figure S3B), presumably by down-regulating epithelial 
adhesion molecules (Senga et al.; Werth et al., 2010).  Transient knockdown of GRHL2 
following cyst formation using a doxycycline-induced shRNA vector, however, clearly indicated 
that the loss of GRHL2 promoted tubulogenesis (figure S4A).  There was no effect of the 
GRHL2 shRNA on cell proliferation (figure S4B).  These results indicated that GRHL2 
suppressed HGF-activated cell scattering and tubulogenesis. 
GRHL2 suppresses the expression of matrix metalloproteases 
 To identify GRHL2 target genes responsible for the attenuation of cellular responses to 
HGF/Met signaling, RNA-Seq was used to compare MDCK cells with constitutive GRHL2 
expression vs. GRHL2 depletion, either with no treatment or with HGF induction (24 hours).  
This experimental scheme allowed for two distinct comparisons:  genes regulated by HGF in the 
absence vs. presence of GRHL2, and genes regulated by GRHL2 with vs. without HGF 
induction.  GRHL2 down-regulated several known matrix metalloproteases (MMP) family 
members (Table 1, confirmed by qPCR in figure 2A).  In light of the established importance of 
 67 
specific MMPs for tubulogenesis in the MDCK and mIMCD-3 cell culture models (Hotary et al., 
2000; Jorda et al., 2005; Hellman et al., 2008; Chacon-Heszele et al., 2014), we verified their 
importance for branching tubulogenesis in embryonic kidneys cultured ex-vivo using the 
generalized MMP inhibitor, batimastat (figure S5).  The down-regulation of MMPs by GRHL2 
could contribute significantly to the tubulogenesis-suppressing effect of constitutive GRHL2 
expression, although additional contributions from EMT/MET-related GRHL2 genes are likely. 
 To investigate the transcriptional mechanisms of MMP gene regulation by GRHL2, 
MMP1 and MMP14 promoters were assayed as luciferase reporter constructs by cotransfection 
in HT1080 fibrosarcoma cells, in which the endogenous MMPs are expressed constitutively 
(Tang and Hemler, 2004; Nonaka et al., 2005).  GRHL2 was found to suppress MMP1 and 
MMP14 promoters using adenovirus E1a protein, a known repressor of MMP genes, as a positive 
control (figure 2B).  These results demonstrated that GRHL2 repressed MMP1 and MMP14 
promoters; however, examination of the promoter sequences utilized in our reporters constructs 
did not indicate the presence of GRHL2 DNA binding consensus sites (Wilanowski et al., 2002; 
Gao et al., 2013; Aue et al., 2015; Walentin et al., 2015), suggesting a more subtle mechanism 
for repression not involving direct DNA binding.  
GRHL2 inhibits p300 function 
 The AP-1 transcription factor family is important in the regulation of most MMP genes 
(Clark et al., 2008).  GRHL2 significantly suppressed AP-1 activity on minimal reporter 
constructs in HT1080 and 293 cells (figure 3A).  GRHL2 did not appear to affect the expression 
of FOS or JUN family members following HGF induction (figure S6).  
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 In light of the functional similarities between adenovirus E1a and GRHL2 (see 
Discussion), we compared a published list of genes that E1a down-regulated through p300 
interaction (Ferrari et al., 2014) against our list of GRHL2-downregulated genes; this latter list 
was derived from the RNA-seq analysis that we performed on GRHL2-expressing human 
mesenchymal subpopulation cells (MSP), reported in (Farris et al., 2016) (as comparison of 
canine vs. human gene lists proved uninformative for technical reasons).  About 43.5% of the 
genes that E1a repressed through p300 were also repressed by GRHL2 (figure 3B). Downstream 
Effector Analysis/Ingenuity Pathway analysis revealed that the expression of GRHL2 suppressed 
the regulation of numerous p300-associated genes that were up-regulated or down-regulated by 
HGF in the absence of GRHL2 expression (figure 3C and figure S7).  These results suggested 
that GRHL2 could potentially inhibit p300 function. 
 To investigate this,  the effect of GRHL2 upon the activity of a GAL4-DNA binding 
domain-p300 fusion protein was assayed by transient transfection using a GAL4-responsive 
luciferase promoter, an established method for testing p300 coactivator function without 
confounding effects from primary DNA binding activator proteins (Snowden et al., 2000).  
Adenovirus E1a protein repressed the AP-1 and GAL4/GAL4-p300 reporter activities, but a 
p300-non-binding mutant of E1a (Ferrari et al., 2014) failed to do so (figure S8), validating the 
p300-dependence of transcription in these assays.  GRHL2 inhibited the co-activator function of 
p300 in this assay (figure 3D).  As additional negative controls, GRHL2 did not affect the ability 
of a p300-independent GAL4-activator fusion protein (VP16-GAL4; (Kutluay et al., 2009)) to 
activate the same reporter; another transcription factor unrelated to GRHL2, c-Myc, failed to 
inhibit GAL4-p300 function in this assay (figure S9). These results indicated that GRHL2 was a 
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potent suppressor of p300 function.  The highly related GRHL1 and GRHL3 proteins were found 
to have similar effects in the reporter assay (figure S10). 
GRHL2 inhibits the histone acetyltransferase (HAT) activity of p300 
 The HAT domain of p300 acetylates numerous substrates, including lysines 18 and 27 in 
the N-terminal tail of histone 3 (H3) (Ogryzko et al., 1996; Kasper et al., 2010; Jin et al., 2011).  
Using recombinant proteins, GRHL2 inhibited acetylation of H3K27 by p300 in a dose-
dependent manner in vitro (figure 4A).  Similar results were obtained using the p300 HAT 
domain alone (amino acids1283-1673) rather than full-length p300 (figure S11).  Recombinant 
GRHL1 and GRHL3 proteins also inhibited the HAT activity of p300 (figure S12). 
To confirm these in vitro effects in cells, we analyzed histone acetylation by CHIP-qPCR 
using the human cell line, HT1080 (as Encode reference data reporting histone acetylation are 
available for the human genome.) Consistent with the in vitro results, the acetylation of H3K27 
was inhibited in HT1080 cells expressing GRHL2 constitutively, specifically on promoters that 
GRHL2 repressed, including MMP1, MMP14, MMP2, and ZEB1; acetylation of GRHL2-
upregulated gene promoter-associated H3K27 was either not affected (CDH1, ESRP1) or up-
regulated (RAB25) (figure 4B).  Unlike the effect of E1a on p300, there was neither an effect of 
GRHL2 on global H3 acetylation nor global chromatin condensation, assayed by Western 
blotting (figure 4B) or by immunofluorescent localization of a LacI-mCherry-GRHL2 protein 
(Ferrari et al., 2014), respectively (figure S13). 
GRHL2 interacted with p300 by the criteria of co-immunoprecipitation of transiently co-
transfected genes, or of endogenous proteins (figure 4C).  The recombinant proteins interacted 
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only weakly, however (figure S14) suggesting that the interaction is transient or requires post-
translational modifications absent from our recombinant proteins. 
GRHL2 inhibits the C-terminal transactivation domain of P300  
Multiple domains of p300 can co-activate transcription independently.  One of these is 
the C-terminal domain (1665aa-2414aa) which interacts with the p160 family of co-activators 
(Stiehl et al., 2007).  Previous reports suggested that the activity of the C-terminal domain is 
stimulated by auto-acetylation, catalyzed by the p300 HAT domain (Stiehl et al., 2007).  In light 
of the HAT-inhibitory effect of GRHL2 described above, we hypothesized that GRHL2 inhibited 
the C-terminal domain through this mechanism.  We confirmed that transcriptional activation by 
the C-terminal domain, assayed as a GAL4-C-term fusion protein, was stimulated by a co-
transfected p300 HAT domain, and that the latter domain had no detectable ability to activate 
transcription independently (figure 5A).  GRHL2 inhibited the enhanced transactivation by the 
p300 C-terminal domain in the presence of co-transfected p300 HAT (figure 5B).  Embedded 
within the C-terminal domain is a small sub-domain called the IRF-3 Binding Domain (IBID; 
amino acids 2050-2096) that mediates the interaction with the p160 co-activator family, 
including the family member Steroid Receptor Coactivator-1 (SRC-1) (Sheppard et al., 2001).  
While neither the IBID domain of p300 nor SRC-1 alone activated transcription efficiently, the 
combination of both activated transcription, as reported previously (figure 5C) (Sheppard et al., 
2001).  GRHL2 potently inhibited transcription that was driven by the complex of p300-IBID 
and SRC-1 (figure 5D).  Interestingly, mutation of the two lysines (K2086 and K2091) of the 
IBID domain that are acetylated in vivo abrogated the ability of the p300-IBID/SRC1 complex to 
activate transcription (figure 5E).  These results indicate that the transcriptional activation by the 
p300 C-terminus -- which is supported by SRC-1 and abrogated by GRHL2 – depends upon 
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acetylation of at least these (and probably other) lysines by p300 HAT, or perhaps other GRHL2-
sensitive HATs that remain to be determined. 
A small region of GRHL2 inhibits p300 and is critical for suppressing tubulogenesis and EMT 
To identify the region of GRHL2 responsible for p300 inhibition, whole domains of 
GRHL2 were deleted initially (figure 6A) and assayed for inhibition of HAT activity and 
transcriptional activation by GAL4-p300.  In light of the lack of GRHL2 binding sites in most 
GRHL2-repressed promoters (data not shown), the surprising result was that the DNA binding 
domain (amino acids 245-494) was critical for inhibition (figures S15, S16).  GST-GRHL2 
protein sub-fragments derived from the DNA binding domain were assayed for HAT inhibition 
(figure 6B). The region 325-475aa, and within that, the thirteen amino acid sequence 425-437aa, 
inhibited HAT activity potently (figure 6C), and a synthetic peptide (aa420-442) was also able to 
inhibit p300 HAT activity (figure S15C).  The 425-437 fragment (IRDEERKQNRKKG) is an α-
helix conserved amongst GRHL1, GRHL2, and GRHL3 (Kokoszynska et al., 2008).  A GRHL2 
∆425-437 construct (with a synthetic nuclear localization signal) was unable to repress an AP-1-
promoter, GAL4-P300 transactivation (assayed on a GAL4-Luc reporter), the MMP1 promoter 
or the MMP14 promoter (figure 6D).  We recently reported that GRHL2 repressed the expression 
of the glutamate dehydrogenase-1 gene (GLUD1), with important consequences for metabolism 
and anoikis (Farris et al., 2016).  Interestingly, GRHL2 also repressed this promoter in a manner 
that required amino acids 425 to 437 (figure S17).  GRHL2 ∆425-437 was still able to interact 
with p300 in a co-transfection assay, however (figure S18). 
We hypothesized that the inhibition of p300 function could provide a mechanism for 
some aspects of transcriptional reprogramming by GRHL2.   Consistent with the inability of the 
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GRHL2 ∆425-437 to repress the AP1-dependent promoters MMP1 and MMP14 (figure 6C), this 
mutant was unable to suppress HGF-induced tubulogenesis in MDCK cells (figure 7A).  
Moreover, wild-type GRHL2 reverses EMT in Mesenchymal Subpopulation (MSP) cells, a 
cancer stem cell-like subpopulation derived from the mammary epithelial cell line HMLE 
(Cieply et al., 2012; Cieply et al., 2013).  The GRHL2 ∆425-437 mutant failed to reverse EMT, 
by the criteria of cell morphology as well as EMT marker protein and mRNA expression (figure 
7B).  These results indicated that the inhibition of p300 by GRHL2 contributes significantly to 
transcriptional reprogramming involved in both tubulogenesis and EMT (figure 8). 
DISCUSSION 
Previously, we proposed that the epithelial cell is the default phenotype from both 
developmental and cancer biologic points of view.  Under this hypothesis, the epithelial 
phenotype is adopted automatically by a cell in the absence of genomic/epigenetic alterations or 
inductive differentiation signaling (Frisch, 1997). Consistent with this idea, E-cadherin-
expressing cells are the first to emerge at the late two cell stage; these eventually give rise to all 
differentiated cell types of the adult organism (Hyafil et al., 1980; Vestweber and Kemler, 1985; 
Fleming et al.,1989; Larue et al., 1994). The adenovirus-5 E1a protein, which interacts with and 
negatively modulates p300, enforces an epithelial phenotype, suppresses EMT, enhances anoikis, 
suppresses MMP expression, and exerts a ubiquitously acting tumor suppression effect in human 
tumor cells (Frisch and Mymryk, 2002). 
The default idea has been invoked in recent studies from other laboratories, to explain, 
for example, the mesenchymal-epithelial transition (MET) occurring at metastatic sites (Thiery 
and Sleeman, 2006; Polyak and Weinberg, 2009; Tam and Weinberg, 2013). The default 
hypothesis could be explained molecularly if critical co-activators such as p300 were required 
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for differentiation-specific but not epithelial-specific gene expression (Frisch, 1997).  
Accordingly, we reported previously that GRHL2, shown here to antagonize the co-activator 
p300, inhibits and reverses the oncogenic EMT, suppressing tumor initiation, drug-resistance and 
anoikis-resistance (Cieply et al., 2012; Cieply et al., 2013).    
The novel observation that GRHL2 antagonizes p300-dependent pathways in the context 
of tubulogenesis provides a potentially unifying mechanism for both the developmental and 
oncologic effects of GRHL2.  GRHL2 probably regulates tubulogenesis by additional, p300-
independent mechanisms.  For example, cells which fail to down-regulate GRHL2 appropriately 
may fail to down-regulate cell adhesion molecules in response to morphogenic factors (Werth et 
al., 2010; Senga et al., 2012).  For example, E-cadherin relocalizes from cell junctions to diffuse 
membrane pattern in protrusive cell extensions during tubulogenesis; this relocalization might be 
envisioned to require GRHL2 down-regulation and subsequent loss of junctional complex 
components in these specific cells (Pollack et al., 1998).   
p300 contributes to tubulogenesis and cancer-related EMT in multiple important ways 
providing a mechanism for GRHL2, via inhibition of p300, to suppress these processes.  With 
regard to cancer, transcription factors that utilize p300/CBP and additional coactivators that 
interact with p300/CBP have been implicated in the oncogenic EMT, tumor drug-resistance and 
tumor recurrence (Matthews et al., 2007; Qin et al., 2009; Santer et al., 2011; Zhou et al., 2012; 
Delvecchio et al., 2013; Ringel and Wolberger, 2013; Yang et al., 2013; Xu et al., 2014; Cho et 
al., 2015). The upregulation of matrix metalloproteases (MMPs) associated with the oncogenic 
EMT requires AP-1, Ets and other p300-dependent factors (Westermarck et al., 1999; Sun et al., 
2004; Chou et al., 2006; Clark et al., 2008; Lee and Partridge, 2010; Santer et al., 2011).   
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 With regard to tubulogenesis, the p300-dependent Ets family transcription factors Etv4 
and Etv5, are key transcriptional regulators of this developmental process (Yang et al., 1998; 
Jayaraman et al., 1999; Goel and Janknecht, 2003; Foulds et al., 2004; Lu et al., 2009; Oh et al., 
2012; Wollenick et al., 2012).  In addition, the family of p300-dependent TCF/β-catenin 
transcription complexes is a central hub for Wnt signaling, crucial for nephron induction (Li et 
al., 2007; Bridgewater et al., 2008; Miller and McCrea, 2010; Ma et al., 2012). 
p300 activates transcription through an array of mechanisms; acetylation of histones, 
acetylation of transcription factors, the binding of the p300 bromodomain to acetylated histones to 
promote transcriptional activity, and recruitment of histone methyltransferases (e.g., Set1b 
complex) (Mizzen and Allis; Ogryzko et al., 1996; Gu and Roeder, 1997; Ito et al., 2001; Wolf et 
al., 2002; Stiehl et al., 2007; Chen et al., 2010; Tang et al., 2013). By inhibiting the p300 HAT 
activity, GRHL2 could enforce an inactive state on p300 in at least two ways.  First, p300 HAT 
activity is substantially increased by auto-acetylation of an autoinhibitory loop on the HAT 
domain, which GRHL2 would suppress, stably inhibiting the enzyme (Thompson et al., 2004).  
Secondly, the p300 HAT domain potentiates p300 C-terminal domain (1665aa-2414aa) 
transactivation (Stiehl et al., 2007), which GRHL2 blocked.  The minimal domain for p300 C-
terminal transactivation is amino acids 2000-2180 which include the IRF-3 binding domain (IBID) 
(Lin et al., 2001; Matsuda et al., 2004).  The p300 IBID domain cooperates with SRC1, a 
p160/steroid receptor coactivator family member, to activate transcription (Sheppard et al., 2001).  
By inhibiting the HAT activity of p300, GRHL2 suppressed co-activation by the p300-IBID 
complex, which was highly dependent upon the two known acetylation sites, K2086 and K2091 
for activity.  Interestingly, SRC1-p300 has been shown previously to induce TWIST expression 
and EMT in breast cancer (Qin et al., 2009), and GRHL2 is a potent EMT suppressor.  
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Although more than four hundred DNA binding proteins interact with p300 and utilize it 
as a co-activator, the inhibitory effect of GRHL2 on p300 is nearly unique, shared by only one 
other family of proteins called the E1a-like inhibitor of differentiation (EID) proteins.  EID1 
inhibits p300 HAT activity (MacLellan et al., 2000) and EID3 blocks the SRC-1/CBP interaction, 
while the mechanism of EID2 is controversial (Ji et al., 2003; Miyake et al., 2003; Båvner et al., 
2005).  The effects of EID proteins upon EMT or tubulogenesis have not yet been investigated to 
our knowledge. 
GRHL2 regulates intracellular metabolism and this could indirectly affect p300 by altering 
the levels of the co-factors for p300 HAT, acetyl-CoA or crotonyl-CoA (Li and Li, 2015; Farris et 
al., 2016).  This may provide an additional, more indirect mechanism for GRHL2 to affect p300 
function.  
In summary, p300 and related co-activators are crucial for cells to differentiate. Under the 
default-phenotype hypothesis, this can be extended to critical roles in EMT, in contexts such as 
tubulogenesis and oncogenesis.  The inhibition of p300 by GRHL2 provides a mechanism for 
GRHL2 to enforce the default epithelial phenotype. 
 
MATERIALS AND METHODS 
Cell lines  
293 HEK cells without T antigen (Doug Black, UCLA, Los Angeles), MDCK cells (Clone M8 
described previously in Frisch et al. (Frisch and Francis, 1994), and HT1080 cells (ATCC) were 
cultured in advanced Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) with 10% fetal 
bovine serum (Hyclone) and 1x penicillin-streptomycin-glutamine (PSG) (Invitrogen).  miMCD-
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3 cells (ATCC) cultured in advanced DMEM:Ham’s F12 (Gibco) with 10% fetal bovine serum 
and 1x PSG.  HMLE and HMLE MSP cells were described previously (Cieply et al., 2013).  
Generation of stable cell lines by retroviral transduction and lentiviral transduction  
Full-length GRHL2/pMXS-IRES-Puro and retroviral packaging protocol were described 
previously (Farris et al., 2016).  GRHL2 ∆425-437 was subcloned into pMXS-IRES-Puro from 
GRHL2 ∆425-437-NLS-3xFLAG/pCDNA3.1+.  GRHL2 shRNA/pGipZ and scramble control 
shRNA/pGipz were obtained from Open Biosystems and packaged as previously described 
(Cieply et al., 2012).  The shRNA construct in pTRIPZ was made by subcloning a MluI-XbaI 
fragment from pGIPZ. 
Cell Scattering Assays 
MDCK cells were plated on collagen coated 6 well dishes to give 25% cell confluency on HGF 
induction.  Cells were treated with 60ng/ml recombinant human HGF (RD Systems) in DMEM 
media or fresh DMEM media for the time periods indicated.  The cells were imaged and then 
harvested for protein or RNA analysis.  Images were obtained using a Zeiss Axiovert 200M, 
Axiocam MRM camera, Phase 20x/0.55, RT, Axiovision Rel. 4.8 software.  Cell scattering time 
lapse movies were taken every 15 minutes over a 24 hour period.  Time lapse images were 
obtained using a Nikon Eclipse TE2000-E with Photometrics CoolSNAP HQ2 Monochrome 
CCD with Phase 40x/0.75 objective using Bioptechs Delta T4 Culture Dish Heater, Prior 
ProScan II Encoded Motorized Stage, and OKO LABS Digital Stage Top Incubator (37 degrees 
and 5% CO2).  For each data point, four 40x images were stitched together using 10% overlap 
with background correction in NIS-Elements AR Nikon.  
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Western Blotting 
Protein lysates were incubated at 95 degrees for 5 minutes in 1X SDS lysis buffer (125mM Tris-
HCl, pH 6.8, 0.04% SDS, 0.024% bromophenol blue, 5% β-mercapatoethanol, and 20% 
glycerol).  SDS-Page was run in 4%-20% gradient Novex Tris-Glycine gel (Invitrogen).  
Proteins were electrophoretically transferred to a polyvinylidene difluoride membrane 
(Immobilon) in Tris-Glycine buffer with 5% methanol.  Membranes were blocked for 1 hour in 
1xTBS+ 5% nonfat milk.  Primary and secondary antibodies were incubated in 1xTBS+5% 
nonfat milk+ 0.1% Tween-20.  Primary antibodies were incubated for 2 hour/RT or overnight/4 
degrees at 1:1000 dilution.  Primary antibodies used were: GRHL2, rb (Sigma); β-actin, ms 
(Thermo-pierce); Fibronectin, ms (BD Biosciences); Vimentin, ms ((Santa Cruz Bio-tech 
[SCBT]); β-actin, ms (Sigma); E-cadherin, ms (BD Biosciences); β-catenin, ms (BD 
Biosciences); GAPDH, ms (Origene); acetyl-lysine, rb (Millipore); H3K18AC, rb (Cell 
Signaling [CS]); H3K27AC, rb (CS); total H3, rb (CS); GST, ms (Thermo-pierce); p300,rb 
(SCBT sc-584); p300, rb (SCBT sc-585); FLAG, ms (Sigma); GAL4, rb (SCBT).  Goat anti-
rabbit or anti-mouse horseradish peroxidase conjugated secondary antibodies (Bio-rad) were 
used at 1:3000 dilution and incubated for 1hour/RT.  Western blot membranes were developed 
using ECL-West Pico (Pierce) and analyzed using standard chemiluminescence techniques.  
MDCK Tubulogenesis assay 
MDCK Tubulogenesis assay was performed as previously described (Elia and Lippincott-
Schwartz, 2001).  Briefly, collagen matrix was made by mixing 10x MEM (Invitrogen), 100x PSG, 
23.5 g/L NaHCO3 (Invitrogen), sterile water, and HEPES (Invitrogen) to working concentrations.  
Vitrogen Bovine Collagen (Advanced Biomatrix 5005-b) was added to a final concentration of 2 
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mg/mL.  NaHCO3 was used to bring the solution to pH 7.3 via pH strip indicator (Elia and 
Lippincott-Schwartz, 2001).  In a 24-well plate, 100 µl of working collagen solution was placed 
in a 1.0 micron pore cell culture insert (Falcon) and allowed to solidify for 3 hours in tissue culture 
incubator.  Sub-confluent MDCK cells were trypsinized and counted using Countess Cell counting 
machine (Invitrogen).  Cells were pipetted into the working collagen solution to give a final 
concentration of 5,000 cells/ml.  Then, 250µl of cell/collagen solution was pipetted onto the pre-
solidified collagen matrix in the cell culture insert.  The cell-collagen matrix was allowed to 
solidify for 2 hours at 37 degrees and 5% CO2 and then 250 µl and 500 µl of media were place on 
cell-collagen matrix cell culture insert and in  the 24 well, respectively.  Media were changed every 
3 days.  After 6 days, 60 ng/ml recombinant human HGF was added to indicated wells, and 
branching morphogenesis was monitored by microscopy.  MDCK cyst staining was performed as 
previously described (Elia and Lippincott-Schwartz, 2001), with the only modification being the 
substitution of 7mg/mL fish skin gelatin for Triton X-100 in permeabilization buffer.  Cysts were 
stained with Alexa Fluor 488 Phalloidin (Molecular Probes) and Hoescht 33258 (Molecular 
Probes). Representative 2 day post-HGF images were obtained using a Zeiss 710 Confocal with 
Airyscan, C-Apochromat 40x/1.2 W Corr, room temperature, AxioObserver.Z1 software, and 
Diode 405 and Argon 488 lasers.  Images were processed in Adobe Photoshop.  Tubulogenesis 
was observed by day 2 post-HGF addition and quantified on day 5 post-HGF addition.  
RNA-Seq Assay 
MDCK+GRHL2/pMXS and MDCK+shGRHL2/Gipz cells were plated in collagen-coated 
60mm2 dishes to obtained 25% confluency upon HGF treatment.  Cells were treated with either 
60ng/ml HGF in DMEM complete or DMEM complete media alone for 24 hours; RNA was 
isolated from all four treatment conditions in triplicate using the RNeasy Plus Kit (Qiagen) and 
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quantified using Nandrop (Fischer).  Raw data were aligned to the CanFam3 reference genome 
using TopHat2 (Kim et al., 2013).  For each sample and each gene, the number of reads 
generated from that sample and mapping to that gene were counted using RSamtools.  Genes 
were as defined in the ensembl database v82 (Cunningham et al., 2015).  The resulting count 
table was analyzed using DESeq (Anders and Huber, 2010), performing two independent 
comparisons: samples with HGF compared to those without, with GRHL2 overexpressed, and, 
samples with HGF compared to those without, both expressing GRHL2 shRNA.  Genes were 
considered differentially expressed if they showed a false discovery rate of 0.05 or less and a 
fold change of 1.5 or higher in either direction.  Genes found to be regulated by HGF with 
shRNA against GRHL2, but not found to be regulated by HGF with GRHL2 overexpressed were 
uploaded to Ingenuity Pathway Analysis (Qiagen), where a Core Analysis was performed using 
default settings. 
Quantitative reverse transcription PCR analysis  
MDCK parent, GRHL2/pMXS, and shGRHL2/pGipZ cells were plated on collagen-coated 
60mm2 dishes and treated as indicated.  Cells were harvested using RNAeasy Plus mini kit 
(Qiagen), analyzed using Nanodrop, and converted to cDNA using SuperScript III First-Strand 
Synthesis SuperMix (Invitrogen) with oligo dT primers and 1ug of RNA.  cDNA was analyzed 
using SYBR Green PCR Master Mix on an Applied Biosystems 7500 Real Time PCR System.  
Values reported were determined using the delta delta CT method using canine CBX1 as internal 
control.  Primers were as follows: CBX1-F (AAGTATTGCAAGGCCACCCA), CBX-R 
(TTTTCCCAATCAGGCCCCAA), GRHL2-F (TTCCTCCCCAGGAGAGATGG), GRHL2-R 
(GGCCCAACACACGGATAAGA), MMP1-F (TGACTGGAAAGGTCGACACG), MMP1-R 
(GACCTTGGTGAAGGTCAGGG), MMP3-F (CTGACCCTAGCGCTCTGATG), MMP3-R 
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(GTCCTGAGGGATTTTCGCCA ), MMP13-F (GGACTTCCCAGGGATTGGTG), MMP13-R 
(ATGACACGGACAATCCGCTT), MMP14-F (CCCAGAGGAGGGCATGTTTT), MMP14-R 
(GACTCCCCACCCTTCCAATG), FOS-F (GGGAGGACCTTATCTGTGCG), FOS-R 
(ACACACTCCATGCGTTTTGC), FOSL1-F (ACACCCTCCCTGACTCCTTT), FOSL1-R 
(CTGAAGAGGGCATGGGATTA), FOSB-F (GGAGAAGAGAAGGGTTCGCC), FOSB-R 
(CACAAACTCCAGACGCTCCT), JUN-F (GACCTTCTACGACGATGCCC), JUN-R 
(TTCTTGGGGCACAGGAACTG), JUNB-F (GTGAAGACACTCAAGGCCGA), and JUNB-R 
(AGACTGGGGGAATGTCCGTA).  
Luciferase Reporter Assays  
HT1080 or 293 NOT cells were transiently transfected using Lipofectamine 2000 (Invitrogen) at 
a 1µg DNA: 3µl Lipofectamine ratio.  After 20 minute incubation in 300 µl of Opti-MEM 
(Invitrogen), a total of 1.0 µg of DNA was transfected into a 12 well with DMEM media and re-
feed 4 hours later with DMEM media.  After 28-36 hours post-transfection, the cells were 
washed twice with cold PBS, lysed in 200 µl of 1x Cell Culture Lysis Buffer (Promega), frozen 
for at least 1 hour at -80 degrees, thawed on ice, and centrifuged at 13,200rpm.  The supernatants 
were assayed for luciferase activity (Promega) and β-galactosidase activity as internal control 
(2x β-galactosidase assay reagent, 200mmol/l sodium phosphate, pH 7.3, 2mmol/L MgCl2, 
100mmol/L 2-mercaptoethanol, and 1.33mg/mL o-nitrophenylgalactoside).  MMP1 promoter      
(-1200 to +60) and MMP14 promoter (-1114 to -242) luciferase reporter plasmids were 
generated by subcloning the promoter from genomic DNA using PCR into the pGL3-basic 
luciferase reporter plasmid. Primer sequences were: MMP1prom-F 
(TTATTACTCGAGCCCTCCCTCTGATGCCTCTGA), MMP1prom-R 
(TATATAAAGCTTCTCCAATATCCCAGCTAGGAA), MMP14prom-f 
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(TTATTACTCGAGCCCTTTCTCACGGTCAGCTT), MMP14prom-R 
(TATATAAAGCTTTCTCGCTCTCTCCTCTGGTC).   GRHL2/pcDNA3.1, TK-LacZ and 
E1a/pCDNA3.1 plasmids were described previously (Grooteclaes and Frisch, 2000; Cieply et al., 
2012).  E1A p300 binding mutant was a generous gift from Arnold Berk (UCLA, Los Angeles, 
California) subcloned into pCDNA3.1+.  GRHL2 ∆425-437 was generated by cloning GRHL2 
1-424aa and GRHL2 438-625aa fragments and ligating together with Bglll and then ligating into 
pCDNA3.1+ using BamHI and Sal1.  Primers used were GRHL2-1-424-F 
(TATATAGGATCCATGTCACAAGAGTCGGACAA), GRHL2-1-424-R 
(ATATAAAGATCTTTTTCTTTCTGCTCCTTTGT), GRHL2-438-625-F 
(TAAATTAGATCTAAAGGCCAGGCCTCCCAAAC), GRHL2-438-625-R 
(TTATATGTCGACCTAGATTTCCATGAGCGTGA).  pGL4.44[luc2P/AP1 RE/Hygro] 
(Promega) was used to assay for AP-1 responsive promoter activity and control plasmid was 
pGL4.27 (Promega).  Phorhol 12-myristate 13-acetate (PMA) induction (10ng/mL) 
(ThermoFisher) was used for assaying AP-1 activity in tranfected 293 cells.  Full length p300-
GAL4/VR1012 and EV-GAL4/VR1012 were generous gifts from Neil Perkins (Newcastle 
University, UK); they were assayed on the GAL4 responsive reporter pG5-Luc (Promega).  
GAL4- p300 HAT (1283-1674aa), GAL4- p300C-terminus (1665-2414aa), and GAL4- p300 
IBID (2050-2096) were generated by subcloning PCR fragments (MluI-NotI) into pBIND 
(Promega).  Primer sequences were: p300 c-terminal-F 
(TATATAACGCGTATCGCTTTGTCTACACCTGCAAT), p300 c-terminal-R 
(TTTAAAGCGGCCGCCTAGTGTATGTCTAGTGTAC), p300 HAT-F 
(TATATAACGCGTATAGGAAAGAAAATAAGTTTTCT), p300 HAT-R 
(TTTAAAGCGGCCGCCTAGTCCTGGCTCTGCGTGTGCAG), p300 IBID-F 
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(TATATAACGCGTATGCCTTACAAAACCTTTTGCG), and p300 IBID-R 
(TTTAAAGCGGCCGCCTAATTAGAGTTGGCATACTTGG).  To generate the p300-IBID 
Mutant (K2086A and K2091A), the p300 IBID lysine nucleotide sequences were mutated to 
alanine and flanking Mlu1 and Not1 restriction enzyme were added to the 5’ and 3’ ends, 
respectively.  The sequence was then generated as a gBlock gene fragment (IDT).  The p300 
mutant sequence was 5’ CACAACCAGG ATTGGGCCAG GTAGGTATCA GCCCACTCGC 
ACCAGGCACT GTGTCTCAAC AAGCCTTACA AAACCTTTTG CGGACTCTCA 
GGTCTCCCAG CTCTCCCCTG CAGCAGCAAC AGGTGCTTAG TATCCTTCAC 
GCCAACCCCC AGCTGTTGGC TGCATTCATC GCGCAGCGGG CTGCCGCGTA 
TGCCAACTCT AATCCACAAC 3”.  The IBID mutant fragment was digested and ligated into 
pBIND vector. HA-SRC1/pACTAG was a generous gift from Timothy Beischlag (Simon Fraser 
University, Canada).   
Immunoprecipitation  
GRHL2-STAP contained full-length human GRHL2 fused to a C-terminal myc-Streptavidin 
Binding Peptide-S-Tag sequence derived by ligating a synthetic oligonucleotide containing the 
S-tag to a PCR product containing the myc-SBP tags from the pCeMM-CTAP vector described 
(Burckstummer et al., 2006).  293 NOT cells were plated on collagen coated 6 well dishes and 
transfected using 1µg of empty vector/pCDNA3.1+ or GRHL2-S-TAP/pCDNA3.1+ and 1ug of 
empty vector/VR1012 or p300/VR1012) with 6ul of lipofectamine (Invitrogen) in 300ul of Opti-
MEM (Invitrogen).  Cells were incubated for 4-6 hours with DMEM media, and then refed with 
DMEM media.  After 28 hours post-transfection, cells were lysed in 600µl of cold p300 Lysis 
Buffer (25mM Tris-HCl pH8, 75mM NaCl, 0.5mM EDTA, 10% glycerol, 0.1% NP40, and 
protease inhibitor tablet (Roche)).  Sample lysates were passed through 1ml syringe with 27g 
 83 
needle 3 times and precleared in 4 degree microcentrifuge at 13,200rpm for 10 minutes.  Total 
lysate samples were obtained, mixed 1:1 with 2X SDS Lysis buffer (250mM Tris-HCl, pH 6.8, 
0.08% SDS, 0.048% bromophenol blue, 10% β-mercapatoethanol, 40% glycerol) and heated for 
5 minutes at 95 degrees.  Lysates were precipitated for 2 hours with 40ul of a 50% of S protein-
agarose (EMD Millipore) which had been pre-equilibrated with p300 lysis buffer containing 
10mg/ml BSA.  Immunoprecipitation lysates were washed three times with p300 lysis buffer, 
diluted with 2X SDS lysis buffer, and heated for 5 minutes at 95 degrees.  Lysates were 
processed using previously described western blotting methods.  For endogenous p300 and 
ectopic GRHL2 co-immunoprecipitation, MSP cells with empty vector/pMXS or GRHL2/pMXS 
were used in the experiment.  For endogenous p300 and endogenous GRHL2 co-
immunoprecipitation, parental HMLE cells were used in the experiment.  The co-
immunoprecipitation method was identical between the different cell lines.  For each cell line, 2 
100mm dishes were grown to 80% confluency, washed twice with cold PBS, lysed in 1mL of 
p300 lysis Buffer with protease inhibitors, and passed through 27g needle three times.  After 
lysates were precleared at 13,200rp, 10µg of p300 antibody (SCBT, SC-584) or rabbit IgG 
(Jackson) was added to lysates and incubated overnight on 4 degree wheel.  Pre-equilbrated 
Protein A-Sepharose (45µl) (GE Healthcare) was added and incubated for 90 minutes.  Samples 
were washed 3 times in p300 lysis buffer, added 45ul of 2X SDS lysis buffer, and heated at 95 
degrees for 5 minutes.  Lysates were processed using previously described western blotting 
methods.    
Histone Acetylation Assays  
Histone acetylation reactions contained indicated amounts of recombinant baculovirus flag-
tagged p300 (37.5ng) (Active Motif) or baculovirus p300 HAT (1283-1673) (Sigma), 250ng of 
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H3 (Cayman), 100 µM acetyl-CoA (MP Biomedical), and indicated amounts of prescission 
cleaved GRHL2, GST-GRHL2 or GST alone in 30µl of p300 acetylation buffer (50mM Tris-
HCl pH 8.0, 1mM DTT, 0.1mM EDTA, 10% glycerol and protease inhibitor).  Acetylation 
reactions were incubated for 15 minutes at 30 degrees on heat block.  Reactions were diluted 
with 2x SDS Lysis buffer and incubated for 5 minutes at 95 degrees.  Lysates were processed 
using previously described western blotting methods.    
Recombinant protein purification  
Full length GRHL2 was subcloned into pGEX-6P-3 vector (GE Healthcare) and transformed in 
to BL21 bacteria (Invitrogen).  GRHL2 fragments were subcloned into pGEX-6p-3 using 
BamH1 and Sal1.  A colony was selected and grown in 20mL of LB+amp overnight at 37 
degrees.  The following day, 10 mL of culture was inoculated into 500 mL of LB+amp and 
incubated for approximately 2 hours at 37 degrees with shaking until OD~ 0.6 was obtained.  
IPTG was added to final concentration of 0.1mM and incubated overnight on shaker at room 
temperature.  The bacteria were spun in chilled centrifuge for 10 minutes at 5000rpm. Bacterial 
pellet was resuspended in 10 mL of BL21 lysis buffer (1xPBS, 1% Triton-100, 1mM DTT, 0.4% 
lysozyme and protease inhibitor tablet), incubated for 10 minutes, and sonicated twice for 30 
seconds.  The suspension was cleared at 13,000 rpm for 10 minutes.  To the supernatant, 150µL 
of 50% glutathione-sepharose beads (GE Healthcare) was added and incubated for 2 hours with 
rotation at 4 degrees.  Glutathione-sepharose beads were washed three times with glutathione 
washing buffer (1xPBS, 1mM DTT and 0.1% Triton-X) and eluted for 30 minutes with 
glutathione elution buffer (100mM Tris pH 8, 150mM NaCl, 20mM Glutathione, and protease 
inhibitors).  Alternatively, glutathione-sepharose beads with GRHL2 protein attached were 
washed 3 times in PreScission cleavage buffer (50mM Tris-HCl, 150mM NaCl, 1mM EDTA, 
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1mM DTT, pH 7.0).  The GST-GRHL2 on glutathione-sepharose beads was cleaved by adding 
80ul of Prescission Protease (GE Healthcare) per mL of PreScission cleavage buffer at 5 degrees 
overnight.  The sample was spun at 2,000rpm and the supernatant with the GST cleaved GRHL2 
was obtained.  Proteins were dialyzed against p300 acetylation buffer overnight at 4 degrees 
using 20,000 MWCO Slide-A-Lyzer MINI Dialysis Unit (Thermo-Scientific).  Protein was 
analyzed on SDS-PAGE by Coomassie Blue staining and quantified by comparison of 
Coomassie staining to a BSA standard and/or a BCA assay.  Synthetic peptides were purchased 
from ThermoFischer Scientific with n-terminus acetyl group and c-terminus amidation: GRHL2 
420-442aa (GAERKIRDEERKQNRKKGKGQAS) and scramble (IDEKNKGRERQRK) 
Chromatin Immunoprecipitation (ChIP) 
For ChIP assay, HT1080 cell lines expressing empty vector/pMXS or GRHL2/pMXS cells were 
used, and chromatin generated as described previously with the following modifications (Kumar 
et al.): (i) Immunopreciptation was performed with 3ug of H3K27-Ac antibody (Cell Signaling) 
or rabbit IgG (Jackson) to 3.3x106 cell-equivalents in ChIP RIPA buffer. (ii) Protein A-sepharose 
was used instead of FLAG-agarose beads. (iii) qPCRs were performed using 2X SYBR green 
master mix (Applied Biosystems; 10 uL), 0.08 uL of 100 micromolar primer, 1 uL ChIP DNA in 
a 20 uL reaction.  Primer sequences were as follows: MMP1-1-F 
(AACCTCAGAGAACCCCGAAG), MMP1-1-R (TACTAACACTGCGCACCTGA) MMP1-2-
F (CAGAGTGGGGCATGAGTAGG), MMP1-2-R (TGTCTTCGGTACTGGTGACC), 
MMP14-F (AAGTAAGTGAGCTTCCCGGC), MMP14-R (GGAGTTCGCCCCAGTTGTAA), 
MMP2-F (TCGCCCATCATCAAGTTCCC), MMP2-R (CCCCCAAGCTGTTTACCGAA), 
ZEB1-1-F (GCGAGGCGTGGGACTGATGG), ZEB1-1-R (AAAGTTGGAGGCTCGGCGGC), 
ZEB1-2-F (CTGCACGGCGATGACCGCT), ZEB1-2-R (TTCCGCTTGCCAGCAGCCTC),  
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CDH1-F (ACTCCAGGCTAGAGGGTCACC),  CHD1-R 
(CCGCAAGCTCACAGCTTTGCAGTTCC), ESRP1-F (GGGAGCTTGGTCAAGTCAAC), 
ESRP1-R (TCTTAAATCGGGCCACGCAG), RAB25-F (AGGTCCTGTCCCTTTTTCGC), 
RAB25-R (TTGGGGGTAAGGGGACTTCT), GAPDH-F (ATGGTTGCCACTGGGGATCT), 
and GAPDH-R (TGCCAAAGCCTAGGGGAAGA). Results were normalized to GAPDH 
values. 
Ex Vivo Kidney Culture 
All experiments involving mice were approved by WVU IACUC.  Hoxb7creEGFP transgenic 
mice and ex vivo kidney culture method were described previously (Zhao et al., 2004).  We 
removed embryonic kidney at E13.5 and the kidneys were cultured in 1uM batimastat (Tocris) or 
vector in culture media for 48 hours.  Images were taken of GFP ureteric buds on Olympus 
MVX10 Macro Zoom equipped with an ORCA-Flash 4.0 camera, using 2x objective and 4x 
zoom 4x, FITC, and using CellSen Imaging Software.  Ureteric buds were counted for 
quantification.  
Confocal microscopy of transfected RRE.1 cells  
 RRE.1 cells, wt e1a-NLS-LacI-mCherry, and empty vector NLS-LacI-mCherry were 
generous gift from Arnold Berk (UCLA, Los Angeles) and experiment was performed as 
previously described (Verschure et al., 2005; Ferrari et al., 2014).  GRHL2 was subcloned into 
empty vector NLS-LacI-mCherry using Sal1.  Images were taken on Zeiss Axiolmager Z1 
microscope LSM 510 Confocal, 63x/0.75 LDPlan-neofluar, DAPI and Rhodamine, and Zeiss 
Zen Software.  Images were quantified using mean area on Image J.  
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Statistical Analysis 
Error bars in graphs represent standard deviation. P-values were calculated using a 
Student’s two-tailed t-test. 
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 Table 1. 
 
  
Genes regulated by GRHL2  
Gene ID  Fold Change 
(shGRHL2+HGF/GRHL2+HGF) 
Significance 
MMP-1 31.7 Interstitial collagenase, necessary for MDCK 
tubulogenesis, p300-dependent expression  
MMP-9 5.8 Gelatinase B, p300-dependent cancer 
invasiveness, upregulated in EMT  
MMP-13 15.1 Collagenase 3, Necessary for MDCK 
tubulogenesis, p300-dependent expression  
MMP-14 5.82 Membrane-type matrix metalloprotease, involved 
in EMT regulation and invasiveness phenotype  
MMP-19 3.5 Increases invasion in multiple cancers  
MMP-24 9.6  
  
 Table 1- HGF-induced MMPs expression in absence of GRHL2 compared to the presence of 
GRHL2 
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Figure Legends 
Figure 1. GRHL2 suppresses HGF-induced cell scattering and tubulogenesis, and is down-
regulated by HGF. A. HGF induction downregulates endogenous GRHL2 protein. Western blot 
and densitometric quantitation of HGF treatment time course in MDCK cells are shown. HGF 
induction downregulates endogenous GRHL2 mRNA in MDCK cells; qPCR results expressed as 
ratios compared to vector control.  B. Constitutive GRHL2 expression in MDCK cells suppresses 
HGF-induced cell scattering; images represent representative morphologies of cells treated for 
42 hours.  C. GRHL2 knockdown in enhanced HGF-induced cell scattering (16 hours), but 
MDCK shGRHL2 cells did not undergo an EMT phenotypic change when EMT markers were 
examined via western blotting. D.  Constitutive GRHL2 expression in MDCK cells prevents 
tubulogenesis (blue-nuclei and green-actin). Scale bar equals 20 microns. Graph represents 
quantification of percentage of cysts that demonstrated tubulogenesis.   
Figure 2. GRHL2 suppresses the induction of MMP genes and MMP promoters by HGF. 
A. GRHL2 suppresses the induction of MMP genes (qPCR analysis; EN: endogenous GRHL2, 
CE: constitutively expressed GRHL2, KD: GRHL2 shRNA knockdown).  B. GRHL2 suppresses 
the induction of MMP promoters by HGF. HT1080 cells were cotransfected with either MMP1 
or MMP14 promoter-luciferase reporter constructs and GRHL2, E1A, or empty expression 
vectors. Values represent relative luciferase activity normalized to TK-β-galactosidase control.  
Figure 3. GRHL2 suppresses AP-1 and p300 function. A. GRHL2 suppresses AP-1 function. 
HT1080 and 293T cells were cotransfected with AP-1 response element- luciferase reporter 
construct and GRHL2 expression vector or empty vector.  Phorbol 12-myristate 13-acetate 
(PMA) was used to induce AP-1 signaling in 293T cells. Values represent relative luciferase 
activity normalized to TK-β-galactosidase control. B. Venn diagram comparing GRHL2-
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repressed genes (Farris et al., 2016) vs. p300 target genes identified via E1a (Ferrari et al., 2014).  
C. GRHL2 suppresses the p300 pathway. p300 effector and target genes induced by HGF in 
MDCK cells with GRHL2 shRNA vs. cells with constitutive GRHL2 determined by IPA 
analysis quantitation of the number of unregulated, HGF up-regulated or HGF down-regulated 
genes for both cell lines is shown in the graph. The p300 interactome diagram on which this is 
based is shown in figure S7. D. GRHL2 suppresses p300 function.  GAL4-minimal promoter-
luciferase activation by a co-transfected GAL4-p300 was assayed in HT1080 cells in the 
presence or absence of cotransfected GRHL2 expression vector; values represent relative 
luciferase activity normalized to TK-β-galactosidase control. 
Figure 4. GRHL2 suppresses the HAT activity of p300. A. In vitro HAT assays with 
recombinant H3, p300 and GRHL2 proteins. Coomassie stains to assess the quality of 
recombinant proteins used throughout this study are shown in figure S19. B. GRHL2 inhibits the 
acetylation of H3 on GRHL2-repressed but not GRHL2-induced promoters in vivo (ChIP assay). 
Crosslinked chromatin from HT1080+vector HT-1080+GRHL2 cells immunoprecipitated with 
H3K27-Ac or rabbit IgG; the indicated promoters were assayed for H3K27Ac by qPCR using the 
primers in Materials and Methods. * indicates p values of < 0.05.  GRHL2 does not affect global 
histone H3K18-Ac or H3K27-Ac (western blotting of total histones).  C. GRHL2 interacts with 
p300.  (left panel): co-transfection of indicated expression constructs, followed by co-
immunoprecipation/western blotting; (middle panel): co-immunoprecipitation of retrovirally 
expressed S-tagged GRHL2 with endogenous p300;  (right panel): co-immunoprecipitation of 
endogenous GRHL2 and endogenous P300.   
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Figure 5. GRHL2 inhibits the C-terminal transactivation domain of p300. A. The p300 HAT 
domain stimulates transactivation by the p300 C-terminus (co-transfection in HT1080 cells).  B. 
GRHL2 inhibits transactivation by the p300 C-terminus. HT1080 cells were cotransfected with 
GAL4 response element luciferase reporter in the presence of the indicated expression 
constructs.  C. The IBID domain of p300 and the co-activator SRC-1 synergize to activate 
transcription. HT1080 cells were cotransfected with GAL4 response element luciferase reporter I 
in the presence of the indicated expression constructs.  D. GRHL2 inhibits transactivation by the 
IBID-SRC-1 complex. HT1080 cells were cotransfected with GAL4 response element luciferase 
reporter in the presence of the indicated expression constructs.  E. Transactivation by the IBID-
SRC-1 complex is contingent upon lysines 2086 and 2091.  HT1080 cells were cotransfected 
with GAL4 response element luciferase reporter in the presence of the indicated expression 
constructs. (a-e):Values represent relative luciferase activity normalized to TK-β-galactosidase 
control.  F. Schematic of p300 domains. KIX- CREB-binding domain, Bd- bromodomain, HAT - 
histone acetyltransferase domain, and IBID- IRF-3 binding domain. 
Figure 6.  A small region within the DNA binding domain of GRHL2, amino acids 425-437, 
inhibits p300. A. Schematic of GRHL2 domains. TAD- transactivation domain , DBD- DNA 
binding domain, and DD- dimerization domain. B. HAT assays using the indicated GRHL2 
fragments, assayed as GST-fusion proteins.  C. GRHL2 aa425-437 inhibits p300 HAT activity. 
The indicated fragments derived from GRHL2 were assayed as GST-fusions (left panels) or as 
recombinant peptides (right panel) for inhibition of HAT activity.  D. GRHL2 amino acids 425-
437 are required for inhibition of an AP-1 reporter, GAL4 reporter in conjunction with GAL4-
p300, MMP1 reporter or MMP14 reporter.  Values represent relative luciferase activity 
normalized to TK-β-galactosidase control. 
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Figure 7. The p300-inhibitory domain of GRHL2 is important for the suppression of 
tubulogenesis and reversion of EMT. A MDCK cells expressing GRHL2 wild-type or GRHL2 
∆425-437 were assayed for tubulogenesis (blue-nuclei and green-actin).  Scale bar equals 20 
microns.; quantitation is shown in the middle panel and Western blot confirmation of protein 
levels in the right panel.  B. MSP cells expressing GRHL2 wild-type or GRHL2 ∆425-437 were 
assayed for reversion of EMT, by western blotting for EMT markers (left panel), cell 
morphology (middle panel), or qPCR (right panel).  
Figure 8. GRHL2 suppresses tubulogenesis and EMT by inhibition of p300. 
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Supplemental Figure Legends 
 
Figure S1.  GRHL2 shRNA accelerates HGF-induced cell scattering (videomicroscopy). 
Cell scattering time lapse movies were taken every 15 minutes over a 24 hour period.  Time 
lapse images were obtained using a Nikon Eclipse TE2000-E with Photometrics CoolSNAP HQ2 
Monochrome CCD with Phase 40x/0.75 objective. (left panel): MDCK + vector; (right panel):  
MDCK+GRHL2 shRNA 
Figure S2.  GRHL2 did not affect Erk or Akt signaling downstream of HGF/Met.  Lysates 
from HGF induction time course using the indicated cell lines was analyzed by western blotting 
using the indicated antibodies.  Densitometry data represent ratios of phospho-Akt or phospho-
ERK to the corresponding total protein levels.  
Figure S3.  Effect of GRHL2 on cyst formation. A. Constitutive GRHL2 expression in 
mIMCD-3 cells prevents tubulogenesis.  B. Knockdown of GRHL2 prevents cyst formation in 
MDCK. (left panel) GRHL2 knockdown by western blotting. (middle panel) Quantification of 
cysts per well. (right panel) Representative images from MDCK collagen cysts 
Figure S4.  Knockdown of GRHL2 following cyst formation (inducible shRNA) promotes 
tubulogenesis. A. MDCK cells with doxycycline inducible GRHL2 shRNA were induced with 
HGF in the presence or absence of doxycycline to induce GRHL2 shRNA. Cyst extensions were 
quantified 24 hours after HGF induction.  Quantification indicates the number of cysts that did 
not have extensions at 24 hours. B. GRHL2 does not alter proliferation in MDCK cells.  The 
indicated cell lines were plated at equal density and counted in triplicate wells at three days post-
plating. 
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Figure S5.  MMPs are important for kidney tubulogenesis.  E13.5 ex vivo mouse kidney 
cultures were grown for 48 hour with batimastat or solvent control and imaged.  Ureteric buds 
were counted for quantification.  
Figure S6.  GRHL2 did not affect FOS or JUN family members. FOS, FOSL1, FOSB, JUN, 
and JUNB mRNA expression levels were determined in the indicated cell lines at one or four 
hours post-HGF induction via qPCR. 
Figure S7.  GRHL2 suppresses the p300 pathway. p300 effector and target genes induced by 
HGF in MDCK cells with GRHL2 shRNA vs. cells with constitutive GRHL2 determined by IPA 
analysis quantitation of the number of unregulated, HGF up-regulated or HGF down-regulated 
(red=up-regulated, green=down-regulated, and grey=unregulated)  
Figure S8.  Validation of p300-dependence of reporter assays using WT vs. p300-non-
binding mutant of E1A. HT1080 cells were cotransfected with the indicated reporters and 
expression constructs. Values represent relative luciferase activity normalized to TK-β-
galactosidase control.  
Figure S9.  Further validation of reporter assays: A.  c-Myc did not inhibit GAL4-p300 pG5 
assay.   B. GRHL2 did not inhibit GAL4-VP16 activation of GAL4- responsive element. 
HT1080 cells were transfected with the indicated reporters and expression constructs. Values 
represent relative luciferase activity with GRHL2 present compared to empty vector alone 
normalized to TK-β-galactosidase control. 
Figure S10. GRHL1 and GRHL3 inhibit transactivation by p300. HT1080 cells were 
cotransfected with the indicated reporters and expression constructs. Values represent relative 
luciferase activity normalized to TK-β-galactosidase control.  
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Figure S11.  GRHL2 suppresses activity of the HAT domain (alone) of p300. Recombinant 
GRHL2 inhibits recombinant p300 HAT (1283-1673) acetylation of H3K27 in a dose dependent 
manner in the H3 acetylation assay. Coomassie stains to assess the quality of recombinant 
proteins are shown in figure S19. 
Figure S12.  GRHL1 and GRHL3 inhibit p300 HAT activity. Recombinant GRHL1 and 
GRHL3 inhibit p300’s acetylation of H3K27 in H3 acetylation assay. Coomassie stains to assess 
the quality of recombinant proteins are shown in figure S19. 
Figure S13.  GRHL2 did not cause global changes in heterochromatin condensation like 
E1A. (left panel) GRHL2-lacI-mCherry, E1a-lacI-mCherry or lacI-mCherry expression 
constructs were transfected into RRE cells and confocal microscopic images of chromatin 
condensation were quantitated. 
Figure S14.  Recombinant GRHL2 and p300 pulldown interaction.  Recombinant GRHL2 
and p300 were assayed for interaction by p300 IP/GRHL2 western blot.  
Figure S15. Mapping of GRHL2 domains involved in inhibiting HAT activity in vitro. A.  
Recombinant GST-GRHL2 fragments were generated without the GRHL2 transactivation 
domain (136-625), DNA binding domain (∆245-494), or dimerization domain (1-520) and 
assayed for inhibition of p300 HAT activity. B. Recombinant GST-GRHL2 fragments were 
generated within the GRHL2 transactivation and assayed for inhibition of p300 HAT activity. 
Coomassie stains to assess the quality of recombinant proteins are shown in figure S19. C. 
Synthetic peptide (aa420-442) and scramble peptide were assayed for inhibition of p300 HAT 
activity. (right panel) Quantification of H3K27-Ac levels compared to no peptide control. 
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Figure S16. Mapping of GRHL2 domains involved in inhibiting transactivation by GAL4-
p300 in reporter assays. HT1080 cells were cotransfected with the indicated reporters and 
expression constructs. Values represent relative luciferase activity normalized to TK-β-
galactosidase control.  
Figure S17.  GRHL2 aa 425-437 important for repressing GLUD1 promoter through p300. 
HT1080 cells were cotransfected with the indicated reporters and expression constructs. Values 
represent relative luciferase activity normalized to TK-β-galactosidase control.  
Figure S18.  GRHL2 ∆425-437 interacts with p300 in a co-transfection assay. p300 and wt 
GRHL2 or GRHL2 ∆425-437  expression vectors were transfected into 293 cells.  Lysates were 
immunoprecipitated with p300 antibody and probed for GRHL2 interaction.  
Figure S19.  Confirmation of recombinant proteins (Coomassie blue staining). A. 
Prescission cleaved GRHL2 for figure 4A H3 acetylation assay.  B. GST-GRHL1 and GST-
GRHL3 for figure S12 H3 acetylation assay.  C and D.  GST-GRHL2 fragments for figure S15 
H3 acetylation assay.  E. GST-GRHL2 fragments for figure 6A H3 acetylation assay.  F. GST-
GRHL2 fragments for figure 6B H3 acetylation assay.  
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The role of GRHL2 in Kidney Cancer and Kidney 
Development 
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Introduction 
Kidney Cancer  
 As discussed in Chapter 1, GRHL2 suppresses EMT, causes MET, and is important in the 
developing kidney (Werth et al.; Cieply et al., 2012; Aue et al., 2015).  Previously published 
microarray data (GEO website, GSE15641) shows that GRHL2 is significantly downregulated in 
clear cell renal cell carcinomas (ccRCC) (figure 1).  ccRCC is associated with an EMT 
phenotype, consisting of gene markers resembling adipogenic and pluripotent mesenchymal stem 
cell-like differentiated states (Tun et al., 2010).   ccRCC overexpresses mesenchymal markers, 
vimentin and N-cadherin (Tun et al., 2010).  Also, TGF-β signaling, an EMT driver, is 
upregulated in ccRCC (Boström et al., 2013).   The most common mutation in ccRCC is an 
inactivating mutation of Von Hippel-Lindau (VHL) (Clark, 2009).  Under normoxic conditions, 
VHL and its E3 ligase complex ubiquitinates hypoxia-induced factor alpha (HIFα) leading to 
HIFα’s degradation (An and Rettig, 2005).   When VHL is mutated in ccRCC, HIFα accumulates 
and trans-activates the EMT transcription factors, Twist and Snail (Banumathy and Cairns, 
2010).   In a breast cancer microarray (GEO website, GSE24202), Twist and Snail are able to 
downregulate GRHL2 suggesting a mechanism of GRHL2 downregulation in ccRCC (figure 1).  
These observations led to the hypothesis that GRHL2 would function as a tumor suppressor in 
ccRCC cell lines and revert the EMT phenotype.  
Kidney development  
Kidney development is an intricate process involving morphogenesis, multiple signaling 
pathways, and cell-cell interactions.  This developmental process occurs via the interaction of the 
ureteric bud and the metanephric mesenchyme.  Growth factors originating from the metanephric 
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mesenchyme include glial cell derived growth factor (GDNF) and hepatocyte growth factor 
(HGF).  These factors activate their cognate receptors on the ureteric epithelium – RET and 
MET, respectively (Costantini, 2010).   Inductive signaling from the metanephric mesenchyme 
results in elongation and branching of the numerous ureteric bud tips.   At this point, the ureteric 
bud induces the differentiation of the metanephric mesenchyme into the glomerulus.   The 
metanephric mesenchyme goes on to form the glomerulus, proximal and distal convoluted 
tubules, and loop of henle.  The ureteric bud is derived from the epithelial Wolffian duct and 
expresses GRHL2 (Werth et al., 2010; Aue et al., 2015).   The ureteric bud goes on to form the 
kidney collecting ducts, calyces, renal pelvis, and ureter.  In the adult kidney, GRHL2 is 
expressed in the collecting duct.  As previously noted, GRHL2 is essential for programming the 
epithelial cell phenotype, partially through activation of various cell-cell adhesion genes, 
including E-cadherin, claudins, and desmosmal genes (Werth et al., 2010).  Therefore, GRHL2 
expression leads to tight epithelial cell-cell connections and may be responsible for collecting 
duct integrity. Also, GRHL2 suppresses the EMT and promotes the reciprocal process, MET 
(Cieply et al., 2012).  Both of these processes are required for kidney development (Faa et al., 
2012).   Cells undergoing EMT demonstrate increased migration and invasion (Kalluri and 
Weinberg, 2009).  Because GDNF and HGF increase migration, GRHL2 is expected to 
antagonize these signaling pathways (Uehara and Kitamura, 1992; Tang et al., 1998).  
Reciprocally, GRHL2 would be inhibited in ureteric bud tip cells allowing the cells to bifurcate 
into tubules and/or invade in response to GDNF and HGF.  To support this hypothesis, ESRP1-/- 
knockout mice increase kidney trifurcations (Russ Carstens, personal communications).  ESRP1 
is a downstream target of GRHL2 and is responsible for some of the epithelial regulatory effects 
associated with GRHL2 expression (Cieply et al., 2012).  The role of GRHL2 as a master 
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epithelial programming transcription factor places it in a position to influence all of these 
processes and signaling pathways.  The investigation of GRHL2 in kidney development will 
elucidate its effect on ureteric bud formation, inductive signaling pathways, ureteric bud tip 
development, and glomerulus maturation.  Furthermore, the examination of GRHL2 and 
HGF/MET signaling will have implication not only in kidney development, but also cancer 
progression. 
Results/Discussion  
Kidney cancer 
 To investigate the role of GRHL2 in ccRCC, 786-0, a clear cell renal cell carcinoma cell 
line lacking functional VHL protein, was utilized (Williams et al., 1978; Jiang et al., 2003).   
Constitutively expressed GRHL2 in 786-0 cells caused a mesenchymal-epithelial transition 
based on cell morphology (figure 2A, B).  786-0 cells undergo branching morphogenesis in three 
dimensional matrigel culture upon HGF induction (Peruzzi et al., 2006; Lee et al., 2008), and 
GRHL2 prevented HGF-induced branching morphogenesis (figure 2C).  Interestingly, this effect 
led us to examine GRHL2 in MDCK tubulogenesis which resulted in discoveries explored in 
Chapter 2.   Constitutively expressed wild type VHL causes a MET in 786-0 cell (Peruzzi et al., 
2006).   Since both VHL and GRHL2 reverted ccRCC cells, the cells were examined for anoikis 
sensitivity which is normally associated with the epithelial phenotype (Frisch and Francis, 1994).  
Indeed, VHL and GRHL2 restored anoikis sensitivity to 786-0 cells (figure 2D).  These results 
suggested that GRHL2 was a bona fide tumor suppressor in the context of ccRCC since it caused 
a MET, restored anoikis sensitivity, and decreased invasion.   
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 The next step was to demonstrate that GRHL2 depletion in normal kidney epithelium 
increased EMT, anoikis resistance, and invasion.  It is a widely held view that ccRCC is derived 
from the proximal tubule of the kidney (Büttner et al., 2015).  Human kidney proximal tubular 
epithelial cell lines, HKC-8 and HK-2, were used to perform GRHL2 shRNA depletion 
experiments.  Surprisingly, when HKC-8 and 786-0 cells were compared to HMLE cells using 
qPCR, there was no detectable level of GRHL2 mRNA in the kidney cells (figure 3A), even 
though HKC-8 cells are classified as proximal tubular epithelial cells.   Next, a panel of kidney 
cell lines were tested for GRHL2 expression with HMLE cells used as a positive control (figure 
3B).  HKC-8 cells displayed a protein band that migrated significantly higher than normal human 
GRHL2.  The protein band was resistant to three GRHL2 shRNAs, suggesting the band was not 
GRHL2 when examined in conjunction with the qPCR data (figure 3A,C).  Both HK-2 cells and 
miMCD cells did not express GRHL2 (figure 3B).  However, Madin-Darby canine kidney cells 
(MDCK) expressed high levels of GRHL2, and MDCK cells are derived from canine collecting 
duct cells (Gekle et al., 1994).  The developmental process of the kidney clearly explains why 
HKC-8 and HK-2 cells do not express GRHL2, but MDCK cells do (See Chapter introduction 
for full description).  During kidney development, the ureteric epithelium (positive for E-
cadherin and GRHL2) interacts with the metanephric mesenchyme (negative for E-cadherin and 
GRHL2) to form the adult kidney.  The ureteric epithelium give rises to collecting duct cells 
from which the MDCK cell line was derived, thereby explaining the GRHL2 positivity of  
MDCK cell.  However, HKC-8 and HK-2 cells were derived from the proximal tubule cells 
originating from the metanephric mesenchyme and do not express GRHL2.    
 Therefore, we were constitutively expressing GRHL2 in ccRCC cell lines that never 
expressed GRHL2 under physiological conditions, making the clinical relevance of GRHL2 as 
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tumor suppressor in ccRCC questionable.  It should be noted that the initial flaw in the 
experiment arises in the published microarray data comparing normal kidney tissue and ccRCC.  
When heterogeneous tissue samples are collected, genes present in only one cell population may 
appear highly regulated.  In this specific case, kidney collecting ducts express high levels of 
GRHL2, but the other mesenchymal originating kidney cells have no detectable GRHL2 levels.  
Therefore when ccRCC expands, the collecting duct cells are not amplified, causing the 
microarray to appear as if GRHL2 was downregulated.    
Even though our results suggest that GRHL2 is not a tumor suppressor in ccRCC, our 
results do have significant implication in the diagnosis of ccRCC.   GRHL2 regulates ESRP1/2 
(See Chapter 1 EMT section) which is responsible for the alternative splicing of fibroblast 
growth factor receptor 2 (FGFR2) isoforms (Warzecha et al., 2009).  The mesenchymal FGFR2 
isoform IIIc (FGFR2-IIIc) is only expressed in metanepheric mesenchyme derived cells whereas 
the epithelial FGFR2 isoform IIIb (FGFR2-IIIB) is only expressed on ureteric epithelial cells.  
GRHL2 upregulates FGFR2-IIIb presumably by its regulation of ESRP1 and subsequent FGFR2 
splicing (figure 4).  In a study with significant clinical implications, Zhao et al. examined 470 
ccRCC specimens and 68 normal kidney specimens for alternative splicing events (Zhao et al., 
2013).  In this cohort, ~90% of ccRCC expressed FGFR2-IIIc compared to the normal kidney 
tissue expressing FGFR2-IIIb.  The 10% of ccRCC cells exhibiting the FGFR2-IIIb isoform were 
associated with higher patient survival, lower tumor grade, and decreased tumor size. More 
importantly, when these FGFR2-IIIb isoform positive tumors were examined by a pathologist, 
the tumors were re-classified as chromophobe renal cell carcinoma or papillary renal cell 
carcinomas.  FGFR2-IIIb isoform, ESRP1, and GRHL2 all correlated with these less invasive 
renal cell carcinomas (Zhao et al., 2013).  The data suggest that GRHL2 expressing cells do not 
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become ccRCC, and GRHL2 could be useful as a biomarker for predicting clinical kidney 
carcinoma subtypes in undiagnosed renal cell carcinoma.     
Kidney Development 
An RNA-Seq from MDCK cells with GRHL2 constitutively expressed or depleted in the 
presence or absence of HGF was previously performed (Chapter 2).   Interestingly, several genes 
with known or implied significance in kidney development, whose HGF regulation was 
modulated by GRHL2, were identified (Table 1,2).  These results, consistent with the MDCK 
data (Chapter 2), suggested that GRHL2 could play a significant role in kidney development.    
Because both GDNF/RET and HGF/MET signaling pathways are able to induce 
scattering (Uehara and Kitamura, 1992; Tang et al., 1998), GDNF and HGF were investigated 
for their ability to downregulate or inactivate GRHL2.  When MDCK with constitutive RET 
expression were treated with HGF and/or GDNF, GRHL2 protein was downregulated (figure 
5A).  Also, GDNF and HGF were both able to downregulate the GRHL2 promoter in promoter-
luciferase reporter constructs (figure 5B).   
Since HGF/MET and GDNF/RET pathways play an important role in kidney development 
and regulate GRHL2, the effect of GRHL2 on kidney development was examined in the murine 
model.  Since GRHL2-/- mice die at E11.5 from neural tube defects precluding them from kidney 
examination, GRHL2+/- mice were examined for kidney abnormalities.  GRHL2+/- mice survived 
to adulthood with no apparent differences in weight, pregnancy, feeding, urine output, or serum 
BUN levels.  Our preliminary data suggested that GRHL2+/- mice have significantly less GRHL2 
protein compared to their GRHL2+/+ littermates (figure 6A).  Because ureteric epithelium stability 
and ureteric tip bifurcation may be affected by depletion of GRHL2, the number of nephrons 
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generated in the adult kidney between GRHL2+/+ and GRHL2+/- mice was examined.  P30 
GRHL2+/+ and GRHL2+/- kidneys were paraffin-embedded, sectioned, H&E stained, and examined 
for glomeruli/mm2.  There was a 10-30% decrease in glomeruli numbers in GRHL2+/- kidneys 
compared to GRHL2+/+ kidneys (figure 6B).  In GRHL2+/+ and GRHL2+/- mice, a ViewRNA ISH 
Tissue 2-plex assay system was used to examine RET and GRHL2 localization in paraffin sections 
of E15.5 kidneys (figure 7).  RET staining was localized to ureteric tips, and GRHL2 was present 
in all the ureteric epithelium. Both GRHL2 and RET co-localized in the ureteric tips, and no 
difference in GRHL2 RNA levels was detected between GRHL2+/+ and GRHL2+/- mice.  These 
results were promising, but needed to be further examined in an ureteric specific GRHL2-/- mouse 
line.   
  GRHL2Flox/Flox mice (from collaborator Stephan Jane, Monash University) were crossed 
with HOXB7promoter-cre-EGFP mice (from collaborator Carlton Bates), a promoter with ureteric 
epithelial specific expression (Zhao et al., 2004).  These mice were used to examine the role of 
GRHL2 in ureteric bud formation and ureteric tip branching.  Embryonic kidneys were examined 
at E18.5 or E13.5 with 48 hour ex vivo culture for ureteric tips quantification (figure 8).  
Surprisingly, there was no difference between ureteric tips in control and GRHL2UB-/- mice. Also, 
there was no renal agenesis observed in D30 GRHL2UB-/- mice which was expected (data not 
shown).  
 After these unexpected results, the GRHL2flox/flox model was examined to ensure GRHL2 
was deleted in the ureteric bud.  The Jane lab GRHL2flox/flox model had placed the two lox P sites 
around exon 2 to create a GRHL2 frameshift mutation rendering the protein nonfunctional. 
However, after detailed analysis of murine Grhl2 mRNA by Peter Stoilov, it was discovered that 
Grhl2 mRNA has ATG start codons in exons 1, 2, and 4.  GRHL2 exon 4 ATG start codon is the 
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strongest match to a Kozak sequence, and GRHL2 exon 1 and 2 ATG start codons were not good 
matches, suggesting the start sequence could be leaky and skipped in preference for the exon 4 
ATG start codon. Therefore, when the Jane GRHL2flox/flox mice excises exon 2, the exon 1 open 
reading frame is only 48 nucleotides which can cause either reinitiation of translation downstream 
at exon 4 or entirely bypass exon 1 and start translation at exon 4.  The initiation of GRHL2 at 
exon 4 would result in a 57 kDA Grhl2 protein with intact DNA binding and dimerization domains.   
To examine if this phenomenon was occurring in the GRHL2flox/flox mice, kidneys were harvested, 
and primary cells were generated.  After the kidney epithelial cells were sorted with Dolichos 
Biflorus Agglutinin (DBA), cells were infected with adenovirus-Cre initiating the deletion of exon 
2.  GRHL2 western blotting clearly shows the creation of a ~57kDA GRHL2 isoform upon adeno-
Cre addition that corresponds to initiation from the exon 4 start codon (figure 9).  This data, in 
conjunction with the phenotype observed in the GRHL2UB-/- mice, suggested that a functional 
GRHL2 protein was being produced, and our GRHL2UB-/- mice were not useful for examining the 
role of GRHL2 in kidney development.  
 During the period of time this research was occurring, Schmidt-Ott et. al. published 
“Grainyhead-Like 2/Ovo-Like 2 Pathway Regulates Renal Epithelial Barrier Function and 
Lumen Expansion”(Aue et al., 2015).  In this Schmidt-Ott study, it was demonstrated that global 
Grhl2-/- mice result in decreased collecting duct luminal expansion at E10.5 (Supported by Chapter 2), and Grhl2 depletion in miMCD cells decreases luminal expansion in three dimensional culture and affected epithelial barrier formation (Aue et al., 2015).  Also, Grhl2 binds and upregulates OVOL2, an epithelial transcription factor (Roca et al., 2013), which is able to rescue the epithelial barrier and luminal expansion defects in the miMCD cells.  Subsequently, in an abstract, the Schmidt-Ott laboratory saw renal agenesis in 6.8% of 
147 
 
ureteric bud specific GRHL2-/- mouse (excising GRHL2 exon 4) and a reduction in kidney size, but these results have not been published to date.   The Schimdt-Ott laboratory used the Hoxb7cre+ mouse generated by McMahon et. al. (Yu et al., 2002) which has lower 
penetrance than the Hoxb7cre+EGFP mouse generated by Bates et. al. (Zhao et al., 2004).   If 
the Schmidt-Ott GRHL2flox/flox mouse was crossed with the Bates Hoxb7cre+EGFP mouse, the 
role of GRHL2 in kidney development would be better understood, and possibly a more severe 
kidney phenotype would be observed.    
 
Material and Methods  
Cell lines  
786-0 and 786+VHL cells (Donald Bottaro, NCI Bethesda, MD) were cultured in RPMI-
1640 (Invitrogen) with 10% fetal bovine serum (FBS) (Hyclone) and 1x penicillin-streptomycin-
glutamine (PSG) (Invitrogen).  Human proximal tubular epithelial cell line (HKC clone 8) 
(Youhua Liu, University of Pittsburgh) and miMCD-3 cells (ATCC) were cultured in advanced 
DMEM:Ham’s F12 (Gibco) with 10% FBS and 1x PSG.  MDCK cells (Clone M8 described 
previously in Frisch et al. (Frisch and Francis, 1994) and MDCK+c-RET (Greg Dressler, 
University of Michigan, Ann Arbor, Michigan) were cultured in advanced Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco) with 10% FBS (Hyclone) and 1x PSG (Invitrogen).  Human 
proximal tubule kidney cells (HK-2) (ATCC) were maintained in Keratinocyte Serum Free 
Medium (Invitrogen) with 0.05mg/ml bovine pituitary extract, 5ng/ml human epidermal growth 
factor, and 1x PSG (Invitrogen).  HMLE culture methods were described previously (Cieply et 
al., 2013).   
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Generation of stable cell lines by retroviral transduction and lentiviral transduction  
Full-length GRHL2/pMIG, GRHL2/pMXS and GRHL2 shRNA/GIPz were described previously 
(Cieply et al., 2012; Farris et al., 2016).   
Western Blotting 
Western blotting was performed as described in chapter 2. Primary antibodies used were: 
GRHL2, rb (Sigma); β-actin, ms (Thermo-pierce); and GAPDH, ms (Origene). 
Cell Imaging Assays 
786-0 cells images were obtained using a Zeiss Axiovert 200M, Axiocam MRM camera, 
Phase 20x/0.55, RT, Axiovision Rel. 4.8 software. 
Matrigel branching morphogenesis assay 
Matrigel was thawed overnight at 4˚C.  Undiluted matrigel (40 µl) was added to 8 well chamber 
slides and allowed to solidify for 15 minutes.  786-0 cells were trypsinized, counted and 
resuspended at 25,000 cells/ml.  The cell solution was mixed 1:1 with DMEM Complete with 4% 
matrigel solution with or without 320ng/ml HGF, and 400ul of this mixed solution was pipetted 
on top of undiluted matrigel. The cells were refed every four days with DMEM complete with 4% 
matrigel with or without HGF.  Branching morphogenesis images were obtained using a Zeiss 
Axiovert 200M, Axiocam MRM camera, Phase 20x/0.55, RT, Axiovision Rel. 4.8 software.   
Anoiks Assay 
 Anoikis assay was performed as previously described (Cieply et al., 2012).  
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Quantitative reverse transcription PCR analysis  
 HMLE, HKC, and 786-0 cell were plated on 60mm2 dishes.  Cells were harvested 
using RNAeasy Plus mini kit (Qiagen), analyzed using Nanodrop, and converted to cDNA using 
SuperScript III First-Strand Synthesis SuperMix (Invitrogen) with oligo dT primers and 1ug of 
RNA.  cDNA was analyzed using SYBR Green PCR Master Mix on an Applied Biosystems 
7500 Real Time PCR System.  Values reported were determined using the delta delta Ct method 
using human GAPDH as internal control.  Primers used: GRHL2-F 
(GCGCCTATCTCAAAGACGAC), GRHL2-R (GGCTTCCAGGGTGTACTGAA), GAPDH-F 
(TGCCAAAGCCTAGGGGAAGA), GAPDH-F (ATGGTTGCCACTGGGGATCT),  
 
RNA-Seq Assay 
 RNA-Seq was previously described in Chapter 2 material and methods.   
GDNF and HGF Cell Scattering Assays 
MDCK+c-RET cells were plated on collagen coated 6 well dishes to give 25% cell 
confluency on HGF and/or GDNF induction.  Cells were treated with 60ng/ml recombinant 
human HGF (RD Systems) and/or 50ng/ml GDNF (RD Systems) in DMEM media for the 32 
hours.  The cells were harvested for protein.  Western blotting was performed as previously 
described in chapter 2. 
Luciferase Reporter Assays  
 MDCK+c-RET were transiently transfected using Lipofectamine 2000 (Invitrogen) at a 
1ug DNA: 3ul Lipofectamine ratio.  After 20 minute incubation in 300 µl of Opti-MEM 
(Invitrogen), a total of 1.0ug of DNA was transfected into a 12 well with DMEM media and 
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refeed 4 hours later with DMEM contain 60ng/ml recombinant human HGF (RD Systems) 
and/or 50ng/ml GDNF (RD Systems).  After 28-36 hours post-transfection, the cells were 
washed twice with cold PBS, lysed in 200 µl of 1x Cell Culture Lysis Buffer (Promega), frozen 
for at least 1 hour at -80 degrees, thawed on ice, and centrifuged at 13,200rpm.  The supernatants 
were assayed for luciferase activity (Promega) and β-galactosidase activity as internal control (2x 
𝛽𝛽-galactosidase assay reagent, 200mmol/l sodium phosphate, pH 7.3, 2mmol/L MgCl2, 
100mmol/L 2-mercaptoethanol, and 1.33mg/mL o-nitrophenylgalactoside).  GRHL2 promoter 
luciferase reporter plasmids were described previously (Cieply et al., 2013).   
FGFR2 splicing assay  
MDCK parental, MDCK+GRHL2/pMXS, and MDCK+shGRHL2/pGIPz cDNA was prepared as 
previously described (Chapter 2).  The cDNA was amplified using 4ul of GoTaq Flexi buffer, 
0.40 ul of 10mM PCR nucleotides, 0.25ul of GoTaq DNA polymerase, 1ul of template cDNA, 
13.95ul of sterile water, and 0.20ul of forward and reverse primers.  Primers were as follows: 
FGFR2-sp-F (6-FAM CGTACAAAGAACGGGGAGCA) and FGFR2-sp-R 
(GCTGAAGTCTGGCTTCTTGG).  PCR products were digested with EcorV and Ava1.  The 
AvaI site was present in FGFR2-IIIb but not FGFR2-IIIc.  The fragments were run on a 4% 
polyacrylamide gel with ROX as internal ladder.  Quantification was performed comparing 
FGFR2-IIIc to FGFR2-IIIb bands.  
RET and GRHL2 ISH Staining and H&E staining  
Kidneys were harvested from mice according to our WVU ACUC protocol.  Kidneys were 
submerged in 10% formalin, paraffin embedded, and sectioned by the WVU Pathology Laboratory 
for Translational Medicine. To perform the section RNA in situs, ViewRNA ISH Tissue 2-plex 
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assay (Affymetrix Panomics) was used.  RNA probes for murine GRHL2 and RET were generated 
and used to evaluated their co-localization. The protocol was followed as described in user manual. 
Briefly, sections were deparaffinized, treated in pre-treatment solution, treated with proteinase K, 
hybridized for 3 hours in a humidified 40° tissue culture incubator without CO2 with specific 
probes for mouse c-RET and GRHL2 designed by Panomic QuantiGENE.  The bound probes were 
amplified using Pre-amp and Amp molecules then the labeled probes with fast red and fast blue 
substrate to produce red dots (RET) and green dots (GRHL2).  Images were obtained using WVU 
MIF Olympus histology 20x microscope.   
For H&E sections, P30 GRHL2+/+ and GRHL2+/- kidneys were harvested, prepared, and 
H&E stained by WVU Pathology Laboratory for Translational Medicine.  Images were obtained 
using Olympus AX70 Provis microscope equipped with an Optronics MicroFire color CCD 
camera Using a 20x/0.70 UPlanApo objective. 
Ex Vivo Kidney Culture 
All experiments involving mice were approved by WVU IACUC.  Hoxb7creEGFP 
transgenic mice were a gift from Carlton Bates (Children’s Hospital of Pittsburgh of UPMC, 
Pittsburgh, PA) and were described previously (Zhao et al., 2004).  GRHL2flox/flox  and GRHL2+/- 
mice were a gift from Stephen Jane (Monash University), and of the C57BL6 inbred background.  
Mice of sexual maturity were timed bred to allow for embryo harvest at the specific 
developmental time points E13.5, E15.5, and E18.5.   Coitus was verified by checking for 
vaginal plugs the following morning after timed mating.   The embryos of pregnant mice were 
considered E0.5 at noon the day of vaginal plug detection.  Embryo’s kidneys were collected as 
described in Barak et al (Barak and Boyle, 2011).  Briefly, a pregnant mouse was euthanized by 
cervical dislocation as approved in our IACUC protocol by highly trained laboratory personnel.  
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Cervical dislocation was necessary to allow for harvest of kidneys before degradation of oxygen 
sensitive molecules occurred as well as to ensure survival of embryonic kidneys for ex vivo 
culturing.  Next, the abdomen was washed with ethanol and an incision was made in the midline, 
cutting through the viscera and peritoneum.  Subsequently, the uterine horn was dissected, and 
the embryos were extracted from the uterus.  The embryos are separated from the yolk sac and 
placenta.  The embryo’s head was removed for PCR genotyping.  An incision was made midline 
on the abdomen of the embryo, and the superficial organs were removed.  The kidneys were 
removed and processed according the experiment being performed.  Ex vivo kidney culture 
method was performed as previously described at indicated times (Zhao et al., 2004).    For 
MMP inhibitor experiment, ex vivo embryonic kidney at E13.5 were cultured in 1uM batimastat 
(Tocris) or vector in culture media for 48 hours. Images were taken of GFP ureteric buds on 
Olympus MVX10 Macro Zoom, ORCA-Flash 4.0 Monochrome camera, Objective 2x, Zoom 4x, 
FITC, and using CellSen Imaging Software.  Ureteric buds were counted for quantification.  
GRHL2flox/flox primary kidney cells and AdenoCre infection 
Kidneys were harvested from GRHL2flox/flox mice as described above, digested with 
Collagenase/Dispase and then trypsin.  Cells were plated on collagen 6 well dishes and allowed 
to grow for 48 hours. Cells were then stained for Dolichos Biflorus Agglutinin (DBA)-GFP 
(Vector Laboratories) to indicate collecting duct epithelial cells and flow sorted for GFP 
positivity.  DBA-GFP positive and DBA-GFP negative cells plated on collagen coated 12 wells 
at 25,000 cells per well (Reichert et al., 2013).  Ad5-CMV-CRE-eGFP (University of Iowa, 
Gene Transfer Vector core) was added at Multiplicity of Infection of 10 and 50 in DMEM+2% 
FBS to each 12 well and protein lysates were made at 48 and 72 hours, and processed using 
previously described western blotting techniques 
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Table 1.  Gene regulated by HGF and GRHL2 via RNA-Seq 
Genes regulated by HGF in the absence of GRHL2     
Gene ID  Fold Change 
(shGRHL2+hgf/shGRHL2) 
Significance in kidney development 
FGF9 -23.6 Maintains stemness of nephron progenitors (Barak et al., 2012) 
DUSP9 -22.6 Controls Erk activity in mouse embryonic stem cells (Li et al.) 
SLIT2 -9.8 Restricts kidney induction to a single site (Ji et al., 2012) 
Wnt11 -7.6 Cooperates with GDNF/RET in regulating ureteric branching (Majumdar et 
al., 2003) 
Wnt8a 6.4 Interacts with the BMP-4 pathway (Marom et al., 1999) 
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Figure legends  
Table 2.  Gene regulated by HGF and GRHL2 via RNA-Seq 
 Genes regulated by GRHL2 
Gene ID  Fold Change 
(shGRHL2/GRHL2) 
Significance in kidney development 
MMP-13 15.1 Necessary for MDCK tubulogenesis 
(Hellman et al., 2008) 
MMP-1 5.0 Necessary for MDCK tubulogenesis 
(Chacon-Heszele et al., 2014) 
BMP-4 3.5 Inhibits ureteric branching morphogenesis 
(Michos et al., 2007) 
TIMP1 3.3 Necessary for MDCK tubulogenesis 
(Hellman et al., 2008) 
Robo1 2.1 Expressed in immature glomeruli (Piper et 
al., 2000) 
FGFR2IIIC 1.9 Predominate FGFR2  isoform in the 
metanephric mesenchyme (Zhao et al., 2004) 
SALL1 1.7 Influences self-renewal and differentiation of 
renal progenitor cells (Basta et al., 2014) 
GFRα -2.7 RET ligand-binding co-receptor Ɨ (38) 
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Figure 1. GRHL2 was downregulated in clear cell renal cell carcinoma. A. GRHL2, 
GATA3, and Snai1 mRNA expression from GEO website, GSE15641. B. Proposed mechanism 
of GRHL2 downregulation in ccRCC. 
Figure 2. GRHL2 caused 786-0 ccRCC cells to undergo MET, prevented invasion, and 
increased anoikis.  A.  Western blot confirming GRHL2 expression in 786-0 cells.  B. GRHL2 
promoted an epithelial phenotype in 786-0 cells.  C.  GRHL2 suppressed HGF-induced invasion 
in 786-0 cell in three-dimensional matrigel culture.  D.  VHL and GRHL2 increased anoikis in 
786-0 as measured by cellular DNA fragmentation assay. Values represent relative DNA 
fragmentation between samples.  
Figure 3.  GRHL2 is not expressed in normal proximal tubule human kidney cell lines. A. 
Quantitative PCR for GRHL2 mRNA in HMLE, HKC-8, and 786-0 cell lines. B. Cell line panel 
for GRHL2 protein across multiple cell lines. (See discussion in results).  C.  HKC-8 western 
band was resistant to GRHL2 shRNA knockdown via western blotting.  
Figure 4. GRHL2 regulated FGFR2 isoform 3b exon inclusion. MDCK parent, GRHL2, and 
shGRHL2 cDNAs were used to amplify FGFR2 3 splicing region.  Differential digest was 
performed to determine the presence of FGFR2 3b (epithelial) and FGFR2 3c (mesenchymal) 
exon.  Quantification was performed by comparing FGFR2 3c fragment to FGFR2 3b fragment 
Figure 5. GRHL2 was down-regulated by HGF and GDNF. A. GDNF and HGF downregulated 
GRHL2.  MDCK+RET cells were treated with vehicle, 60ng/ml HGF and/or 50ng/ml GDNF for 
32 hours (Western blot). B.  GDNF and HGF downregulated induction of GRHL2 promoters. 
MDCK+RET cells were cotransfected with GRHL2 promoter-luciferase reporter constructs. 
Values represent relative luciferase activity normalized to TK-β-galactosidase control. 
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Figure 6. GRHL2+/- mice showed lower number of glomeruli.  A. Representative western blot 
of GRHL2+/+ and GRHL2+/-  kidney GRHL2 protein levels. B. Day 30 GRHL2+/+ and 
GRHL2+/- kidney sections were compared via glomerulis/mm2 (n=5). GRHL2+/+ mice had a 
9.7±2.6 per mm2 whereas GRHL2+/- mice had 6.4±1.3 per mm2.  p value < 0.01.  C.  
Representative images of GRHL2+/+ and GRHL2+/- glomeruli in H&E sections imaged with 
200.75 Fluar an Axiovert 200M microscope.  
Figure 7. RET and GRHL2 co-localization in GRHL2+/+ and GRHL2+/- mice.  Representative 
images of RET (Red), GRHL2 (Green), and merged co-localization using a ViewRNA ISH 
Tissue 2-plex assay system.  Images were obtained using Zeiss Violet Confocal, 20x.   
Figure 8. Effect of ureteric epithelial specific GRHL2-/- on ureteric tip count.  A. Control 
and GRHL2UB-/- kidneys were harvested at E13.5 and cultured for 48 hours.  B. Control and 
GRHL2UB-/- kidneys were harvested at E18.5.   Both A,B ureteric tips were counted and 
normalized to area (mm2).  Images were obtained using Olympus MVX10 Macro Zoom, ORCA-
Flash 4.0 Monochrome camera, Objective 2x, Zoom 4x, FITC, and using CellSen Imaging 
Software.   
Figure 9.  GRHL2flox/flox mice generated a 57 kDA active GRHL2 isoform. A. Schematic of 
Jane GRHL2flox/flox mouse model. B. Predicted GRHL2 isoform size depending on ATG Start 
Codon.  C. GRHL2flox/flox primary kidney cells treated with adenoviral-Cre.  DBA is an epithelial 
marker used for flow sorting of primary kidney cells.   
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Conclusions 
The present work examined the role of GRHL2 in an array of different systems and 
circumstances.  GRHL2 was not expressed in the normal kidney proximal tubule, and therefore 
highly unlikely to regulate clear cell renal cell carcinoma tumor progression. However, GRHL2 
could be used as a biomarker to distinguish between different renal cell carcinoma subtypes.  
GRHL2 was involved in multiple signaling pathways and processes that are crucial in kidney 
development, but further investigation using a ureteric epithelium specific GRHL2flox/flox mouse 
is required to understand the role of GRHL2 in the developing kidney.   
 In the MDCK model, GRHL2 was critical for cystogenesis but suppressed tubulogenesis.  
For the first time, GRHL2 was shown to interact with the histone acetyltransferase co-activator 
protein, p300, and inhibit its HAT activity thereby preventing its transcriptional activation of 
target genes.  These findings place GRHL2 among a rare group of proteins that can inhibit p300 
HAT activity.  The p300 HAT inhibitory domain of GRHL2 was mapped to amino acids 425-
437 with the following sequence: IRDEERKQNRKKG.  These 13 amino acids were required for 
GRHL2 to suppress tubulogenesis and cause a mesenchymal-epithelial transition.  Since p300 is 
critical for cells to differentiate, GRHL2’s inhibition of p300 HAT activity provides a 
mechanism for GRHL2 to enforce the default epithelial phenotype.   This work mechanistically 
positions GRHL2, a master regulator of the default epithelial phenotype, to antagonize p300, a 
co-activator required for cell differentiation, having vast implications in both developmental and 
cancer contexts.     
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Future Directions 
Because the ureteric epithelium GRHL2flox/flox model our laboratory generated was not 
informative, there are many unanswered questions left about GRHL2 and kidney development.  
Previous results from our laboratory and from Schmidt-Ott et. al. show that GRHL2 depletion in 
global GRHL2-/- mice, miMCD cells, and MDCK cells affect kidney tubulogenesis and lumen 
size, highly suggestive of an important role in kidney development (Werth et al., 2010; Aue et 
al., 2015).  The GRHL2flox/flox mice generated by Aue et. al. (which deletes exon 4) could be 
used in cooperation with the Zhao et. al. HOXB7creEGFP mice to elucidate the role of GRHL2 
in kidney development (Zhao et al., 2004; Walentin et al., 2015).  The expected outcome of 
these experiments would be renal agenesis because of the role of GRHL2 in establishing 
epithelial phenotype and cell polarity.  GRHL2 would be a tool for examining the importance of 
the ureteric bud in kidney development.  From a clinical perspective, GRHL2 mutations could be 
examined for causing renal agenesis or renal duplication anomalies.  
 As one of the main focuses of our laboratory is breast cancer, it would be highly 
informative to examine the effects of GRHL2 on mammary development.   OVOL2, a GRHL2 
regulated epithelial transcription factor, is known to affect mammary morphogenesis.   When 
OVOL2 is depleted in the mammary glands, the cells undergo an EMT and decrease milk 
production and alveologenesis (Roca et al., 2013).   At the very least, GRHL2 would be expected 
to have a similar effect as OVOL2 on mammary development.  The loss of GRHL2 in these cells 
would most likely cause a mesenchymal phenotype.  Also, GRHL2 may cause a more severe 
phenotype than OVOL2 since it regulates a vast number of genes other than OVOL2 in RNA-
Seq (Farris et al., 2016).  If the GRHL2 phenotype was more severe, a rescue of OVOL2 would 
be highly informative demonstrating alternative pathways not regulated through the 
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GRHL2/OVOL2 axis.  These results would significantly expand the understanding of GRHL2 in 
organogenesis.  This examination might provide novel GRHL2 interaction partners that occur 
during the developmental process with potential influences on breast cancer progression.   
Our laboratory proposed the default epithelial phenotype hypothesis for both 
development and cancer differentiation.  Under this hypothesis, the epithelial phenotype is 
adopted automatically by a cell in the absence of genomic/epigenetic alterations or inductive 
differentiation signaling (Frisch, 1997). Consistent with this idea, E-cadherin-expressing cells are 
the first to emerge at the late two cell stage; these eventually give rise to all differentiated cell 
types of the adult organism (Hyafil et al., 1980; Vestweber and Kemler, 1985; Fleming et al., 
1989; Larue et al., 1994).  Furthermore, GRH, the Drosophila GRHL2 homolog, is one of the 
first proteins expressed in the pre-cellular blastoderm zygote.  GRH is responsible for the 
regulation of the maternal-to-zygotic transition, the process where a zygote degrades maternal 
mRNA and starts transcribing its own mRNA (Harrison et al., 2010).     
In recent studies, other laboratories have suggested the default epithelial phenotype 
hypothesis may explain the mesenchymal-epithelial transition (MET) that occurs at metastatic 
sites (Thiery and Sleeman, 2006; Polyak and Weinberg, 2009; Tam and Weinberg, 2013). Our 
results demonstrating the interaction between p300 and GRHL2 provide another piece of support 
for this hypothesis.  The critical role of p300 in the differentiation of muscle, erythroid lineages, 
osteoblasts, oligodendrocytes, and stem cells has been clearly established.  The role of p300 in 
differentiation demonstrates the importance of epigenetic modifications in this process (Puri et 
al., 1997; Oike et al., 1999; Blobel, 2000; Polesskaya et al., 2001; Narayanan et al., 2004; Teo 
and Kahn, 2010; Zhang et al., 2016).  The ability of GRHL2 to inhibit p300 can explain the 
default epithelial phenotype hypothesis since critical co-activators such as p300 are required for 
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differentiation-specific but not epithelial-specific gene expression (Frisch, 1997).  These findings 
could also extend to critical roles in EMT, in contexts such as tubulogenesis and oncogenesis. In 
summary, p300 and related co-activators are crucial for cells to differentiate. Under the default-
phenotype hypothesis, the inhibition of p300 by GRHL2 provides a mechanism for GRHL2 to 
enforce the default epithelial phenotype. 
As described in Chapter 1, Roeder et. al. demonstrated that p300 interacts with the SET1 
complex through a p53 mediated event to regulate H3K4 trimethylation at activated promoters 
(Tang et al., 2013).   The SET1/MLL histone methyltransferase family is comprised of SET1A, 
SET1B, SET1C MLL1, MLL2, MLL3 and MLL4 (Yokoyama et al., 2004; Dou et al., 2005; Cho 
et al., 2007; Wu et al., 2008). MLL1 has also been shown to interact with CBP (Ernst et al., 
2001).  Also noted in Chapter 1, EMT is highly dependent on epigenetic regulation.  In our 
laboratory, GRHL2 was found to interact with MLL3/4 by a yeast two hybrid screen, and these 
results were confirmed by MLL3/GRHL2 co-immunoprecipitation (data not shown).  These 
findings have interesting implications.  GRHL2 interacts with two histone modifying factors, 
p300 and MLL3/4 which collaborate for gene activation (Tang et al., 2013).  Our laboratory has 
formed a collaboration with Robert Roeder (Rockefeller University) to examine these 
interactions.   Theoretically, GRHL2 could be recruiting these proteins to specific promoters, 
inhibiting the histone modifying factors, and/or modulating their enzymatic activities.  This 
would link GRHL2 directly to epigenetic methylation and acetylation events, and provide 
another mechanism of how GRHL2 establishes and maintains the epithelial phenotype.    
The result of our research with the most potential impact is the inhibition of p300 HAT 
domain by GRHL2.  p300 HAT inhibitors are currently an intense area of research with 
implications in cancer, diabetes, HIV infections, heart disease, and platelet cell production 
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(Chapter 1) (Dancy and Cole, 2015).  p300 HAT inhibitors have not been investigated in clinical 
trials to date (Dancy and Cole, 2015).   Two of the major issues facing p300 HAT inhibitors are 
lack of specificity when compared to other histone acetyltransferase families and/or cell 
impermeability making the chemicals difficult to use in vivo conditions.   GRHL2 appears to 
potently inhibit the p300 HAT domain, but more kinetic experiments need to be completed to 
determine the half maximal inhibitory concentration.  The GRHL2 13aa peptide could be 
targeted for cellular uptake by attaching the peptide to a peptide/protein transduction domain 
(Lönn and Dowdy, 2015), and its effect on cellular acetylation would be examined.  
Furthermore, the GRHL2 peptide could be mutated to find the critical residues for p300 
inhibition.  These critical residues could be used to model the GRHL2 and p300 interaction 
providing more information about the HAT domain and targetable sites that may have previously 
gone undiscovered.  The ability of GRHL2 to inhibit CBP or other histone acetyltransferase 
families would be informative and demonstrate the generalizability of GRHL2’s HAT inhibition.    
Our laboratory has previously published that activation of both the TGF-β and Wnt 
pathways are able to downregulate GRHL2 (Cieply et al., 2012), and our present work has 
demonstrated that HGF pathway is able to downregulate GRHL2.  All of these pathways are 
involved in tumor progression, and clinical trials are underway with selective inhibitors of these 
pathways in different cancers (Blagodatski et al., 2014; Neuzillet et al., 2015; Zhang et al., 
2015).  The examination of these inhibitors in the context of GRHL2 could provide a mechanism 
to pharmacologically upregulate GRHL2 and maintain the epithelial phenotype thereby 
preventing cancer metastasis.   
In summary, GRHL2 is critical for establishing the epithelial phenotype, and more 
research is required to understand its complex biological role.   
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31st, 2016) – WVU Cancer Institute undergraduate research program invited speaker  
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Pifer, PM. Advancements in Melanoma- PD1 inhibitors. (Jan. 21st, 2016) – WVU Cancer Cell Biology Journal 
Club  
 
Pifer, PM. Role of grainyhead-like 2 in the establishment of the epithelial phenotype (Jun. 24st, 2015) – WVU 
Genomics Group invited speaker  
 
Pifer, PM. The MD-PhD Track: A Brief Overview. (Jun. 8st, 2015) – IDeA Network of Biomedical Research 
Excellence (INBRE) invited speaker 
 
Pifer, PM, Frisch SM. GRHL2 in Kidney Tubulogenesis. (Nov. 16, 2014) Department of Biochemistry– Cancer 
Cell Biology Seminar.  
 
Pifer, PM, Frisch SM. GRHL2 in Kidney Tubulogenesis. (Apr. 28, 2014) Department of Biochemistry – Cancer 
Cell Biology Dissertation Proposal.  
 
Pifer, PM. Sharma SB, Farrugia MK. The MD-PhD Track: A Brief Overview. (Feb. 27st, 2014) – WVU American 
Chemical Society Student Affiliates invited speaker 
 
Pifer, PM, Frisch SM. The role of GRHL1 and GRHL2 in clear cell renal cell carcinoma. (Jan. 30, 2013) Department 
of Biochemistry – Cancer Cell Biology Seminar.  
 
Pifer, PM, Sharma SB, Farrugia MK, Pilkerton CK, Turner RC. The Physician-Scientist career track: How to be a 
successful MD-PhD candidate – (2011) WVU chapter of the American Physician-Scientist Association (APSA) 
sponsored talk 
Conferences 
American Physician Scientist Association Regional Meeting, (Oct 2015) SUNY UPSTATE Medical University, 
Syracuse, NY,  
Tackling Translational Challenges, 14th Annual World Preclinical Congress Conference, (Jun 2015) Focus on 
Novel Preclinical Models in Oncology and Targeting Histone Acetylation, Boston, MA  
54th Annual Meeting of Biophysical Society, (Feb 2010) San Francisco, CA,  
 
HONORS & AWARDS 
 
Featured Researcher, WVU Microscope Imaging Facility Newsletter                                                       2013 
• My research images were featured in the November issue 
 
Class Honors (Top 15%), West Virginia University School of Medicine                               2010-2011, 2011-2012 
• Awarded in Human Function, Public Health, Physical Diagnosis & Clinical 
Integration 1, Human Structure, Neurobiology, Pathology, Microbiology, 
Pharmacology, and Physical Diagnosis & Clinical Integration 2B 
 
Early Decision Scholar, West Virginia University School of Medicine                       2010  
• Early acceptance with priority scheduling  
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West Virginia University Medical Scholarship, West Virginia University School of Medicine                    2010  
• Awarded based on merit and financial need; ½ tuition waiver 
 
Most Outstanding Senior, West Virginia University                                      2010 
• One of thirty-five WVU graduating seniors of West Virginia University by 
the WVU Foundation 
 
Phi Beta Kappa Society, West Virginia University Chapter                         2010 
• Recognizes excellence in liberal arts and sciences 
 
Most Outstanding Chemistry Student, WVU College of Arts and Sciences                                          2010 
• Only one student per major chosen 
 
Phi Lambda Epsilon Member, West Virginia University                                                                2009–2010 
• WVU Chemistry Honorary  
 
Eberly College of Arts and Sciences Certification of Achievement Recipient, WVU                                2007-2010 
• Undergraduate and Graduate Division     
 
West Virginia PROMISE Scholarship Recipient, West Virginia University                                             2006 – 2010 
 
WVU Presidential Award for Excellence in Scholarship, West Virginia University          2006 - 2010 
• 4.0 GPA for four semesters 
 
Outstanding Junior Chemistry Major, ACS Northern WV Section                                                                           2009 
 
1st Place in WVNano Initiative Research Symposium, West Virginia University                                                 2009 
• Undergraduate  Division  
 
1st Place in WVU ACS Student Affiliates Chemical Symposium, WVU                                                                2009 
• Undergraduate and Graduate Division     
 
LEADERSHIP EXPERIENCE 
  
President of WVU American Physician Scientist Association Chapter                                2011-2015, 2015-2016  
• Member from 2011-present, President from 2015-20016 
 
Pre-Health Advisor Workshop, WVU School of Medicine                                                                           2014 
• Panelist 
 
President/Member of WVU Neurology Specialty Group                                                           2011-2012, 2010-2011  
• Member from 2010-2011, President from 2011-2012 
 
President/ Member of WVU American Chemical Society Student Affiliates                                           2007-2010 
• Secretary for 2008-2009, President from 2009-2010 
 
Coordinator of Chemistry Learning Center                                                                                                      2007-2010 
• Volunteer teaching Chemistry 115 and 116 and coordinating tutors  
 
Officer in WVU Undergraduate Mortar Board Honorary                                                                            2009 - 2010 
• Active leader in service events, social events and academic endeavors 
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COMMITTEES 
 
MD/PhD Student Admissions Committee            2012-2013, 2015-2016 
• Interviewed perspective incoming MD/PhD candidates  
 
Cancer Cell Biology Faculty Meeting Student Representative                                                   2015-2016 
• Advocate for student issues  
 
Eberly College Outstanding Teacher Award Committee Member                                                  2009-2010 
• Advocate for student issues  
 
TEACHING EXPERIENCE 
 
Mentorship of Undergraduate Researchers, West Virginia University School of Medicine                         2012-2016 
• Mentor of multiple undergraduate Biology Honor Thesis students 
 
Peer Advisor for MS1s, WVU School of Medicine                                                                                               2011-2012 
• Mentor to MS1 WVU medical students 
 
Head Tutor for Academic Resource Center, West Virginia University                                                           2008-2010 
• Chemistry tutor/teacher for WVU students 
 
Tutor for Chemistry Learning Center, West Virginia University Chemistry Department                           2007-2010 
• Chemistry tutor/teacher for WVU students 
 
Teaching Assistant, West Virginia University Chemistry Department                                                                     2008 
• Teaching Assistant for Honors Chemistry class  
 
WORK EXPERIENCE 
 
Pifers’ Service Center, Mineral Wells, WV                                                                               2003 - 2010 
• Light mechanic, cashier, CDL wrecker driver 
 
Tutor at Academic Resource Center, Morgantown, WV                                                                  2008-2010    
• Tutor from 2008-2009, Head tutor from 2009-2010 
 
Undergraduate Researcher, WVU Honors Sure, Morgantown, WV                                                               2009 
• Researching using Atomic Force Microscopy 
 
Teaching Assistant in WVU Chemistry Department, Morgantown, WV                                     2008 
• Teaching assistant for honors CHEM 117  
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VOLUNTEER ACTIVITES 
 
Community Service 
• Bartlett House:  Volunteer on Wednesday evenings in the kitchen to prepare dinner for residents of 
this transitional housing in Morgantown, WV 
• The MD-PhD Track Presentations for multiple undergraduate programs 
• WVU Fly-fishing Club, Get Trashed Event- picking up trash on Decker’s Creek 
• SAFE Clinic: participant; student and faculty run free health clinic  
• Class Trip to New Orleans, LA:  Service work with Habitat for Humanity in the Lower Nine 
• Coordinator of the Chemistry Learning Center  
 
*Over 200 hours logged in undergraduate; 140+ hours in medical school 
 
PERSONAL INTERESTS & HOBBIES 
 
Fly-fishing, traveling, backpacking, reading, and scuba diving  
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Tumor and Stem Cell Biology
Suppression of the Epithelial–Mesenchymal Transition by
Grainyhead-like-2
BenjaminCieply1, Philip Riley IV1, PhillipM.Pifer1, JosephWidmeyer1, JosephB. Addison1, AlexeyV. Ivanov1,2,
James Denvir3, and Steven M. Frisch1,2
Abstract
Grainyhead genes are involved in wound healing and developmental neural tube closure. In light of the high
degree of similarity between the epithelial–mesenchymal transitions (EMT) occurring in wound-healing
processes and the cancer stem cell–like compartment of tumors, including TGF-b dependence, we investigated
the role of the Grainyhead gene, Grainyhead-like-2 (GRHL2) in oncogenic EMT. GRHL2 was downregulated
specifically in the claudin-low subclass breast tumors and in basal-B subclass breast cancer cell lines. GRHL2
suppressed TGF-b–induced, Twist-induced or spontaneous EMT, enhanced anoikis sensitivity, and suppressed
mammosphere generation in mammary epithelial cells. These effects were mediated in part by suppression of
ZEB1 expression via direct repression of the ZEB1 promoter. GRHL2 also inhibited Smad-mediated transcription
and it upregulated mir-200b/c as well as the TGF-b receptor antagonist, BMP2. Finally, ectopic expression of
GRHL2 in MDA-MB-231 breast cancer cells triggered an MET and restored sensitivity to anoikis. Taken together,
ourfindings define amajor role for GRHL2 in the suppression of oncogenic EMT in breast cancer cells.Cancer Res;
72(9); 2440–53. 2012 AACR.
Introduction
The oncogenic epithelial–mesenchymal transition (EMT) is
a transcriptional reprogramming event that endows restricted
subclasses of tumor cells with enhanced metastatic and stem
cell–like properties. These properties include increased migra-
tion/invasion, chemo- and radiation resistance, anoikis resis-
tance, and extraordinary tumor initiation frequency, a cancer
stem cell–like capability (1, 2). In breast cancer, 2 subclasses of
tumors, "claudin-low" and "metaplastic", exhibit frank EMT-
like gene expression signatures. These are among the most
aggressive and least treatment-responsive tumors (3).
In general, TGF-b signaling can either promote or suppress
tumorigenicity and progression (4, 5). It can suppress tumors
through Smad-mediated induction of cyclin-dependent kinase
inhibitor genes such as p15, and inactivating mutations in this
pathway occur in certain tumors. In other contexts, however,
TGF-b can promote tumor progression by supporting onco-
genic EMT induction, through both transcriptional and non-
transcriptional mechanisms. For example, in claudin-low and
metaplastic mammary tumors—as well as in the stem cell–like
CD44high/CD24low tumor cell subpopulation fractionated from
breast tumors of other subclasses—TGF-b pathway compo-
nents are strikingly upregulated and, indeed, TGF-b receptor
kinase inhibitors partially revert the EMT-related gene expres-
sion profile (3, 6). This indicates a protumorigenic role of the
TGF-b pathway in this context.
Cell culture models confirm these conclusions. An exten-
sively characterized SV40 large T/hTERT-immortalized mam-
mary epithelial cell line, HMLE, exhibits spontaneous EMT in a
subpopulation of CD44high/CD24low cells (7). This EMT is
accompanied by upregulation of autocrine TGF-b signaling,
mainly through downregulation of antagonists such as BMP2/
4. Reversion to an epithelial phenotype could be achieved by
inhibition of this signaling pathway. Moreover, even Twist-
induced EMT in this system was partially dependent upon
autocrine TGF-b signaling, showing its functional significance
in multiple contexts.
The similarities between oncogenic and wound-healing–
related EMT, including TGF-b dependence, have been docu-
mented (8–10). In this light, we hypothesized that perhaps
other "dedicated" wound-healing genesmight prove important
in oncogenic EMT. Grainyhead family genes have been shown
to play an important role in wound healing, epidermal integ-
rity, and the mechanistically related process of embryonic
neural tube closure (11–14). Relevant, albeit limited, Grainy-
head family target genes identified so far include E-cadherin,
claudin-4, desmoglein-1, transglutaminase-1, rho-GEF19, sev-
eral Zelda-targeted genes expressed during the maternal–
zygotic transition (MZT) in Drosophila, and telomerase (11,
12, 14–17). With regard to cancer, Grainyhead-like-2 (GRHL2)
gene amplification has been noted in several tumor types,
including breast cancer, and suppressed death receptor
expression, conferring resistance to apoptosis mediated by
the corresponding ligands, indicating that GRHL2 was a
Authors' Affiliations: 1Mary Babb Randolph Cancer Center, 2Department
of Biochemistry, West Virginia University, Morgantown; and 3Department
of Biochemistry and Microbiology, Marshall University, Huntington, West
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potential oncogene (18). On the other hand, GRHL3 was
recently shown to suppress squamous cell carcinoma, due to
its activation of PTEN expression (19).
Inspired by its role in wound healing, we hypothesized and
report here thatGRHL2 suppressed EMTmediated by theTGF-
b signaling pathway. Consistent with this effect, GRHL2 was
downregulated specifically in EMT-dependent mammary
tumors (claudin low, metaplastic) and cell lines (basal-B).
ZEB1 was found to be required for EMT and was a direct
target for repression by GRHL2. GRHL2 also enhanced anoikis
sensitivity. These data suggest an EMT-suppressive function of
GRHL2 that is downregulated in the context of TGF-b/EMT-
driven tumor types.
Materials and Methods
Cell lines
HMLE, HMLEþ Twist-ER, and HMLEþ Ras cells (HMLER)
were generous contributions from R. Weinberg (The White-
head Institute, Cambridge, MA). HMLE and HMLEþ Twist-ER
were grown in a 1:1 mixture of Mammary Epithelial Growth
Medium (MEGM; Lonza) and [Dulbecco's Modified Eagle's
Medium (DMEM): Ham's F-12 (Gibco) þ 5% horse serum þ
1 penicillin-streptomycin-glutamine (PSG)þ 10mg/mL insu-
lin, 10 ng/mL EGF, 0.5 mg/mL hydrocortisone], where indicat-
ed, 4-hydroxytamixofen (10 ng/mL) was added to the HMLEþ
Twist-ER cells to activate the Twist-ER protein. HMLER cells
were grown in MEGM. MDA-MB-231LN were provided by E.
Pugacheva (West Virginia University) and were grown in
advanced DMEM (Invitrogen) þ 10% FBS þ 1 penicillin–
streptomycin–glutamine (PSG).
Generation of stable cell lines by retroviral transduction
Human GRHL2 was amplified from a template purchased
fromOpen Biosystems (MHS4426-99625903) and subcloned by
standard molecular biology methods into the pMIG or MSCV-
IRES-puro retrovirus (Addgene; XhoI site). Retroviruses were
packaged and amplified in GP2þ 293T cells by transfection of
4.5 mg of retroviral plasmid and 2.5 mg of pCMV-VSV-G per 60
mm2 dish of cells, with Mirus TransIT reagent. Viral super-
natants were collected 48 hours later, filtered through 0.45-
micron filters (Whatman) and 0.6 mL of supernatant was used
to infect 1 well of a 6-well dish of target cells by centrifugation
at 1,400 rpm for 1 hour followed by 6 hours to overnight
incubation. Infected cells were either selected for puromycin
(2 mg/mL for HMLE, 0.5 mg/mL for MDA-MB-231) or flow
sorted for GFP, followed by Western blot analysis to verify
expression.
Generation of stable cell knockdown cell lines by
lentiviral transduction and transient knockdown
(siRNA)
GRHL2, ZEB1, and scrambled control short hairpin RNA
(shRNA) were purchased from Open Biosystems in the pGIPZ
vector. (catalog numbers: shGRHL2a: RHS4430-99291384;
shGRHL2b: RHS4430-99614394 and shZEB1a: V3LHS_356186;
shZEB1b: 3 V3LHS_356187; the latter were also subcloned into
vector pTRIPz using Mlu1/Xho fragments). SiZEB1 Smartpool
was from Dharmacon catalog number (L-006564-01-0005) and
was transfected transiently using Lipofectamine RNAi-max
(Invitrogen).
Mammosphere assay
Mammospheres were seeded at 1 104 cells per well of a 6-
well Ultra Low Cluster Plate (Corning) and grown for 7 to 10
days in the appropriate growth media þ 0.5% methylcellulose
(MC). Wells were fed every third day with 1 mL media þ MC.
Total mammospheres per well were counted and the size
cutoff value was set at 150 mm in diameter; the same cells
were plated at 2  105 cells per well of a 6-well plate and the
number of cells was counted each day for 4 days, to measure
normal growth rate. Error bars represent the SD of replicates.
Anoikis assays
Cells were dissociated using TrypLE Express (Invitrogen),
counted and afixed amount 1 105 to 2 105 cells perwell of a
6-well Ultra-Low Attachment Cluster Dish (Costar) were sus-
pended in normal growth media þ 0.5% MC for the indicated
for 6 to 24 hours to induce anoikis. For cell death ELISA (CDE)
analysis of apoptotic DNA fragmentation, the cells were col-
lected in 3 volumes of media and then spun down at 1,500 rpm
for 3 minutes. The pellet was then washed with D-PBS (Invi-
trogen) transferred to a microfuge tube, pelleted at 7,000 rpm
for 15 seconds, and lysed in PBS þ 0.5% Triton X-100 þ 10
mmol/L EDTA (note: the lysis buffer with the Cell Death ELISA
kit from Roche was found to lyse cells inadequately). Lysates
were incubated on ice for 15 minutes with occasional mixing
and then centrifuged at 13,000 rpm for 12 minutes. The super-
natants were subjected to the CDE according to the manual
provided with the kit (Roche). Alternatively, percentage of cell
death was determined by a Trypan blue exclusion assay,
wherein cells were suspended in same manner but collected
and resuspended in Accumax (Innovative Cell Technology) to
ensure a single-cell suspension. After brief incubation (2–3
minutes), Trypan blue was added to this solution and the
percentage of dead cells were immediately counted on a
hemocytometer. All samples were analyzed in either duplicate
or triplicate, and time-zero cell death values were subtracted
from the data presented here.
Three-dimensional culture
Three-dimensional (3D) Matrigel culture methods were
adapted from (20). To summarize, 2.5  103 cells per well
were seeded onto 8-well chamber slides (Labtek) where 45 mL
Matrigel (Trevigen) had been evenly distributed. The cells were
overlaid with the appropriate growthmedia (see above)þ 2.5%
Matrigel. After 6 days in culture 3D migration/invasion was
quantified by counting the number of structures that had
formed protrusions versus those that grew as lobular struc-
tures defined by their contact with matrix (see images for
clarification). At least 200 structures were counted per exper-
iment; error bars represent the SD across 3 samples.
Microarray methods
RNA isolated by RNeasy Plus kit (Qiagen) was quantified
using Nanodrop (Fisher Scientific). The RNA quality was check
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on Bioanalyzer (Agilent). Two hundred fifty nanograms of each
RNA sample with an RNA integrity number (RIN) value greater
than 7 was processed by the Ambion WT Expression Kit
according to the manufacturer's instructions. The typical yield
from the reactionwas 6 to 9micrograms of cDNA. The required
amount of cDNA (5.5 mg) was processed for fragmentation and
biotin labeling by the GeneChip WT Terminal Labeling Kit
(Affymetrix). The efficiency of fragmentation reaction was
checked via Agilent Bioanalyzer. The entire reaction of frag-
mented and biotin-labeled cDNA (50 mL) with added hybrid-
ization controls was hybridized to the human GeneChip 1.0 ST
Exon Arrays (Affymetrix) at 45C for 17 hours in GeneChip
Hybridization Oven 640 (Affymetrix). Human GeneChip 1.0 ST
Exon Arrays were stained with FS 450_0001 protocol in Affy-
metrix GeneChip Fluidics Station 450. Briefly, biotin-labeled
cDNA was reacted using 2 rounds of washes with a solution
containing a streptavidin-phycoerythrin complex, with an
intermediate treatment of biotin-labeled antistreptadvidin
antibody to amplify the signal. Phycoerythrin labeling was
detected within the Affymetrix GeneChip Scanner 3000 7G
plus using 532 nm light and detected by a photomultiplier tube.
Expression Console software (Affymetrix) was used to check
quality controls of hybridized chips. All chips that passed
quality controls were RMA normalized with Expression Con-
sole software. The microarray data were deposited into the
NCBI GEO database as accession number GSE36081.
To examine the extent to which GRHL2 affects the pro-
pensity to undergo epithelial–mesenchymal transition
(EMT), we compared the relative expression of genes in an
identified EMT signature (21) to the relative expression of
genes in cells with constitutive GRHL2 expression. Specif-
ically, we obtained the expression profile of the 251 Core
EMT signature genes from Supplementary Table S1 (21) and
computed the mean log ratio of the relative expression. We
restricted the genes to those that appeared on our array
platform and computed the Pearson correlation coefficient
of those genes to the log expression ratio of GRHL2-regu-
lated genes compared with the control.
Reporter assays
HMLE were transiently transfected using Lipofectamine
2000 (Invitrogen) at a 1 mg DNA:2 mL Lipofectamine ratio. A
total of 1.5mgDNAperwell of a 12-well platewas themaximum
amount of DNA found to be tolerable. Transfection mixtures
were incubated for 20 minutes in 200 mL Opti-MEM (Invitro-
gen) and then added to the cells in normal growth media
lacking antibiotics. Cells were incubated for 4 hours then refed
with normal growth media. Lysates were made by washing the
cells once with PBS then lysing in 1 Cell Culture Lysis Buffer
(Promega). Lysates were centrifuged at 13,000 rpm for 10
minutes, and the supernatants were assayed for luciferase and
b-galactosidase activity as internal control. Luciferase assay
reagent was obtained from Promega and the b-galactosidase
2 assay reagent was 200 mmol/L sodium phosphate (pH 7.3),
2 mmol/L MgCl2, 100 mmol/L 2-mercaptoethanol, and 1.33
mg/mL o-nitrophenylgalactoside. The Smad reporter con-
struct 3TP-Lux was from Addgene. The ZEB1 promoter-lucif-
erase construct in pGL3 (22) was kindly provided by Antonio
Garcia de Herreros (Universitat Pompeu Fabra, Barcelona,
Spain). CMV-LacZ or TK-LacZ were used as internal controls.
The GRHL2 clone was purchased from Open biosystems,
catalog no MHS4426-99625903, and the coding sequence was
cloned into the XhoI site of pcDNA3.1þ. Subfragments of the
ZEB1 promoter were generated and cloned into pGL3-pro-
moter (MluI-BglII) using the following primers: fragment 1:
ZPfr1-f: Ttaat ACGCGT CCTTAAGGTCCTGCACGGCG, ZPfr1-
r: tatat agatct AAGTTCCGCTTGCCAGCAGC; fragment 2:
ZPfr2-f: TtaatACGCGT CTAGCCTCTCTTTCAATCCA, ZPfr2-
r: tatatagatctTCCGCCCCCCGCACCCCGGGGC; fragment 3:
ZPfr3-f: TtaatACGCGTCACGCGAGGCGTGGGACTGA, ZPfr3-
r: tatat agatct GGATGCCGGGAAACCGTAGG; fragment 4:
ZPfr4-f: Ttaat ACGCGT GCCTCCCTCTCCCCACCACA,
ZPfr4-r: tatat agatct ACCGCACCTGGTTTACGACA; fragment
5: ZPfr5-f: TtaatACGCGT GCGGACCGGGTGTGGGAGGC,
ZPfr5-r: tatat agatct TACCTGACCCGCGCAGCCCG; fragment
6: ZPfr6-f: Ttaat ACGCGT GCCTCTCTCCGGTCGCCGCG,
ZPfr6-r: tatatagatct GGGGCAGGGAGGGATCTGGC, fragment
7: ZPfr7-f: Ttaat ACGCGT GGGCAGCCGCGGCGGGTGTG,
ZPfr7-r: tatat agatct ACCGTGGGCACTGCTGAATT.
The primers used to mutate the fragment 4 construct
(using Stratagene Quickchange II XL kit) were: Mut-f,
gtaaagccgggagtgtcgtcccacaggtgcggtagatctgcg; and Mut-r,
cgcagatctaccgcacctgtgggacgacactcccggctttac.
Immunofluorescence
For Smad2 localization, TGF-b (5 ng/mL) was added for 6
hours and the coverslips were fixed with 4% paraformaldehyde
(PFA) in PBS for 10 minutes. PFA was quenched with 100
mmol/L glycine in PBS. Cells were permeabilized with 0.2%
Triton X-100 in PBS at 4 degrees for 10 minutes, washed twice
with PBS, and blocked for 1 hour in: PBS þ 10% goat serum þ
0.1% Tween-20þ 0.1% BSA. Primary and secondary antibodies
were diluted in blocking buffer. Primary antibodies were as
follows: SMAD2; Cell Signaling, rb, 1:200. Secondary: rb Alexa
555 (red); Molecular Probes, 1:1,000. Mounting media: Prolong
Gold w/DAPI (Invitrogen).
For E-cadherin, vimentin, and GRHL2 the cells were fixed in
100% methanol at 20C for at least 1 hour. They were then
washed twice with PBS and blocked as earlier. E-cadherin, ms
(BD Biosciences), 1:200; Vimentin, rb (Cell Signalling), 1:200;
GRHL2, rb (Sigma), 1:200. Secondaries used were anti-mouse
Alexa 555 (red) or anti-rabbit Alexa 488 (green) or A555 (red);
Molecular Probes, diluted 1:1,000. Coverslips were mounted in
Prolong Gold as above. Images were produced with the Axio-
vert 200M microscope, AxioCam MRM camera, and Axio
Vision 4.3.1 software (Zeiss).
Chromatin immunoprecipitation
A total of five 100-mm2 dishes of 4-hydroxytamoxifen
(4-OHT)–induced HMLE þ Twist-ER (þGRHL2, in some
experiments) were each fixed in 1.2 mL 10% electron micros-
copy grade PFA for 10 minutes. Following quenching with
glycine, chromatin immunoprecipitation (ChIP) was con-
ducted exactly as described previously (23) with the fol-
lowing antibodies, 3.3 mg each: GRHL2 (Sigma); Histone
H3 (Cell Signaling), or nonimmune rabbit IgG (Pierce).
Cieply et al.
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ChIP-derived DNA was analyzed by PCR using the fol-
lowing primer sets: ZEBf6, GCGAGGCGTGGGACTGAT-
GG; ZEBr6, AAAGTTGGAGGCTCGGCGGC; ZEBf10, CTGCA-
CGGCGATGACCGCT; ZEBr10, TTCCGCTTGCCAGCAGCC-
TC; GAPDH-f, ATGGTTGCCACTGGGGATCT; and GAPDH-r,
TGCCAAAGCCTAGGGGAAGA. For quantitative PCR analy-
sis, ChIP DNAs were analyzed using 2 Power-Sybr Green
Master Mix (Applied Biosystems) and signals were calculat-
ed relative to input DNA using the "DDCt" method; a cor-
rection of 1.5 was applied to adjust for the higher efficiency
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
amplification compared with ZEB1 amplification obtained
in a control reaction using lysates from GRHL2-null cells.
The primer set used was F8, GCCGCCGAGCCTCCAACTTT;
and R8, TGCTAGGGACCGGGCGGTTT.
Western blotting
SDS-PAGE was conducted using 4% to 20% gradient Tris
Glycine gels (Invitrogen). Proteins were immobilized by elec-
tophoretically transferring them to a polyvinylidene difluoride
filter (Immobilon) in 5% MeOH containing Tris-Glycine trans-
fer buffer. Filters were blocked in PBS þ 5% nonfat milk,
primary antibodies were incubated in PBS þ 0.1% Tween-20
þ 5% nonfatmilk, secondary antibodies were incubated in PBS
þ 0.1% Tween-20 þ 5% milkþ 0.01% SDS. Primary antibodies
were typically incubated for 2 hours to overnight, secondary
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antibodies were incubated for 1 hour. Primaries used were:
E-cadherin, ms (BD Biosciences); Vimentin, ms [Santa Cruz
Bio-Tech (SCBT)]; N-cadherin, ms (BD Biosciences); CD44
(HCAM), ms (SCBT); ESRP1/2, ms (Contributed by Russ Car-
stens, University of Pennsylvania, Philadelphia, PA); Actin, ms
(Millipore); Akt, rb or ms (Cell Signaling); GRHL2, rb (Sigma);
Zeb1, rb (Sigma) or rb (Cell Signaling); Ankyrin-G, rb (S.M.F.
custom generated; ref. 23); total-Smad2/3,ms (BDBiosciences);
phospho-Smad2/3, rb (Cell Signaling); NF2 (merlin), rb (SCBT).
Secondary antibodies for chemiluminescence were either anti-
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Figure 2. GRHL2 suppresses EMT. A, ectopic expression of GRHL2 suppresses the CD44 expression in the spontaneously occurring MSP of HMLE cells.
HMLE þ Twist-ER cells (without 4-OHT) infected with GRHL2 or empty retroviral vector (pMIG) were analyzed for CD44 expression by FACS. B, GRHL2
reverts MSP cells to an epithelial phenotype. The CD44high MSP of HMLE, obtained by flow sorting of HMLE cells, were infected with empty vector
(vec) or GRHL2 and then (top) stained for the indicated proteins by immunofluorescence or (bottom) probed for epithelial andmesenchymal marker genes by
Western blotting. C, GRHL2 expression in MSP cells restores anoikis sensitivity (left, top graph represents a DNA fragmentation ELISA assay; bottom graph
represents a Trypan blue permeability assay) and reduces mammosphere (middle), without affecting growth rate (right).
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mouse or anti-rabbit, conjugated to horseradish peroxidase
(Bio-Rad) and were used at 1:3,000 dilution; Western blot
analysis were developed using (ECL-West Pico; Pierce). Fluo-
rescently tagged secondary antibodies were mouse IRDye
800CW or rabbit IRDye 680LT (Li-Cor) used at 10:000 and
detected using the Odyssey Infrared Imaging System (Li-Cor).
Fluorescent images were converted to gray scale.
Other bioinformatics methods
We obtained GRHL2 expression data from NCBI Gene
Expression Omnibus (accession number GSE10885; ref. 3). We
compared the log expression of GRHL2 among the tumor types
basal, claudin, Her2, luminal, and normal. We carried out a
Tukey HSD test to determine which comparisons among these
groups showed statistically significant differences; family-wise
95% confidence intervals for the log expression were plotted.
Statistical analyses were conducted with R version 2.13.1
(www.r-project.org).
Results
Loss of GRHL2 expression is associated with a
mesenchymal phenotype
On the basis of the specific expression of GRHL2 in mouse
epithelia (12–14, 24), we investigated its potential regulation
during EMT. Using HMLE cells that express a Twist-ER
fusion—a previously characterized model of inducible EMT
(21)—we analyzed the levels of GRHL2 over a time course of
Twist induction by tamoxifen and found that, indeed, GRHL2
protein was downregulated during EMT with kinetics similar
to the loss of E-cadherin and gain of N-cadherin (Fig. 1A).
Consistent with this finding, spontaneous, stable EMT in a
subpopulation of HMLE cells ("mesenchymal subpopulation")
obtained by sorting for CD44high phenotype, described previ-
ously (7), also displayed low GRHL2 expression (Fig. 1B).
Breast cancer cell lines have been classified by gene expres-
sion profiles. One particular subclass, basal-B, was character-
ized by amesenchymal profile. GRHL2was dramatically down-
regulated, specifically in this subclass (Fig. 1C). Analogously,
the "claudin-low" subclass of mammary tumor samples—also
characterized by a mesenchymal gene expression profile and
poor prognosis—expressed substantially lower levels of
GRHL2 than other subclasses, which, in fact, showed a modest
upregulation, comparedwith normal breast tissue (Fig. 1D, and
see Discussion). GRHL2 was also downregulated dramatically
in a different tumor type characterized by EMT, clear cell renal
carcinoma (Supplementary Fig. S1). Moreover, chemoresistant
subpopulations of primary breast tumor cells obtained after
chemotherapy of patients by sorting for CD44high/CD24low
marker expression or mammosphere generation (25)
expressed decreased levels of GRHL2 as well (Fig. 1E).
These data suggested that GRHL2 loss is a widespread
characteristic of both primary and cultured tumor cells that
have undergone EMT and acquired a tumor-initiating pheno-
type, informed the hypothesis that GRHL2 downregulationwas
functionally important for EMT.
GRHL2 is an EMT suppressor
The spontaneously occurring, CD44highCD24low mesenchy-
mal subpopulation (MSP) cells within the heterogeneous
HMLE cell line are characterized by EMT, attributed to
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autocrine TGF-b signaling pathway activation (7). Infection
of HMLE cells with a GRHL2 expression construct and selec-
tion for the infected cells using a GFP marker caused the
disappearance of the CD44high subpopulation (Fig. 2A) within a
few days after infection, suggesting a conversion effect rather
than selective growth (as shown later).
To further characterize this phenomenon, we isolated
MSP cells from the HMLE cell line by flow sorting and
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infected these with the GRHL2 retrovirus. On the basis of E-
cadherin immunofluorescence and Western blotting for
epithelial and mesenchymal markers, GRHL2 reverted MSP
back to an epithelial phenotype (Fig. 2B). Anoikis resistance
and the ability to form mammospheres are key character-
istics associated with EMT in HMLE cells. GRHL2 expression
in the MSP cells restored anoikis sensitivity and reduced
mammosphere formation dramatically, without affecting
adherent cell growth (Fig. 2C).
These data indicated that GRHL2 reverted the sponta-
neous EMT and accompanying tumor-initiating cell char-
acteristics of MSP cells. To test the effect of GRHL2 in
other scenarios of EMT, we expressed it constitutively in
HMLE þ Twist-ER cells and in the prototypical EMT-like/
triple-negative breast cancer cell line, MDA-MB-231, where it
caused dramatic reversion of EMT and anoikis resistance in
both cases (Fig. 2D and E), indicating a surprisingly broad
specificity for this effect.
GRHL2 suppresses TGF-b–induced EMT
MSP cells and Twist-expressing HMLE cells rely on auto-
crine TGF-b signaling for their maintenance of mesenchymal
and tumor-initiating properties (7), suggesting that GRHL2
could be suppressing EMT through this common pathway. We
confirmed that Twist-mediated EMT and acquisition of anoi-
kis resistance were TGF-b–dependent by using LY364947, a
specific inhibitor of the TGF-bR1 kinase activity (Supplemen-
tary Fig. S2). Because this inhibitor mimicked the effects of
ectopic GRHL2 in some respects, we tested the effect of GRHL2
on TGF-b–induced EMT.
TGF-b alone was previously reported to be insufficient for
EMT induction in HMLE, a process requiring activation of
multiple pathways (7). When GRHL2 was partially depleted by
2 distinct shRNAs, TGF-b alone induced EMT more efficiently
than in cells with control shRNA (Fig. 3A). GRHL2 knockdown
facilitated several activities of TGF-b: induction of a mesen-
chymal morphology, downregulation of epithelial-specific
genes (E-cadherin, ESRP1 and ankyrin-G—an epithelial cyto-
skeletal protein that regulates anoikis; ref. 23), and upregula-
tion of vimentin as well as the tumor-initiating cell marker,
CD44S; surprisingly, TGF-b induced N-cadherin partly inde-
pendently of GRHL2 expression. Coincident with this facilita-
tion of EMT, GRHL2 knockdown also permitted TGF-b to
confer a mammosphere-generating, anoikis-resistant state
(Fig. 3A and B). GRHL2 also suppressed another feature of
EMT, the formation of large protrusive structures during the
growth of colonies in 3DMatrigel culture, indicative of invasive
potential (Supplementary Fig. S3).
These results suggested that signaling downstream of the
TGF-b receptor might be suppressed by GRHL2. We focused
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on Smad-mediated transcription, as it plays an important,
although not exclusive role in the response to exogenous
TGF-b–mediated EMT (4). Using a well-characterized reporter
assay (3TP-lux; ref. 4), GRHL2 knockdown stimulated TGF-b/
Smad-mediated transcription by approximately 4.6 relative
to control cells (Fig. 3C). Correspondingly, GRHL2 knockdown
promoted the induction of the TGF-b/Smad target genes,
CTGF (26), and ZEB1 (27), by exogenous TGF-b. Surprisingly,
there was no discernable effect of GRHL2 on either the phos-
phorylation or nuclear translocation of Smad2, suggesting that
other mechanisms of inhibition were operative (see Discus-
sion). These results indicated that GRHL2 inhibited Smad-
mediated transcription in response to exogenous TGF-b.
In HMLE cells expressing low levels of activated K-ras,
(HMLER), GRHL2 knockdown sufficed to induce EMT—that
is, even without exogenous TGF-b based on the criteria used
earlier (Fig. 3D). This EMT was clearly dependent upon auto-
crine TGF-b signaling, in that LY364947 reversed it (Supple-
mentary Fig. S4). The TGF-b signaling antagonists BMP2 and -4
were previously shown to be downregulated in MSP cells
relative to normal HMLE, which promoted autocrine TGF-b
signaling (7). Interestingly, BMP2 expression was activated by
GRHL2 (Fig. 3E), consistent with the idea that GRHL2 sup-
pressed not only TGF-b signaling in response to exogenous
ligands but also (by comparison with reported data on the
same cell lines; ref. 7) autocrine signaling.
GRHL2 represses ZEB-1 expression
Suppression of EMT by GRHL2 could occur by a diversity of
mechanisms. To elucidate one or more of these in an unbiased
manner, we conducted a microarray-based gene expression
profiling comparing the HMLE-Twist cells with or without
GRHL2 expression. This analysis revealed that genes regulated
by GRHL2 (GEO database accession number GSE36081) cor-
related negatively (R ¼ 0.7508) with genes regulated during
EMT (by multiple transcription factors) in the HMLE system,
validating the EMT-suppressive effect of GRHL2 (Fig. 4A). The
genes regulated by GRHL2 included markers of epithelial
versus mesenchymal phenotypes, several of which were ZEB1
target genes; transcription factors implicated in the control of
EMT were also noted.
Interestingly, one of themajor downregulated GRHL2 target
genes was the E-cadherin repressor/EMT inducer ZEB1, as
shown by RT-PCR (Fig. 3E) and Western blotting in MSP cells
(Fig. 2B), MDA-MB-231 cells (Fig. 2E), HMLEþ shGRHL2 cells
with TGF-b (Fig. 3A), HMLER þ shGRHL2 cells (Fig. 3D) and
HMLE þ Twist-ER cells (Fig. 2D). Functional consequences of
ZEB1 downregulation (28) such as the upregulation of mir-
200b/c (Fig. 4B) and ESRP1 (Fig. 3E) were also evident. The
downregulation of ZEB1 by GRHL2 was investigated further as
a potential mechanism for suppression of EMT.
To determine whether the ZEB1 gene could be a direct target
for GRHL2, we cotransfected the previously characterized ZEB1
promoter (22) together with GRHL2 into the MSP cells (which
express low endogenous GRHL2). This revealed a marked
repression of the ZEB1 promoter by GRHL2, as did the converse
experiment, transfection of the ZEB1 promoter into cells with or
without knockdown of endogenous GRHL2 (Fig. 4C).
Inspection of the approximately 1 kb of promoter sequence
that was GRHL2 responsive revealed several potential binding
sites for Grainyhead proteins. We tested approximately 200-bp
nested fragments of the ZEB1 upstream region, in the context of
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those due to Twist in the same cell line; a regression plot of this
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an SV40 promoter, for repression by GRHL2, and identified
one fragment (fragment 4) that was highly repressed. This
fragment contained a consensus GRHL2-binding site and also
carried a strong enhancer; the repression by GRHL2 was
completely eliminated by a 4-base mutation of this consensus
site (Fig. 4D). To determine whether the ZEB1 promoter was a
direct target for repression by GRHL2, ChIP analysis was
conducted, showing a strong enrichment of PCR signal using
GRHL2 antibody, with respect to nonimmune IgG or a primer
set (using GRHL2 antibody) representing an unrelated region
of the genome (Fig. 4E). These results indicated that GRHL2
repressed ZEB1 expression and interacted directly with the
ZEB1 promoter.
Suppression of ZEB1 is critical for the suppression of
EMT by GRHL2
ZEB1 plays a critical role in EMT in response to vari-
ous stimuli including TGF-b (29–33), informing the hypo-
thesis that GRHL2 suppressed EMT, at least in part, by
repressing ZEB1 expression. To test this, ZEB1 was
expressed ectopically, using a doxycycline-inducible pro-
moter, in the HMLE þ Twist-ER þ GRHL2 cells. By the
criteria of morphology, expression of epithelial and mes-
enchymal markers, and anoikis resistance, ZEB1 restored
EMT that had previously been blocked by GRHL2 expres-
sion (Fig. 5A). Analogous effects of ZEB1 expression were
also observed in MSP cells that had been reverted to an
epithelial phenotype by stable GRHL2 expression (Supple-
mentary Fig. S5). Conversely, in the HMLE cells where
GRHL2 knockdown predisposed the cells toward TGF-b–
induced EMT, ZEB1 knockdown blocked this induction
(Fig. 5B). Similarly, EMT that was induced by GRHL2
knockdown in HMLER cells was reversed by ZEB1 knock-
down (Supplementary Fig. S6). These results indicated
that the repression of ZEB1 was a key mechanism by
which GRHL2 suppressed EMT.
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Discussion
Mammalian GRHL2 is a transcription factor that plays
important role in epidermal junctions, in part due to activation
of target genes including claudin-4 and E-cadherin. Consistent
with this role, the Drosophila Grainyhead gene is among the
first transcription factors used in the MZT during embryonic
development (16), and the 3mammalian Grainyhead genes are
critical for embryonic and adultwound healing (11–14). In light
of the fact that wound healing is orchestrated in part by TGF-b
signaling (9), the suppressive effect of GRHL2 on this pathway
suggests that GRHL2may contribute to the resolution phase of
wound healing, wherein transient EMT-like cell conversions in
keratinocytes are instructed to reverse. The suppressive effect
of GRHL2 on oncogenic EMTmay be understood by analogy to
this function, given the similarities between the 2 contexts of
EMT (8).
The significance of mammalian Grainyhead proteins in
cancer is emerging. GRHL3 was recently shown to function
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as a tumor suppressor in squamous cell carcinoma, acting, at
least in part, as a direct activator of PTEN expression (19);
EMT-related issues were not examined, however. The GRHL2
gene shows frequent amplification in unclassified breast tumor
samples, and has been proposed as a potential oncogene in
breast cancer, due, in part, to its suppression of death receptor
expression (18). Consistent with this, modest upregulation of
GRHL2mRNAwas observed in luminal A, B, andHER2-positive
tumor types (Fig. 1D; although it is unclear whether this is an
artifactual result of expansion of the epithelial cell compart-
ment relative to normal mammary gland during tumor out-
growth). In contrast, our results show that GRHL2 is down-
regulated in EMT models and EMT-driven tumor subclasses,
and that it suppresses TGF-b–induced ZEB1 expression; in
light of the established protumorigenic potential of ZEB1, this
result predicts that GRHL2 will specifically suppress EMT-like
tumors (34, 35).
These results can be reconciled in light of the diametrically
opposed, context-dependent effects of TGF-b: growth arrest
and tumor suppression in certain tumors versus tumor pro-
motion in others (4). In breast cancer, fewer than 10% of
patients have tumor types (claudin low, metaplastic) in which
EMT/TGF-b contributes critically to tumor progression,
whereas in the majority of tumors (other basal, luminal A,
B, and HER2-positive subclasses)—which most transgenic
mouse models emulate—TGF-b is tumor suppressive (3, 36).
By targeting the TGF-b pathway, GRHL2 is predicted usually to
act as an oncogene (i.e., in the most common subclasses of
breast cancer) or, less frequently, as a tumor suppressor gene
(i.e., in EMT-like subclasses).
The results here indicate that GRHL2 interferes with the
response to TGF-b by at least 2 mechanisms, interference with
Smad2/3–mediated transcriptional activation and direct
repression of the ZEB1 promoter (diagrammed in Fig. 6).
Consistent with previous observations in other systems
(28, 37), ZEB1 was required for EMT in response to Twist,
TGF-b, and spontaneous conversion. GRHL2 also upregulated
mir-200b/c, consistent with a critical role of the established
ZEB1/mir-200 feed-forward regulatory loop in EMT (28). The
precise mechanism by which GRHL2 represses the ZEB1
promoter may relate to Grainyhead proteins' ability to repress
transcription, by recruiting polycomb repression complex
components or by interfering with the binding of a transacti-
vator (16, 38).
The mechanism by which GRHL2 inhibits Smad-mediated
transcription is unresolved at present. Previous work has
shown that ZEB1 protein can bind to the Smad2/3 complex,
enhancing transactivation (39); our preliminary observations
indicated that this mechanism did not apply in our system.
Smad2/3 nuclear versus cytoplasmic localization is regulated
by phosphorylation as well as signaling from the Crumbs
polarity complex through Hippo pathway components (26).
These mechanisms were, however, unlikely to explain the
suppression by GRHL2, because Smad phosphorylation and
nuclear translocation were not apparently affected. Other
nuclear proteins that affect Smad2/3 transactivation, such as
TGIF, Ski, and Sno (4), remain to be tested in the context of
GRHL2.
TGF-b–induced EMT is a highly restricted phenomenon in
cell culture models, occurring in only a small number of
epithelial cell lines (40). In fact, we observed that the mouse
mammary epithelial cell line NMuMg, commonly used to study
this phenomenon, has undetectable GRHL2 expression, where-
as other mouse mammary lines that are unresponsive do
express GRHL2 (Supplementary Fig. S7). These results are
consistent with the previous finding that additional factors
from the tumor microenvironment confer TGF-b responsive-
ness upon HMLE cells, suggesting that one or more of these
factors could function by downregulating GRHL2 (7). More
generally, the GRHL2 expression profile in breast cancer
samples and cell lines indicate that GRHL2 is a general barrier
to EMT. Accordingly, GRHL2 preventedTGF-b from conferring
anoikis resistance, mammosphere formation (a tumor-initiat-
ing cell behavior), and invasive growth in 3D culture, predicting
a tumor-suppressive effect in this context.
These results also suggest that GRHL2 may be a useful
biomarker for tumors predicted to respond to TGF-b receptor
inhibitory drugs currently in clinical trials (41): GRHL2-null
tumors, being susceptible to the tumor-promoting effects of
TGF-b, are predicted to respond specifically to this class of
drugs, an approach that could improve their efficacy
substantially.
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Abstract  
 
Resistance to anoikis is a pre-requisite for tumor metastasis. The epithelial-to-mesenchymal 
transition (EMT) allows tumor cells to evade anoikis. The wound healing regulatory transcription 
factor Grainyhead-like 2 (GRHL2) suppresses/reverses EMT, accompanied by suppression of the 
cancer stem cell (CSC) phenotype and by re-sensitization to anoikis. Here, the effects of GRHL2 
upon intracellular metabolism in the context of reversion of the EMT/CSC phenotype, with a view 
toward understanding how these effects promote anoikis sensitivity were investigated. EMT 
enhanced mitochondrial oxidative metabolism. While this was accompanied by higher 
accumulation of superoxide, the overall level of Reactive Oxygen Species (ROS) declined, due to 
decreased hydrogen peroxide. Glutamate Dehydrogenase 1 (GLUD1) expression increased in EMT, 
and this increase, via the product α-ketoglutarate (α-KG), was important for suppressing hydrogen 
peroxide and protecting against anoikis. GRHL2 suppressed GLUD1 gene expression, decreased α-
KG, increased ROS and sensitized cells to anoikis.  
Implications: These results demonstrate a mechanistic role for GRHL2 in promoting anoikis 
through metabolic alterations. 
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Introduction  
When deprived of connections to their extracellular matrix, normal epithelial cells trigger a 
process of programmed cell death referred to as anoikis (1). The ability to metastasize depends 
critically upon a cancer cell’s ability to evade anoikis (2-4).  The transcriptional reprogramming 
event known as the Epithelial to Mesenchymal transition (EMT) confers anoikis resistance and 
ultimately, increased metastatic potential (5). The increased phenotypic plasticity underlying 
transitions between epithelial and mesenchymal states is thought to be epigenetically driven (6-
10). One additional manifestation of this increased plasticity, aside from EMT, is that cancer stem 
cell subpopulations emerge, that, like cells resulting from EMT, are resistant to anoikis;  these 
contribute crucially to both metastasis and disease recurrence.  
The wound healing regulatory transcription factor, Grainyhead-like 2 (GRHL2), plays an 
indispensable role in the maintenance of the epithelial phenotype and branching morphogenesis 
(11-14). Previously, we reported that GRHL2 suppresses the oncogenic EMT, i.e., promotes MET 
(15-17).  The loss of GRHL2 expression is associated with aggressive, metastatic breast tumor types 
that contain an unusually large fraction of EMT-like subpopulations, and in the cancer stem cell-like 
subpopulation of tumors resulting from EMT and/or drug resistance. Interestingly, the constitutive 
expression of GRHL2 invariably led also to anoikis-sensitivity (15, 16).  The mechanism underlying 
this effect was unclear, however. 
Reactive oxygen species (ROS) are ubiquitously important in apoptosis through 
mechanisms such as direct mitochondrial peroxidation of cardiolipin, a lipid which sequesters 
cytochrome c, as well as direct inactivation of the anti-apoptotic Bcl-2 (18).  Accordingly, ROS 
contributes to anoikis as well as the non-apoptotic cell death of detached cells accompanying ATP 
loss (19, 20). It is unclear at present, however, whether changes in ROS levels occur in EMT or 
cancer stem cell transitions, and, if so, what drives these changes. 
The HMLE cell line is an immortalized mammary epithelial cell line that contains a 
CD44hi/CD24low subpopulation referred to as the Mesenchymal Sub-Population (MSP) that co-
expresses EMT and cancer stem cell phenotypes (21, 22).  Previously, we reported that MSP cells 
have low GRHL2 expression, and are resistant to anoikis (15, 16). Forced expression of GRHL2 in 
MSP suppressed their cancer stem cell-like as well as EMT phenotypes and sensitized them to 
anoikis.  The possibility that GRHL2 achieves the latter effect by altering intracellular metabolism 
has not been explored. 
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Glutaminolysis is a critical metabolic pathway on which tumors rely as a major alternate 
carbon source to glucose, with significant ramifications for cell proliferation, metabolic adaptability 
and cell survival (23-25). Following deamination of glutamine to produce glutamate, glutamate 
dehydrogenase-1 (GLUD1 or GDH1) generates the Krebs cycle intermediate α-ketoglutarate (α-KG), 
which is converted by the Krebs cycle to fumarate, an important cofactor for glutathione peroxidase 
enzymes.  Accordingly, α-KG is an important protective factor against oxidative stress, and GLUD1 
is over-expressed in breast and lung carcinomas (26, 27).  
In this paper, we report that, in reversing EMT, GRHL2 suppresses GLUD1 expression, 
elevating H2O2 ROS levels and promoting anoikis-sensitivity. GRHL2 also reversed the cancer stem 
cell-like shift to oxidative phosphorylation-based ATP production and cell survival. These results 
inform a novel connection between EMT, metabolic pathways, ROS and anoikis-sensitivity, 
regulated by GRHL2.  
 
Materials and Methods 
 
 Cell lines 
 HMLE, and HMLE+Twist-ER cells and generously provided by R. Weinberg (The Whitehead 
Institute, Cambridge, MA); MCF10A neoT cells were provided by F. Miller (Karmanos Cancer 
Center).  HMLE and HMLE+Twist-ER cells were maintained in Advanced Dulbecco’s Modified 
Eagle’s Medium (DMEM): Ham’s F-12 (Gibco) + 5% horse serum + 1X penicillin-streptomycin-
glutamine (PSG) + 10 μg/mL insulin, 10 ng/mL EGF, 0.5 μg/mL hydrocortisone. MCF10A neoT cells 
were maintained in the same media as HMLE cells with the addition of 0.1 μg/mL cholera toxin.  If 
indicated, HMLE+Twist-ER cells were growth in the presence of 4-hydroxytamoxifen (10 ng/mL) in 
order to activate the ER inducible Twist construct.  MSP cells were obtained from HMLE cells by 
sorting for CD44-APC high population/CD24-Cy5.5 LOW.  HMLE cells were sorted according to 
CD24-Cy5.5 high and CD44-APC low.  
 
Generation of stable cell lines by retroviral transduction  
The template for Human GRHL2 was purchased from Open Biosystems (MHS4426-
99625903). GRHL2 was subcloned by standard molecular biology protocols into the pMXS-IRES-
puro retroviral vector in frame with the C-terminal 3X-FLAG tag (vector contribution of Russ 
Carstens, University of Pennsylvania). Retroviral packaging and amplification was done in 
GP2+293T cells by transfection of 4.5 μg of retroviral plasmid and 2.5 μg of pCMV-VSV-G on 
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collagen coated 60 mm2 dishes that were pre-coated for >1 hr with 50 μg/mL collagen using 
Lipofectamine 2000 (Invitrogen). Plates were refed 4-6 hours following transfection and viral 
supernatants were harvested approximately 36 hours following refeed. Viral stocks were filtered 
through 0.45 μm filters (Whatman) and 1 mL of supernatant was used to infect 1 well of target cells. 
This was followed by 1,400 RPM centrifugation for 1 hour at room temperature followed by 6 hour 
or overnight incubation. Infected cells were passaged to 100 mm dishes, and incubated for 48 hours 
following infection.  Cells were then selected for puromycin (2 μg/mL for HMLE or MCF10A neoT 
cells).  
 
Generation of stable cell knockdown cell lines by lentiviral transduction 
 Lentiviral GLUD1 short hairpin RNA (shRNA) was purchased from Open Biosystems in the 
pLKO vector. ShRNA #1 was Open Biosystems catalogue number RHS3979-201758959 and 
shRNA#2 was RHS3979-201758962.  pLKO scramble control vector was generously contributed by 
the laboratory of Dr. Scott Weed (WVU).  Lentiviral constructs were packaged and amplified in 
293T cells by transfection of 3.5 μg shRNA vector, 2.3 μg sPAX2, and 1.2 μg CMV-VSV-G on 60 mm2 
dishes that were pre-coated for >1 hr with 50 μg/mL collagen using Lipofectamine 2000.   GRHL2 
shRNA was described previously and was shown to duplicate the biologic effects of transfected 
siRNAs (15). 
 
Western Blotting  
 SDS-PAGE was conducted using 4-20% gradient Tris-Glycine gels (Invitrogen). Proteins 
were electrophoretically transferred to polyvinylidine difluoride filters (Immobilon) in 5% 
methanol Tris-Glycine transfer buffer containing 5% methanol. PBS + 0.1% Tween-20 + 5% nonfat 
milk  were used for blocking filters, primary antibodies were incubated in PBS+0.1% Tween-20 + 
5% nonfat milk. Primary antibodies were typically incubated between 2 hours at room temperature 
or overnight at 4 degrees C. Primaries used were: E-cadherin, ms (BD Biosciences), CD44 (HCAM) 
ms [Santa Cruz Biotech (SCBT)]; GRHL2, rb (Sigma), Akt or pAkt, rb (Cell Signaling); GLUD1, rb 
(Abcam 168352), α-tubulin, Rb (Cell Signaling), Fibronectin, ms (BD Biosciences), GAPDH, ms 
(Origene), β-actin, ms (Thermo-pierce), SOD2, Rb (Cell Signaling), HIF1α, ms (BD Biosciences), 
p110, ms  (BD Biosciences), TOMM20, ms (BD Biosciences), VDAC1, Rb (Cell Signaling). Secondary 
antibodies for chemiluminescence were either anti-mouse or anti-rabbit, conjugated to horseradish 
peroxidase (HRP) enzyme (Bio-Rad). Secondary antibodies (Biorad) were used at 1:3000 dilution 
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and filters were incubated for approximately 1 hour at room temperature. Western blots were 
developed via ECL Super Signal West Pico (Thermo-Pierce).  
 
Anoikis Assays 
 For anoikis assays, caspase activation was measured using the Caspase-Glo 3/7 assay kit 
(Promega). Cells were dissociated using TrypLE Express (Invitrogen) and a fixed number of cells 
(1.5 x 105 cells) were placed per 6 well poly-(2-hydroxyethyl methacrylate) (poly-HEMA) coated 
low attachment plates in 2.0 ml of normal growth medium + 0.5% methylcellulose for the indicated 
time.  Aliquots of cells were mixed 1:1 with caspase glo reagent at indicated time points and 
assayed for luminescence utilizing a Wallac Envison Perkin Elmer plate reader according to 
manufacturer’s instructions.  Where indicated, time-zero cell death values were subtracted from 
the data presented to normalize for small loading variation.  
 
ROS Assays  
For ROS assay, cells were seeded as above and attached for 48 hours.  Cells were detached 
by trypsinization, and equal numbers of cells were placed in a 15 mL centrifuge tube. Cells were 
assayed immediately by flow cytometry after staining for 15 min at 37 degrees with 1 uM CM-
H2DCFDA (Invitrogen) protected from light.  If indicated, 24 hr ROS was examined after plating cells 
in low attachment polyHEMA (2 mg/mL) coated 100 mm dishes in 5 mL of 0.5% methylcellulose to 
prevent excess cell clumping. Cells were harvested by diluting well with 10 mL DME/F12 + 10% 
Horse Serum containing media. Cells were centrifuged at 2000 RPM for 2 minutes. Pellets were 
washed 2X with HBSS and stained in 1 uM CM-H2DCFDA as indicated previously. In some cases, 
Amplex Red (Invitrogen) assays were used to measure ROS in order to compare attached and 
suspended conditions and were used according to manufacturer’s instructions.  For measurement 
of general cellular superoxide, cells were processed as above and stained with 5 uM 
dihydroethidium (DHE) (Invitrogen) for 15 minutes at 37 degrees C protected from light followed 
by flow cytometric analysis at 605 nm fluorescence. Mitochondrial specific superoxide was 
measured using mitoSOX (Invitrogen) dye by staining cells with 5 uM mitoSOX solution for 10 
minutes at 37 degrees C protected from light. Samples were analyzed by flow cytometry at 580 nm 
fluorescence using a BD LSRFortessa Cell analyzer.  
ATP Assays  
 For the measurement of ATP in attached cells, Cell Titer Glo (Promega) reagent was added 
to 96 well plates. Luminescence was read after 10 minute incubation at room temperature. Values 
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were normalized based on BCA protein assay (Pierce).  To measure ATP in detached conditions, 
cells were detached and placed in 6 well poly-HEMA dishes. Aliquots were mixed 1:1 with Cell Titer 
Glo reagent. Values were normalized based on BCA protein assay (Pierce).  
 
JC1 Assay 
 Cells were seeded on poly-d-lysine coated MatTek dishes. Cells were incubated in 2 ug/mL 
JC1 (5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide) (Invitrogen) at 37 
degrees for 30 minutes protected from light. After incubation, dye was washed off of cells and 
replaced with normal growth medium. Cells were analyzed using an Axiovert 100M LSM510 Zeiss 
Confocal microscope.  Cells were excited with an argon-ion laser source at 488 nm.  JC1 monomer 
emission was observed at 529 nm and J-aggregate emission was observed at 590 nm.  Images were 
acquired using 20X/0.75 Plan-Neofluar objective.  Software used was Zeiss AIM software, version 
3.2.  
 
Oxygen Consumption and Extracellular Acidification Rate 
 The oxygen consumption rates (OCR) and extracellular acidification rate (ECAR) of 
adherent cells were measured utilizing the Seahorse XF Extracellular Flux Analyzer (Seahorse 
Biosciences Inc., North Billerica, MA). This method of analysis allows for real time monitoring of 
extracellular acidification rates and oxygen consumption based on two fluorimetric probes inserted 
into the small volume well. Equal numbers of cells (7500 cells per well) were seeded in a defined 
small volume in Seahorse XF-96 well plates.  The following day, wells were refed with fresh HEPES 
buffered media approximately 1 hour prior to assay.  In short, the sensor cartridge was loaded with 
metabolic inhibitors to target specific components of the electron transport chain at specific times, 
while monitoring pH change as well as oxygen consumption. The metabolic inhibitors used are 
oligomycin (ATP synthase inhibitor), followed by the protonophore FCCP (an uncoupler of 
oxidative phosphorylation), and finally a combination of rotenone (complex I inhibitor) and 
antimycin A (complex III inhibitor). Basal OCR and ECAR measurement during time course 
treatment with the inhibitors listed above allow for calculations of basal OCR, maximum 
mitochondrial respiratory capacity, OCR due to proton leak, ATP production, spare respiratory 
capacity, and non-mitochondrial derived OCR.   Fatty acid oxidation study was done by treating 
cells overnight prior to assay with substrate limited media (DME/F12 media + 1% horse serum, 0.5 
mM carnitine hydrochloride [pH adjusted], 1X PSG, 0.5 mM D-(+)-Glucose, 5 mM HEPES buffer). On 
day of assay, substrate limited media was replaced with FAO medium 45 minutes prior to the start 
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of the assay (Homemade Krebs Henseleit Buffer modified with CaCl2: To 500 mL sterile water the 
following was added: 111 mM NaCl, 5.7 mM KCl, 1.25 mM CaCl2, 2.0 mM MgSO4, 1.2 mM Na2HPO4; 
This buffer was supplemented with 2.5 mM glucose, 0.5 mM carnitine, 5 mM HEPES, pH adjusted to 
7.4 with NaOH). 15 minutes prior to start of assay, 40 μM Etomoxir was added to the appropriate 
wells. At the beginning of the assay, either palmitate:BSA or BSA control was added to appropriate 
wells. Mitostress test was the conducted according to manufacturer’s instructions.  For glycolytic 
stress test, cells are deprived of glucose for approximately 1 hour prior to the beginning of the 
assay. ECAR is measured and glucose is re-introduced to the media. The increase in ECAR is 
attributed to glucose conversion to pyruvate through glycolysis. Oligomycin is then added to shunt 
all metabolic function to glycolysis, which results in a large increase in ECAR indicating the 
glycolytic reserve. Following addition of 2-deoxy-glucose (competitive inhibitor of hexokinase), the 
non-glucose derived OCR can be calculated.  
 
Flow Cytometry Sorting  
 Trypsinized cells (1 x 106) were stained with APC tagged mouse anti-human CD44 (BD 
Biosciences 560890), and PerCP-Cy5.5 tagged mouse anti-human CD24 (BD Biosciences 561647) in 
100 uL of flow sorting buffer (1X PBS, 2.5 mmol/L EDTA, 10 mmol/L HEPES, and 2% horse serum) 
on ice protected from light for 30 minutes.  Following staining, cells were washed with 1X HBSS and 
resuspended in flow sorting buffer. Cells were analyzed and sorted using a FACS-Aria.  
 
Cell Culture Antioxidant Treatments  
 For suppression of reactive oxygen species, the following antioxidants were used. Where 
indicated, HMLE cells were treated with N-acetyl cysteine (NAC) at the concentration indicated for 
1 hr prior to assay.  Reduced glutathione (GSH) was added to HMLE cells after pH correction to 7.4 
and incubated for approximately 1-2 hours depending on experiment at the indicated 
concentration. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) was added to 
cells at the indicated concentration for overnight pretreatment of HMLE or HMLE+shGLUD1 cells.  
HMLE or HMLE+shGLUD1 cells were treated with cell permeable di-methyl-α-ketoglutarate 
(Sigma) which was pH corrected to 7.4. Cells were treated at the indicated concentration between 
overnight and 2 hour pre-treatment.  
 
RNA Sequencing  
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 RNA was isolated in triplicate from both MSP cells expressing vector alone or stably 
expressing GRHL2.  For RNA isolation, the RNeasy Plus Kit (Qiagen) was used and was quantified 
using Nanodrop (Fisher Scientific). The RNA quality check was performed on Bioanalyzer (Agilent). 
RNA quality check and libraries builds were done by the WVU genomics core.  RNA samples were 
then sent to the University of Illinois Core Facility for 100BP single end data RNA sequencing. 
FastQC was used to visualize quality of sequencing.  After it was determined that no filtering was 
needed, the reads were mapped to hg38 using STAR. The data was then quantified with 
featureCounts with the following flag set: —ignore dup—primary. This count data was used as input 
into DEseq2 to produce a list of differentially expressed genes with some visualizations also included. 
The list of genes with FPKM was also acquired and was produced from the count data with a simple 
custom script.  
 
 Kinetic α-KG assay 
 HMLE, MSP, or MSP+GRHL2 cells were seeded in 6 well dishes in duplicate wells and 
allowed to attach for 24 hours. Wells were washed 2X with PBS, followed by lysis in 300 uL RIPA 
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton-X100, 1% Sodium Deoxycholate, 0.1% sodium 
dodecyl sulfate, + pierce miniprotease inhibitor table per 10 mL lysis buffer). Lysates were scraped 
into microfuge tubes and cleared in cold centrifuge at 4ºC at full speed for 10 minutes. Supernatants 
were saved and assayed in 100 uL reaction buffer (100 mM KPO4 pH 7.2, 10 mM NH4Cl, 5 mM 
MgCl2, and 0.15 mM NADH added immediately prior to assay).  10 uL of sample were added to 100 
uL reaction buffer. Immediately prior to the beginning of the assay, 0.7 uL (0.5 units) of L-
Glutamate Dehydrogenase enzyme (bovine liver, sigma G2626) was added to each of the wells 
using a multi-channel pipettor. Positive control samples were done to ensure linear range of α-KG 
concentration in samples.  OD was read kinetically at 37 ºC at 340 nm reading the sample every 10-
20 seconds depending on the number of samples in the assay.  Depending on the level of α-KG in the 
sample, the reaction would proceed more quickly or more slowly. The slope of the line created by 
monitoring the decline in NADH absorbance as it was used up in the reaction was calculated and 
indicated the relative concentration of α-KG.  Calculated slopes were normalized to protein in the 
samples as determined quantitatively by BCA assay (Pierce).  
 
Extraction of Cells for LC-MS Analysis  
 All solvents used were high quality HPLC gradient grade and sterile milliQ grade water was 
used.  Cells were plated in triplicate per condition in 6 well dishes.  Cells were seeded for at least 24 
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hours prior to extraction.  Wells were washed 3X with PBS. Extract solution was made up of 50% 
methanol, 30% acetonitrile, and 20% milliQ water.  Extraction buffer was pre-chilled in a dry ice 
ethanol bath.  Eppendorf tubes were pre-chilled in a dry ice/ethanol bath placed in a metal heating 
block for maximum cooling.  Intracellular extracts were made by adding 500 uL of pre-chilled 
extraction buffer to wells and placing plate on a shaker in the cold room for 10 minutes. The 
solution was then transferred into pre-chilled Eppendorf tubes. Samples were centrifuged at 0 ºC at 
full speed for 10 minutes. Supernatants were transferred to HPLC vials and stored at -80 ºC. For LC-
MS method, Column was the sequant Zic-pHilic (150 mm × 2.1 mm i.d. 5 μm) with the guard column 
(20 mm × 2.1 mm i.d. 5 μm) from HiChrom, Reading, UK. Mobile phase A: 20 mM ammonium carbonate 
plus 0.1% ammonia hydroxide in water. Mobile phase B: acetonitrile. The flow rate was kept at 
100 μl min−1 and gradient as follow: 0 min 80% of B, 30 min 20% of B, 31 min 80% of B, 45 min 80% of B. 
The mass spectrometer (Thermo Exactive Orbitrap) was operated in a polarity switching mode. 
 
Immunofluorescence 
Cells were plated on chamber slides (LabTek154526) using ~0.5 ml medium per 
chamber.  Wells were pre-coated with sterile 0.5 mg/ml poly-lysine or 20 ug/ml collagen for ~1 
hour, and washed off prior to plating.  Cells were washed in HBSS or D-PBS, and fixed in EM grade 
4% formaldehyde in 1X PBS for 20 minutes at room temperature.  Cells were washed 2X with 
PBS.  Samples were then permeabilized in 0.5% TX100 in PBS at 4 degrees for 10minutes. 
Permeabilization solution was washed 2X with PBS.  Cells were incubated in 100mM glycine in PBS 
for 10 minutes to quench the formaldehyde.  Cells were blocked for one hour in PBS+10% goat 
serum+0.1% Tween-20+0.1%BSA for 1 hour. Primary antibody was diluted in blocking solution, 
and incubated 1 hr/RT or overnight/4 degrees (TOMM20, ms; BD Biosciences). Primary antibody 
was typically diluted 1:250.  After probing, cells were washed with PBS+0.1% Tween-20, 3X. 
Secondary antibody (Anti-mouse Alex Fluor 555; Invitrogen) was diluted in blocking solution, and 
incubated 1-2 hr/RT (typically 1:1000 dilution).  Cells were washed again with PBS+0.1% Tween-
20, 3X.  Samples mounted in ProLong Gold+DAPI.  
 
Statistical Analysis 
Error bars in graphs represent SDs. P-values were calculated using a Student’s two-tailed t-
test. 
 
Results  
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EMT shifts metabolism from glycolysis to oxidative phosphorylation, which is reversed by GRHL2. 
 
MSP and TGF-β-induced MCF10aneoT cells result from EMT that requires GRHL2 down-
regulation (15, 16, 28), accompanied by a CD44highCD24low marker profile (figure 1A).  Re-
expression of GRHL2 sensitized these cell lines to anoikis significantly, as assessed by a caspase 
activation assay (figure 1B, 1C, figure S1A).  Conversely, the stable knockdown of GRHL2 using 
shRNA conferred anoikis-resistance in HMLE+Twist-ER cells as well as MCF10A neoT cells (figure 
1D, S1B).  
We first endeavored to characterize the effect of EMT and, conversely, the effect of GRHL2-
induced MET on metabolism in our system.  We found that the ATP level in attached MSP cells was 
elevated significantly compared to HMLE cells.  When cells were suspended, ATP level declined 
significantly in HMLE cells, but was maintained in MSP cells, even at twenty-four hours of 
suspension (Figure 2A).  GRHL2 reduced the level of ATP in both suspended and attached MSP cells 
(figure 2B).  
In light of the higher efficiency of mitochondrial oxidative phosphorylation compared to 
glycolysis in the production of ATP, these results suggested that EMT perhaps caused a shift to the 
former. MSP cells had a higher mitochondrial membrane potential (ΔΨ), reflecting increased 
oxidative phosphorylation.  Conversely, GRHL2 overexpression resulted in decreased ΔΨ in MSP 
cells (Figure 2C).  These results, and the marked ATP differences, indicated that EMT shifted cells 
toward an increased utilization of mitochondrial oxidative phosphorylation to increase basal ATP 
levels and sustain ATP even in suspended cells.   
In order to test the effect of EMT or GRHL2-induced MET on regulation of oxidative 
metabolism specifically, we compared oxygen consumption rate in HMLE, MSP, and MSP+GRHL2 
cells using the Seahorse mitochondrial stress test.  The Seahorse XF assay system measures 
extracellular acidification rate (ECAR) as well as oxygen consumption rate (OCR) in order to 
determine fluxes in metabolic parameters that occur upon addition of various inhibitors and 
stimulators of the electron transport chain.  Our results indicated that MSP cells had greater ATP, 
maximum respiration, as well as spare oxidative capacity relative to HMLE cells, and re-expression 
of GRHL2 reversed these effects (figures 3A,B).  The increased mitochondrial activity of MSP and 
reversal by GRHL2 were not limited to cells utilizing glucose and glutamine as carbon sources, as 
similar effects were seen with the fatty acid carnitine as the sole carbon source (figures S4A,S4B). 
Moreover, HMLE cells had higher glycolytic activity than MSP cells (figure S2A). Stably depleting 
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GRHL2 in both HMLE+Twist-ER and MCF10A neoT cells partially reversed the mesenchymal 
metabolic phenotype, increasing ATP and maximum respiration (figure S2B, S2C, S2D). To 
determine whether the increased OCR observed was due to elevated mitochondrial number, cell 
lines were stained for a mitochondrial structural protein, TOMM20. Surprisingly, we found that 
MSP cells had lower mitochondrial staining than HMLE cells (figure S2E, S2F). This may indicate 
that HMLE cells partially compensate for low mitochondrial activity by up-regulating mitochondrial 
biogenesis.  Taken together, these results confirmed that mesenchymal cells enhanced oxidative 
phosphorylation, and partially suppressed glycolysis, both of which are counteracted by GRHL2. 
Confirming this observation, we found that treatment with 2-deoxyglucose (2-DG) resulted in 
greater decrease in ATP level in HMLE cells (58% of no treatment control) and MSP+GRHL2 cells 
(59.1% of no treatment control) than in MSP cells (72.1% of no treatment control) (figure S3A). 
GLUD1 depletion did not directly affect ATP levels, as reported (29).  The loss of GLUD1 did, 
however, result in a decrease in mitochondrial membrane potential (figure S3B).      
 
EMT suppresses the accumulation of ROS; reversal by GRHL2 
 
 To identify genes regulated by GRHL2 underlying its metabolic effects, we conducted RNA-seq 
analysis.  Surprisingly, we did not find that major ETC components or Krebs cycle metabolic 
enzymes were significantly affected by GRHL2 expression, with the possible exception of pyruvate 
dehydrogenase kinase 4 (PDK4), but its levels were highly sensitive to the initial conditions of each 
individual experiment, precluding definitive conclusions as to its regulation (data not shown).  
GRHL2 did, however, regulate several genes that participate in reactive oxygen species (ROS) 
regulation (Table 1).  Interestingly, GRHL2 expression did not significantly affect expression of the 
major ROS regulatory enzymes superoxide dismutase or catalase (Table 1).  
We compared endogenous ROS levels in HMLE, MSP, and MSP+GRHL2 cells. We found that the 
MSP cells display a significant reduction in ROS by fluorigenic reporter assay (CM-H2DCFDA) in 
both 0 hour and 24 hour suspended conditions, and that GRHL2 increased ROS to the approximate 
level detected in HMLE cells (figure 4A). Inducing EMT in the basal mammary epithelial cell line, 
MCF10A neoT, with TGF-β treatment resulted in decreased ROS; further, overexpression of GRHL2 
elevated ROS level (figure S5A). Conversely, shRNA depletion of GRHL2 suppressed ROS levels both 
in  HMLE+Twist-ER cells and MCF10A neoT cells (figures 4C, S5D).  
To identify the species of ROS present, we analyzed cells with a variety of fluorometric dyes 
with varying species selectivities. CM-H2DCFDA staining is a general ROS indicator that responds 
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well to hydrogen peroxide (H2O2).  In order to verify that this was the predominant species, we 
stained cells with MitoSOX red, dihydroethidium (DHE), and Amplex red-hydrogen peroxide 
reporter.  Amplex Red, which reports hydrogen peroxide specifically, indicated ROS trends similar 
to those obtained by CM-H2DCFDA staining in both attached and suspended conditions (figure 4B).  
MitoSOX red and DHE staining report mitochondrial and generalized superoxide, respectively.  
These probes showed that HMLE cells had lower mitochondrial and general superoxide (O2.-) levels 
than MSP cells and that overexpression of GRHL2 resulted in a decreased O2.- level (figure S5B, S5C). 
Mitochondrial electron transport is the major source of cellular superoxide (30).  In this light, our 
superoxide data correlated well with our data on mitochondrial oxidative phosphorylation.  These 
data indicated clearly that mitochondria are not the major source of higher ROS in normal epithelial 
cells or GRHL2-reverted epithelial cells, as this ROS was hydrogen peroxide, not superoxide, and 
mitochondria were more active in mesenchymal cells, which had lower overall ROS. 
   We further sought to examine the role played by ROS in contributing to anoikis sensitivity. 
HMLE cells were treated with two common antioxidant compounds including reduced glutathione 
and the vitamin E derivative, Trolox.  We found that these compounds reduced ROS level in cells 
and significantly reduced both ROS and sensitivity to anoikis (Figure 4D). In figure S5A, we show 
that MCF10a neoT cells experience a large ROS burst between 0 and 24 hours.  Speculatively, this 
burst may occur much earlier in HMLE cells, resulting in little difference between 0 and 24 hours. It 
is also plausible that in HMLE cells at 24 hours, enough cell death has occurred to obscure the ROS 
burst. These findings support the crucial role of ROS in triggering anoikis. 
We have previously reported that CD44S, which is upregulated in MSP cells, contributes to 
anoikis resistance (31). CD44 was shown elsewhere to decrease ROS by shifting metabolism from 
oxidative phosphorylation toward glycolysis and pentose phosphate pathways, thereby increasing 
reduced glutathione levels (32). Consistent with this, the stable knockdown of CD44 resulted in 
increased ROS, and increased sensitivity to anoikis (figure S7A, S7B).  Our metabolic findings were 
inconsistent with the mechanism proposed in (32) because we observed a shift toward oxidative 
phosphorylation in MSP cells (figure 3) and because reduced glutathione levels in HMLE and MSP 
cells were similar (figure S8).  
Interestingly, neutralizing cellular ROS in HMLE cells with the scavenger N-acetyl cysteine 
(NAC) resulted in a significant increase in ΔΨ (Figure 4E). Neutralizing ROS in MSP+GRHL2 cells  
replicated this effect (figure S6A),  indicating that the low-ROS cellular environment could play a 
role in sustaining the elevated mitochondrial function that we observed in mesenchymal cells 
(figure 2). 
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EMT up-regulates glutamate dehydrogenase-1; reversal by GRHL2 
 
Our RNA-seq data indicated that GRHL2 down-regulated several genes that have well 
established effects on ROS in other systems (Table 1). Although NQO1 knockdown potentiated 
anoikis in non-small cell cancer cells (33), manipulation of the levels of NCF2/p67PHOX, ALOX15, 
FAT4 and NQO1 produced no significant change in ROS in our cells (data not shown).  GRHL2 also 
down-regulated Glutamate Dehydrogenase 1 (GDH1 or GLUD1), an enzyme implicated in the 
suppression of ROS (27).  By western blotting, we found that GLUD1 protein was upregulated in 
MSP cells relative to HMLE cells, and downregulated in MSP by GRHL2 expression, in agreement 
with our RNA-seq data (figure 5A).  Similarly, EMT that was generated by transient activation of 
Twist-ER protein also up-regulated GLUD1, which was prevented by GRHL2 (figure 5B);  similar 
effects were found in TGF-β-induced MCF10a neoT cells (Figure S8). Conversely, GLUD1 expression 
increased following depletion of GRHL2 in both HMLE+Twist-ER and MCF10A neoT cells (figure 
5C), indicating that GRHL2 is an important repressor of GLUD1.  
 Depletion of GLUD1 was previously shown to reduce α-ketoglutarate (α-KG) levels, 
indicating that GLUD1, through glutaminolysis, is a major source of α-KG (27).  Interestingly, we 
found that MSP cells have an elevated α-KG:succinate ratio relative to HMLE cells and that GRHL2 
decreased α-KG, using both enzymatic and liquid chromatography/mass spectrometric assays, 
consistent with the expression levels of GLUD1 (Figure 5D, 5E, 5F).     
 
GLUD1 suppresses ROS and anoikis  
  
Next, we tested the effects of altered GLUD1 and α-KG levels on ROS and anoikis. The stable 
knockdown of GLUD1 enzyme using shRNA transduction resulted in both an increase in ROS level 
as well as increased sensitivity to anoikis (figure 6A). A similar effect of GLUD1 knockdown was 
observed in HMLE+Twist-ER cells (figure S8C).  
To confirm that the GLUD1 effect on ROS was mediated by α-KG, we tested the effect of α-
KG supplementation using the cell-permeable di-methyl-α-ketoglutarate derivative in GLUD1-
depleted cells.  This resulted in a dose dependent protection from anoikis as well as a reduction in 
ROS in HMLE cells (figure 6B).  Moreover, the excess anoikis observed in HMLE cells as well as 
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MSP+GRHL2 cells was suppressed by α-KG replacement, demonstrating that the loss of GLUD1 
promoted anoikis through ROS (figure 6C, 6D, S10).  Neutralizing ROS with antioxidants or α-KG 
partially protected HMLE+shGLUD1 cells against anoikis as well (figure 6E, 6F).  These data 
indicate the critical role of GLUD1 up-regulation during EMT, resulting in protection from anoikis 
by suppressing ROS, and the converse role of GRHL2 in promoting anoikis through GLUD1 down-
regulation (summarized in figure 7). 
 
Discussion  
 
The role and mechanism of the Warburg-like shift to aerobic glycolysis in tumor cells has 
received extensive investigation, but this effect is now known to be highly context dependent. In 
fact, recent studies indicate that cancer stem cells (related, in some instances, to EMT) develop an 
enhanced capacity for and dependence on oxidative phosphorylation ((34),see (35) for an excellent 
review). Moreover, oxidative phosphorylation can contribute to tumor metastasis (36, 37). This is 
thought, counter-intuitively, to have advantages for slow-cycling cancer stem cells, such as better 
maintenance of ATP in nutrient-poor tumor environments due to the higher efficiency of the 
TCA/ETC pathway (using fatty acids or glutamine as carbon sources); moreover, the tumor 
microenvironment is rarely, if ever, hypoxic enough to inhibit oxidative phosphorylation (35).   Our 
metabolic results comparing MSP vs. HMLE cells are highly consistent with this new understanding, 
and they show that GRHL2 reverts MSP cells back to an epithelial type metabolism (higher 
glycolysis, lower oxidative phosphorylation), accompanying re-sensitization to anoikis. 
Metabolic changes due to oncogenic transformation, EMT or transition to cancer stem cells 
have been reported extensively, with unique effects in each system (36, 38-41).  In this paper, we 
provide a mechanism by which EMT/cancer stem cell transition lowers ROS so at protect cells 
against anoikis.  Under this model, GRHL2 reverses EMT, suppressing mitochondrial oxidative 
function by repression of the critical enzyme regulating glutaminolysis, GLUD1, resulting in loss of 
glutamine utilization, increased ROS level, ultimately shifting metabolism resulting in anoikis 
sensitivity (Figure 6).   
There may be multiple mechanisms of ROS neutralization downstream of α-ketoglutarate.   
First, it can act synergistically with other compounds (e.g., ascorbic acid) as a co-antioxidant (42).  
Secondly, the reverse GLUD1 reaction yields glutamate, contributing to glutathione synthesis.  
Thirdly, α-ketoglutarate is a co-factor for both histone demethylase and DNA demethylase enzymes. 
Changes in the level of this co-factor could affect gene expression epigenetically, as observed in 
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other settings (43), with effects on metabolism and ROS.  Finally, a recent report shows that up-
regulated GLUD1 in tumor cells led to increases in α-ketoglutarate, increasing fumarate, in turn, 
through Krebs cycle enzymes.   This contributed to the neutralization of cellular ROS, because 
fumarate activated glutathione peroxidase activity.  GLUD1 up-regulation was, accordingly, shown 
to be pro-tumorigenic, and this effect was mediated by decreased ROS levels (27). In renal cell 
carcinoma, fumarate hydratase (FH) deficiency was increased fumarate to millimolar levels, 
contributing to oxidative stress rather than alleviating it (44).  However, the major ROS in that 
study was superoxide rather than hydrogen peroxide, and GRHL2 did not affect FH level in our cells 
(data not shown). We speculate that the contradictory effects of fumarate in FH-deficient vs. 
GLUD1-over-expressing tumor cells may be reconciled by these considerations.  
Interestingly, autophagy, which may play positive or negative roles in anoikis and non-
apoptotic cell death after detachment, is regulated by glutaminolysis as well, through mTORC 
complexes (25). Speculatively, GLUD1/ α-ketoglutarate alterations due to EMT or GRHL2 may 
affect cell survival through these additional pathways.  
The upregulation of GLUD1 would have multiple advantages for EMT/CSC cells, including 
increased use of glutamine or glutamate as alternative carbon sources in glucose-poor 
environments, protection against ROS, and the increased ETC/oxidative phosphorylation capability 
afforded by less ROS-induced mitochondrial damage.   Interestingly, the aspartate/glutamate 
transporter SLC1A6 was down-regulated dramatically by EMT, and, conversely, up-regulated by 
GRHL2 (table 1). Recently, SLC1A6 was found to act primarily as a glutamate exporter (45).  
EMT/CSC cells are predicted, therefore, to have increased accumulation of intracellular glutamate, 
contributing to the pathway that we have emphasized here.  
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Figure Legends 
 
 Figure 1. MSP cells are an anoikis resistant subpopulation of HMLE cells which have 
undergone EMT and lost GRHL2 expression. A. (upper panel): HMLE cells were sorted for CD44 
and CD24 by FACS (insert shows up-regulated CD44S in MSP cells); B: Resulting sub-populations 
were assayed for anoikis sensitivity by caspase 3/7 activation assay; C. MSP cells in which GRHL2 
was re-expressed were assayed for anoikis compared to vector control (24 hour time point with 
zero time subtracted). (lower panel):  confirmation of GRHL2 expression by western blotting. D. 
HMLE+Twist-ER cells depleted of GRHL2 by shRNA transduction were assayed for anoikis;  the 
confirmation of GRHL2 knockdown is shown as part of figure 5C. 
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Figure 2. ATP levels are elevated in mesenchymal relative to epithelial cells due to increased 
mitochondrial membrane potential (ΔΨ) A. HMLE and MSP cells were analyzed for ATP level 
under attached or suspended (16 h, 24 h) conditions. (The line indicates that the attached level 
cannot be directly compared to the suspended levels due to proliferation in attached condition). B. 
GRHL2 suppresses ATP level in MSP cells in both attached and suspended conditions. C. ΔΨ is 
elevated in MSP cells, which is reduced by GRHL2 overexpression (JC1 fluorescent probe; 
green=monomers to indicate free JC1, orange=aggregates of JC1 proportional to ΔΨ); (right panel): 
Image J quantification and ratio calculation of raw intensity pixel density for single phase red and 
green images.  
 
Figure 3. Shift from glycolysis to oxidative phosphorylation accompanies EMT; reversal by 
GRHL2 A. MSP cells have higher ATP production, maximum respiration, and higher spare capacity 
for oxidative phosphorylation than HMLE; B.  Reversal by GRHL2  
 
Figure 4. Epithelial cells have higher ROS than mesenchymal cells, and the excess ROS 
promotes anoikis. A.   HMLE cells have higher ROS compared to MSP cells, which is elevated by 
GRHL2 expression in MSP cells: CM-H2DCFDA fluorescence at the indicated times of suspension. B. 
Hydrogen peroxide is the major regulated ROS type (Amplex Red assay); C.  shRNA depletion of 
GRHL2 decreases ROS in HMLE+Twist-ER cells. D. Antioxidant compounds protect against anoikis. 
MSP+GRHL2 cells were pre-treated overnight with reduced glutathione (GSH, 5 mM) and Trolox 
(100 uM) followed by ROS and anoikis assay; E. Suppression of ROS resulted in increased JC1 
aggregate formation and elevated ΔΨ.  HMLE cells were treated with N-acetyl cysteine (NAC) at 
0.25 and 0.5 mM for 1 hr before staining with JC-1 fluorimetric dye. (right panel): Image J 
quantification and ratio calculation of raw intensity pixel density of single phase red and green 
images. 
 
FIGURE 5. GRHL2 regulates Glutamate dehydrogenase-1 and α-ketoglutarate levels.  A, 
GLUD1 is downregulated by GRHL2 in MSP cells (upper panel: RNA-seq data lower panel: western 
blot); B. GLUD1 expression is upregulated during EMT and  is downregulated by GRHL2 in HMLE-
Twist cells;  C. shRNA depletion of GRHL2 results in increased GLUD1 protein. D. α-KG is higher in 
MSP cells relative to HMLE cells, and GRHL2 overexpression decreases it (enzymatic assay 
measuring loss of NADH absorbance); E. α-KG:succinate ratio is higher in MSP than in HMLE or 
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MSP+GRHL2 cells (mass spectrometric assay).  F. α-KG:succinate ratio is decreased by GRHL2 in 
HMLE cells induced to undergo EMT by Twist-ER activation (mass spectrometric assay). 
 
FIGURE 6. GLUD1 and α-KG regulate anoikis through ROS.  A. (upper panel): Western blot 
analysis of HMLE+shGLUD1 cells. (lower panel): GLUD1 knockdown elevates ROS level; (B) GLUD1 
knockdown promotes anoikis as assessed by CM-H2DCFDA assay and caspase 3/7 activation assay 
(respectively); C.  Dimethyl-α-KG lowers ROS;  (D)   Dimethyl-α-KG protects HMLE cells against 
anoikis; E. DM-αKG and Trolox lower ROS level;  (F) DM-αKG and Trolox protect GLUD1 
knockdown cells against anoikis. 
 
FIGURE 7. GRHL2 suppresses EMT and results in the loss of GLUD1.  This decreases α-KG, 
suppressing oxidative metabolism, increasing ROS, and sensitizing cells to anoikis.  
 
 
 
Table 1.  Effect of GRHL2 on expression of ROS-regulatory genes 
Gene ID Fold Change 
(MSP+GRHL2/ 
MSP+vec control) 
Significance in ROS or Metabolism 
ALOX15 
ALOXE3 
ALOX12P2 
+236.0 
+21.0 
+18.3 
Can reportedly generate lipid peroxide radicals from 
arachidonic acid substrates  
SLC1A6 +165.7 
Glutamate/Aspartate transporter which may alter α-KGDH 
activity resulting in H2O2 radicals and reduce its TCA activity 
NCF2 (p67-
PHOX) 
+23.4 
Cytoplasmic subunit of NADPH-Oxidase (NOX) Complex 
FAT4 -19.6 
Human homologue of Drosophila Fat. Potentially contains Ftmito 
fragment which binds complex I and stabilizes it to reduce 
ROS/increase mitochondrial activity  
SOD1 -1.4 
Soluble superoxide dismutase enzyme involved in cytoplasmic 
O2.- detoxification.  Not significantly by GRHL2 overexpression 
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SOD2 +1.2 
Mitochondrial isoform of superoxide dismutase involved in 
conversion of mitochondrial O2.- into diffusible H2O2.  Not 
significantly altered by GRHL2 overexpression 
SOD3 NA Extracellular superoxide dismutase  
Cat -1.3 
Catalase enzyme involved in detoxification of H2O2 ROS species. 
Appears to be slightly regulated by EMT, but not significantly 
altered by GRHL2 overexpression 
NQO1 -1.9 
ROS detoxifying enzyme which reduces quinines to 
hydroquinones – major Nrf2 target gene  
GLUD1 -2.5 
Reported be the primary source of cellular regulation of α-KG 
which feeds to TCA cycle to increase Fumarate and stabilize 
GPx1 
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